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ABSTRACT 
MATERNAL ABO BLOOD PHENOTYPE AND FACTORS ASSOCIATED WITH 
PREECLAMPSIA SUBTYPE 
by 
 Adriane Burgess  
 
The University of Wisconsin-Milwaukee, 2017                                                                                          
Under the Supervision of Professor Teresa Johnson Ph.D., RN 
 
  
Preeclampsia affects 3-8% of all pregnancies and is a global issue that significantly effects 
the short and long-term health of women and neonates.  The pathophysiology of preeclampsia 
remains unclear and there seems to be two distinct subtypes, early and late onset.  Each subtype 
may have a unique pathophysiology and set of risk factors.  Preeclampsia is linked to long-term 
risk of cardiovascular disease in previously affected women.  Subsequently, risk factors shared 
between preeclampsia and cardiovascular disease should be explored.  The main aim of this study 
was to determine the strength of association between maternal ABO blood type and preeclampsia 
subtype.  This hospital-based case control study was completed at one community hospital in the 
Mid Atlantic, United States.  The study included 126 female subjects with early onset 
preeclampsia (≤ 33 6/7 weeks gestation), 126 female subjects with late onset preeclampsia (≥ 34 
weeks gestation) and 259 control subjects with no history of preeclampsia.  Strict diagnostic 
criteria were used and preeclamptic subjects were classified by subtype based on gestational age at 
diagnosis.  Data on ABO blood type, as well other physical and socio-demographic variables were 
extracted from the electronic health record.  No significant association was noted between 
iii 
 
preeclampsia subtype and non-O blood type (p=.456) and ABO blood phenotype trended towards 
significance (p=.062).  After exclusion of subjects with comorbidities (CHTN, GDM and DM) 
from the sample (n=403), there was a significant association noted between ABO blood type and 
preeclampsia subtype (p=.001).  A significant association was also noted between preeclamptic 
subjects with growth restriction and ABO blood type (p= <.001).  Preeclamptic subjects with the B 
blood type had OR=3.44, 95% CI 1.58, 7.50 of having a growth-restricted fetus than did those with 
other blood types.  Finally, when adjusting for race only, subjects with AB blood type had the 
following odds (OR=3.03, 95% CI 1.04, 8.80; OR=3.35, 95% CI 1.02, 11.03.) of developing pre-
eclampsia and late onset preeclampsia respectively.  When other clinical risk factors of 
preeclampsia are included in the model, AB blood type significantly predicts membership in the 
early onset preeclampsia subtype (OR=5.41, 95% CI, 1.19, 24.55) and was trend-level in the late 
onset group (p=.053).  Preeclamptic women with B blood type had three times the odds of having 
a growth-restricted fetus, subsequently; they may require close ultrasound surveillance.  AB blood 
type was significantly associated with three times increased odds of late onset preeclampsia.  
When included in a model with other common risk factors of preeclampsia, ABO blood type only 
accounted for a small amount of variability in the model.  ABO blood type may not be a valuable 
addition to a preeclampsia-screening algorithm that already includes common clinical risk factors 
of preeclampsia.  However, when controlling for other common clinical risk factors of 
preeclampsia, women with AB blood type had over 5 times the odds of developing early onset 
preeclampsia.  Further research is necessary to examine if blood type regulates biomarkers that 
mediate the development of each preeclampsia subtype or in some way is associated with severe 
features of the disease. 
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CHAPTER 1 
 
This chapter begins by introducing the problem of preeclampsia.  Preeclampsia is linked 
to a variety of poor short and long-term outcomes for both mother and neonate.  The disease is 
heterogeneous in nature and there are two distinct subtypes, early and late onset.  Preeclampsia 
has been associated with increased risk of cardiovascular disease in previously effected women 
and shared risk factors should be investigated.  Next, this chapter provides a pathophysiologic 
framework that describes the role of blood type in both disease processes.  The purpose of this 
proposed dissertation study is given and research questions posed.  Finally, contributions to the 
future of nursing science and practice are discussed.  
Introduction 
Incidence 
      Preeclampsia affects 3-8% of all pregnancies and is a global issue that significantly 
affects the short and long-term health of both women and neonates (Hutcheon, Liskonova & 
Joseph, 2011).  Roughly, 1 in 12 pregnancies are affected by preeclampsia (Ilekis, Reddy & 
Roberts, 2007).  Rates of preeclampsia have risen by 25% in the past two decades in the United 
States and the disease is linked to significant maternal morbidity and mortality as well as listed 
as a major contributor to prematurity (Ferrazzani et al., 2011; Wallis, Saftlas, Hsia, & Arish, 
2008).  Preeclampsia is a global issue, related to significant maternal and neonatal morbidity and 
mortality.  Worldwide, hypertensive disorders of pregnancy are responsible for 76,000 maternal 
and 500,000 infant deaths each year (The Preeclampsia Foundation, 2016).  Hypertensive 
disorders of pregnancy account for 16% of maternal deaths in developed countries and even 
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higher rates of maternal mortality related to these disorders are seen in Latin American and 
Caribbean countries (Khan, Wojdyla, Say, Gülmezoglu, & Van Look, 2006).   
Maternal Complications 
    Hypertensive disorders of pregnancy account for 9.4% of maternal deaths in the United 
States (Creanga et al., 2015).  In addition to the significant associated maternal mortality, 
preeclampsia is also linked to severe maternal morbidity, such as, eclampsia, acute renal failure, 
pulmonary edema, placental abruption, end organ damage and neurologic sequelae such as stroke 
(Sibai, Dekker & Kupferminc, 2005; Lisonkova & Joseph, 2013).  These women, particularly 
those with early onset disease, are at higher risk for induction of labor and cesarean section 
(Alanis et al., 2008).  The risk of serious complication increases with the severity of the disease 
(Hutcheon et al., 2011).   
Infant Complications 
    Although preeclampsia is a maternal hypertensive disorder, with significant associated 
short and long-term maternal morbidity and mortality, there is also significant fetal and neonatal 
risk associated with the disease.  Fifteen percent of pregnancies affected by preeclampsia result 
in spontaneous or medically indicated preterm birth (Alanis et al., 2008).  There is a twofold risk 
of neonatal death in infants born to women diagnosed with preeclampsia, and significant 
associated neonatal morbidity, such as lower Apgar scores, seizures, and neonatal 
encephalopathy (Lisonkova, & Joseph, 2013).  Fetal growth restriction (FGR) is commonly seen 
in infants of preeclamptic mothers, particularly those with early onset disease.  Although rates of 
stillbirth are decreasing, women with preeclampsia continue to have far higher rates of stillbirth 
than unaffected pregnancies in both developed and developing countries (Hutcheon et al., 2011).   
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Definition and Diagnostic Criteria 
      Preeclampsia is defined by ACOG (2013) as the new onset of hypertension, with blood 
pressure greater than or equal to 140 mmHg systolic or greater than or equal to 90 mm Hg 
diastolic on two occasions at least 4 hours apart after 20 0/7 weeks gestation in a previously 
normotensive women, and proteinuria (≥ 300mg in a 24-hour urine collection).  In the absence of 
proteinuria the patient may have any one or more of the following in order to meet diagnostic 
criteria: 
● platelets < 100,000 microliter 
● serum creatinine > 1.1 or doubling of serum creatinine in the absence of renal  
      disease 
● elevated concentrations of blood liver transaminases to twice normal levels 
● pulmonary edema  
● new onset of cerebral or visual disturbances (ACOG, 2013, p. 4).   
 
Non-proteinuric pre-eclampsia occurs in about 25% of all cases (Tranquilli, Brown, Zeeman, 
Deeker & Sibai, 2013).  Removal of proteinuria from the definitive diagnosis of preeclampsia 
proved important, as previously, many women with other signs and symptoms preeclampsia 
went undiagnosed solely due to lack of proteinuria.  Unfortunately, while providers waited for 
women to become proteinuric in order to meet diagnostic criteria, the severity of the illness 
increased.   
Severity.  Due to the documented aggressive and dynamic nature of preeclampsia, there 
has been a change in nomenclature when documenting severity (ACOG, 2013).  Preeclampsia is 
no longer documented as mild or severe, but rather “with severe features” and “without severe 
features” (ACOG, 2013, p. 8).  Preeclampsia “with severe features” is documented when patients 
meet the basic criteria for diagnosis of preeclampsia and have any one or more of the below 
findings: 
● systolic blood pressure ≥160 mmHg and/or diastolic blood pressure >/=     
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      110mmHg 
● platelet count <100,000 per microliter 
● impaired liver function as evidenced by severe persistent right upper quadrant or     
      epigastric pain or elevated liver enzymes twice normal blood concentration 
● progressive renal insufficiency as evidenced by worsening serum creatinine 
● pulmonary edema 
● cerebral or visual disturbances (ACOG, 2013). 
Quantity of urinary protein, uric acid levels, FGR and edema are no longer diagnostic of 
increasing severity, however, may warrant closer surveillance of the pregnancy (ACOG, 2013).  
Additionally, even in the absence of preeclampsia diagnosis, maternal report of individual 
symptoms such as new onset of cerebral or visual disturbance, severe epigastric or right upper 
quadrant pain, or an objective clinical finding of an elevation in blood pressure compared with an 
early pregnancy baseline blood pressure should result in close obstetrical evaluation (ACOG, 
2013).  
Classic Risk Factors 
   Clinical risk factors for preeclampsia include nulliparity, extremes in maternal age (<18 
or >35 years), multiple gestation, obesity, African American race, utilization of assisted 
reproductive techniques, family history of preeclampsia, and history of previous preeclamptic 
pregnancy.  Other preexisting diseases such as chronic hypertension, anti-phospholipid 
syndrome, lupus and diabetes have also been shown to increase risk of preeclampsia (Bartsch, 
Medcalf, Park, & Ray, 2016; Boyd, Tahir, Wohlfahrt & Melbye , 2013; Lisonkova & Joseph, 
2013; O'Brien, Ray, & Chan, 2003; Paré et al., 2014).  Women not affected by preeclampsia 
during their first pregnancy, have only a 1% chance of developing preeclampsia in a subsequent 
pregnancy if the pregnancy is with the same partner.  However, if preeclampsia occurs in the first 
pregnancy, and the women is pregnant again by the same partner, the chance of preeclampsia 
recurring is 7-15% (Hutcheon et al., 2011).  Chance of recurrence increases even further in the 
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third pregnancy if both of the previous pregnancies were affected.  Early gestational age at onset 
of preeclampsia also seems to increase risk of reoccurrence (Hutcheon et al., 2011).   
Risk screening models.  Due to the heterogeneous nature of disease, developing risk-
screening models has proven difficult, as there are modifiable, non-modifiable, graded and 
interactional risk factors for preeclampsia (Osol & Bernstein, 2014).  Additionally, over 200 
biomarkers have also been explored alone and in combination, however, none have been 
revealed to be sensitive enough to result in prediction (Osol & Bernstein, 2014).  Further 
research is necessary on the use of biochemical and biophysical markers already commonly 
collected during prenatal care for use in preeclampsia prediction. 
Subtypes of Preeclampsia 
Preeclampsia is heterogeneous in nature (Founds et al., 2011; Myatt et al., 2014).  There 
are two distinct subtypes, early and late onset.  It is important to note that these two subtypes are 
defined in relation to the timing of onset of the disease during pregnancy, not necessarily 
severity, and either subtype can have severe features (Kucukgoz Gulec et al., 2013).  The 
American College of Obstetricians and Gynecologist guidelines for management of preeclampsia 
are based on the presence or absence of severe features.  However, the subtypes seem to have 
differing clinical and laboratory findings of each subtype seem to differ (Kucukgoz Gulec et al., 
2013).  Subsequently, ACOG (2013) has called for more research into each preeclampsia 
subtype in order to determine if each subtype has a unique pathophysiology or risk factors and 
thus could require different management and/or treatment.  
  It has been difficult to synthesize research literature on preeclampsia subtypes as studies 
have used differing definitions of the early and late onset subtypes.  In the literature, the 
definition of early onset preeclampsia varies, typically stated as onset of preeclampsia 
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symptomology occurring anywhere from prior to 28 0/7 weeks gestation to 37 0/7 weeks 
gestation (Tranquilli et al., 2013).  Recently, the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) set out to construct clear definitions of each preeclampsia 
subtype, in order to allow for improved synthesis of the research literature moving forward.  
Early onset preeclampsia is now defined by the ISSHP as occurrence of preeclampsia ≤ 33 6/7 
weeks gestation, while late onset preeclampsia occurs ≥ 34 0/7 weeks (Lisonkova, & Joseph, 
2013).  Late onset preeclampsia is further subdivided to include preterm preeclampsia, which can 
occur anywhere between 34 1/7 weeks until 37 0/7 weeks gestation, and term preeclampsia, 
which occurs ≥ 37 1/7 weeks gestation (Tranquilli et al., 2013).   
Myatt et al. (2014) further support the importance of standardizing preeclampsia research 
design and provide guidelines for preeclampsia research.  Myatt and colleagues (2014) also 
recognized variation in the definition of each preeclampsia subtype, noting that most research 
which explored preeclampsia subtypes do so in relation to timing of delivery, and utilized  <37 
0/7 weeks gestation and >37 0/7 weeks gestation as criteria for the early and late onset subtypes.  
Noting the significant increased risk of perinatal morbidity associated with preeclampsia cases 
that occur prior to 34 0/7 weeks gestation, Myatt and colleagues (2014) support the criteria 
outlined by the ISSHP and also recommend using <34 0/7 weeks gestation as criteria for early 
onset preeclampsia. 
Early onset preeclampsia.  Early onset preeclampsia is often more severe in nature than 
its late onset counterpart (Kucukgoz Gulec et al., 2013).  It is suggested that early onset 
preeclampsia may have a significant genetic component and poor early placentation is seen more 
frequently in this subtype (Boyd et al., 2013; Steegers, Von Dadelszen, Duvekot, & Pijnenborg, 
2010 ).  Kucukgoz Gulec et al. (2013) observed increased rates of Hemolysis, Elevated Liver 
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Enzymes and Low Platelets (HELLP) syndrome, eclampsia, and admission to critical care units 
in women with early onset preeclampsia.  These authors also reported that gestational age at 
admission seems to indicate worse neonatal outcomes.  Early onset preeclampsia is also more 
often associated with abnormal uterine artery doppler velocimetry (Phillips, Janowiak, Badger & 
Bernstein, 2010) as well as FGR (Kucukgoz Gulec et al., 2013).  Early onset preeclampsia may 
be unique in that there seems to be a significant uteroplacental component, as well as certain 
maternal pre-pregnancy characteristics that may predispose women to both the early onset 
subtype as well increased long-term cardiovascular risk (Phillips et al., 2010).  “Early 
preeclampsia appears to be characterized by a state of high total vascular resistance and low 
cardiac output, whereas low total vascular resistance and high cardiac output mark term and 
near-term preeclampsia” (Phillips et al., 2010, p. 624).  Although the ACOG Task Force (2013) 
did not construct preeclampsia treatment/management guidelines based on preeclampsia 
gestational age at onset, however, ACOG (2013) did make recommendations for initiation of late 
first trimester aspirin therapy based on prior pregnancy with early onset preeclampsia. 
Late onset preeclampsia.  Although early onset preeclampsia is often more severe in its 
presentation, late onset preeclampsia can also include “severe features” as described by ACOG 
(2013).  The late onset subtype has been shown to have a higher incidence than early onset 
preeclampsia (Lisonkova, & Joseph, 2013).  Boyd and colleagues (2013) suggest that 
environmental factors may contribute most to late onset preeclampsia.  
Cardiovascular Disease and Preeclampsia 
     Previously it was thought that preeclampsia was completely cured by delivery of the 
pregnancy.  However, more recently, research has begun to support that preeclampsia increases 
long-term risk of cardiovascular disease in women and infants who survive the pregnancy 
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disorder  (Firoz & Melnik, 2011; Fraser et al., 2012; Geelhoed et al., 2010;  Hermes et al., 2013; 
Herrera-Garcia, & Contag, 2014; Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al., 
2013).  Women who were previously affected by early onset preeclampsia have been shown to 
have seven to nine times the increased risk of cardiovascular disease.  Late onset preeclampsia 
has been shown to impart twice the risk of cardiovascular disease later in life in those who have 
been previously affected (Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al., 2013).   
Currently, no postpartum evidenced based cardiovascular risk reduction programs have 
been designed for women who have been diagnosed with either subset of preeclampsia, nor have 
screening strategies been created (Bushnell et al., 2014; Cusimano, Pudwell, Roddy, Cho,  & 
Smith, 2014; Firoz & Melnik, 2011).  Although traditional cardiovascular interventions may be 
used, there is no evidence to support their efficacy among women with preeclampsia and these 
interventions may differ by preeclampsia subtype (Celi et al., 2013; Firoz & Melnik, 2011; 
Veerbeek et al., 2015).  Recent American Heart Association guidelines (2014) for the prevention 
of stroke in women reported that 18.2% of women with a history of preeclampsia had a 
cardiovascular event in the 10 years following the delivery of the effected pregnancy compared 
to 1.7% of women with uncomplicated pregnancies (Bushnell et al., 2014).  With an 
understanding of the connection between cardiovascular disease (CVD) and preeclampsia, health 
care providers and women should view pregnancy as a unique opportunity, one that allows 
women and their health care providers an early glimpse into future health risk.  Additionally, this 
provides women with an opportunity to begin to utilize preventative strategies proactively with 
an aim towards health promotion (Bushnell et al., 2014).   
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Blood Type as a Risk Factor 
Due to the link between later life cardiovascular disease and preeclampsia, researchers 
should explore shared risk factors.  Both cardiovascular disease and preeclampsia may be 
associated with blood type.  Further examination of risk factors shared between the two disease 
processes is necessary, in the hope of establishing a clearer pathophysiologic basis for 
preeclampsia (Biswas et al., 2013; Bushnell et al., 2014).  Several studies have revealed a 
correlation between ABO blood type and preeclampsia (Alpoim et al., 2011; Alpoim et al., 2012; 
Clark, Walker, Govan, Wu, & Greer., 2007; Hiltunen et al., 2009; Phaloprakarn & Tangjitgamol, 
2013; Seyfizadeh et al., 2014; Than et al., 2011).  No recent research has been done in the United 
States looking at the correlation between blood type and preeclampsia subtype.   
Early onset preeclampsia has been linked to higher risk of cardiovascular disease than its 
late onset counterpart (van Rijn et al., 2013).  It is proposed that the two subtypes have differing 
pathophysiology.  Since ABO blood type has also been linked to cardiovascular disease, it is 
necessary to explore its role in the pathophysiology of both preeclampsia subtypes.  With an 
understanding of the link between preeclampsia and cardiovascular disease, the pathophysiologic 
basis for preeclampsia may in fact be revealed through further investigation of biomarkers shared 
between preeclampsia and CVD (Biswas et al., 2013; Bushnell et al., 2014).  Understanding non-
manipulable risk factors of preeclampsia may help to find manipulable agents that can used in 
treatment and management of preeclampsia (Shadish, Cook & Campbell, 2002).   
Pathophysiologic Framework of the Study 
Pathophysiology 
There are four major human blood groups A, B, O and AB (Seyfizadeh et al., 2014).  
Current research supports that ABO blood phenotypes are now far more useful than in 
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hematology and transfusion medicine alone (Franchini & Lippi, 2015).  Research indicates that 
blood phenotype may be linked to cancer particularly gastric and pancreatic cancers, 
cardiovascular disease as well as a variety of infectious disease (Biswas et al., 2013; Edgren et 
al., 2010; Franchini & Lippi, 2015).  ABO antigens are expressed differently on the red cell 
surface as well as in a “variety of human cells and tissues, including epithelium, sensory neurons, 
platelets, and vascular endothelium” (Franchini & Lippi, 2015, p. 1).  ABO blood phenotype 
effects hemostasis, due to varying levels of Von Willebrand factor (VWF) and Factor VIII by 
blood type (Franchini, Mengoli, Lippi, 2016).  Non-O groups have approximately 25% higher 
levels of VWF than other types (Franchini & Lippi, 2015).  Thusly, those with Non-O blood 
phenotypes are at increased risk for venous thrombosis, arterial thrombosis, myocardial 
infarction (MI) and ischemic stroke (Franchini & Lippi, 2015).  The link between alteration in 
hemostasis seen in certain blood types as well as preeclampsia supports the biologic plausibility 
of this study. 
Feminism 
Traditional science holds significant power to improve outcomes, however, long held 
beliefs surrounding the biologic similarities of male and female bodies have hampered progress 
particularly related to cardiovascular research focused on women’s health.  Although the basis of 
this study is highly pathophysiologic, feminism provides an excellent framework by which to 
examine the role preeclampsia plays in risk of future CVD.  It is important for researchers in this 
area to have an understanding of how women’s oppression plays into their social reality (Yuill, 
2012).  A feminist framework allows for in-depth analysis of phenomena surrounding women 
bodies as well as their overall health, and provides a platform by which researchers can advocate 
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for the health of women and challenge a patriarchal dominated medical community (Routledge, 
2007).   
Purpose of the Proposed Study 
This study will focus on identifying the strength of association between maternal blood 
type and preeclampsia subtype with an aim at improving identification and screening of those at 
increased risk for future cardiovascular disease.  Additionally, the study will aim to identify risk 
factors and birth outcomes associated with both early and late onset preeclampsia. 
Hypotheses and Research Questions 
The research questions that will be addressed in this study include: 
Research Question 1: 
What are the maternal characteristics of women with preeclampsia and with each preeclampsia 
subtype? 
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional 
cardiovascular risk factors such as higher body mass index (BMI) and chronic hypertension and 
diabetes; additionally, more subjects in the early onset subtype will be of African American race 
and of lower socioeconomic class. 
Research Question 2: 
Is there an association between preeclampsia subtype and ABO blood phenotype? 
Hypothesis 2: Early onset preeclampsia will be more highly correlated with non-O blood 
types than its late onset counterpart will.  This directional hypothesis is based on several previous 
studies, which showed women with non-O blood types were at increased risk of preeclampsia 
due to elevated coagulation factors noted in these blood types as well as differences in 
inflammatory biomarkers (Alpoim et al., 2011; Hiltunen et al., 2009; Lee, Zhang et al., 2012; 
Phaloprakarn & Tangjitgamol, 2013).  The main aim of these studies was not to assess this 
association by preeclampsia subtype, but rather preeclampsia as a homogenous group.  Since 
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there is evidence to support two distinct subtypes of the disease, it is important to look at if blood 
type more significantly correlates with one subtype.  Since cardiovascular risk is higher in the 
early onset subtype and non-O blood types correlate with increased cardiovascular risk (Chen et 
al., 2014; Etemadi et al., 2015; Gong et al.,  2014a; Gong et al. 2014b; He et al., 2012; Karabuva, 
Carević, Radić, & Fabijanić , 2013; Lee, Zhang et al.,  2012; Zakai et al., 2014), this author 
hypothesizes that non-O, blood types will also be more common in the early onset preeclampsia 
subtype. 
Research Question 3: 
What is the association between preeclampsia subtype and Rh type? 
Hypothesis 3:  Rh factor will not be associated with preeclampsia or preeclampsia 
subtype.  In most previous studies which assessed the association between Rh factor and both 
preeclampsia and CVD no relationship was reported (Etemadi et al., 2015; He et al., 2012; 
López-Pulles et al., 2010; Shamsi et al., 2010).  Although most studies did not find an association 
between Rh factor and preeclampsia, Sezik, Toyran and Yapar (2002) reported an association 
between O negative women and increased risk of HELLP syndrome.  Subsequently, Rh data will 
be included in the study in order to determine if Rh factor is associated with either subtype of 
preeclampsia. 
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation and 
preeclampsia development? 
 
Hypothesis 4:  ABO blood type will be associated with platelet count at ≥ 28 6/7 weeks 
gestation in each preeclampsia subtype.  Preeclampsia diagnostic criteria can include platelet 
count < 100,000 microliter in the absence of proteinuria, and  platelet count < 100, 000 microliter 
can also indicate increasing severity of the disease.  ABO antigens are expressed on both the red 
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cell as well as on platelets (Franchini & Lippi, 2015).  Since risk of preeclampsia is said to differ 
by ABO blood type, platelet count may also differ (Freitas, Alpoim, Komatsuzaki, Carvalho, & 
Dusse,  2013; Hiltunen et al., 2009; Lee, Zhang et al., 2012; Phaloprakarn & Tangjitgamol, 
2013).   
Research Question 5: 
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
Hypothesis 5:  ABO blood type will be associated with FGR in preeclamptic women.  
Preeclampsia, particular early onset has been associated with increased risk of FGR (Kucukgoz 
Gulec et al., 2013).  Hiltunen et al. (2009) discovered an association between AB blood type and 
growth restriction in preeclamptic women.  
Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
Hypothesis 6: Non-O blood types will have increased odds of preeclampsia and 
preeclampsia early onset subtype.  Traditional clinical and sociodemographic risk covariates 
such as increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal 
age will increase odds of the early onset preeclampsia subtype (Bartsch et al., 2016; Boyd et al., 
2013; Lisonkova & Joseph, 2013; O'Brien, Ray, & Chan, 2003; Paré et al., 2014).   
Study Setting  
Due to accessibility, the electronic health record (EHR) from a large suburban 
community hospital in the Mid Atlantic United States that has roughly 3000 births per year was 
utilized to obtain the desired data.  There are only two other small community hospitals with in 
the area; however, the majority of high-risk pregnancies are delivered at this hospital due to its 
NICU and high risk obstetrical facilities.  Additionally, maternal fetal medicine specialists also 
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care for women not geographically close to this institution.  Subsequently, women go on to 
deliver at this institution while following up with their high-risk care.  This may result in a higher 
proportion of women with preeclampsia being seen at this institution.   
Contributions to Nursing 
Over the past 20 years, scientists have learned much about preeclampsia and the focus 
has moved away from blood pressure as the central etiology of the disease.  Recent research has 
begun to focus on biomarkers that may provide insight into origins of the disease this however, 
has not resulted in earlier recognition or improved management (Myatt et al., 2014).  In 
November of 2013, preeclampsia diagnostic criteria was updated and no longer requires 
proteinuria for diagnosis (ACOG, 2013).  In turn, this may result in women that would 
previously not have been diagnosed with preeclampsia now being included in studies.  Inclusion 
of this new population of women may in turn reveal new characteristics about women with 
preeclampsia.  Many previous studies did not explore specific subtypes of preeclampsia; research 
aimed at exploring specific subtypes of preeclampsia may lead to an enhanced understanding of 
the pathophysiology of the disease (Myatt et al., 2014).  A more clear understanding of the 
pathophysiology may improve prediction.  Additionally, with the known association between 
cardiovascular disease and preeclampsia, a better understanding of risk factors that mediate the 
two diseases may lead to the creation of targeted therapies as well as cardiovascular preventive 
interventions specific to each subtype of preeclampsia. 
Chapter Summary 
Preeclampsia in heterogeneous in nature, each subtype is associated to a varying degree 
with poor long-term cardiovascular sequelae.  Thusly, it is important to explore shared risk 
factors.  If the primary hypothesis of this study is supported, non-O blood types will be 
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associated with an increased risk of early onset preeclampsia, which in turn may shed light on 
the pathophysiologic process that mediates its relationship to cardiovascular disease.  This study 
may then provide new information on how to tailor cardio preventive therapies geared towards 
women who have had preeclampsia or aid in the design of tools aimed at preeclampsia 
prediction.   
 
 
 
 
 16 
 
 
CHAPTER 2 
Philosophical Framework and Literature Review 
Introduction to the Chapter 
The aim of this study is to 1) examine the association between ABO blood type, Rh factor 
and preeclampsia subtype and to 2) determine which other factors most significantly influence 
the development of each preeclampsia subtype.  Additionally, epidemiological data will be 
collected in order to better describe each preeclampsia subtype.  It is well established  that 
women with preeclampsia have an increased risk of CVD (Mongraw-Chaffin, Cirillo, & Cohn, 
2010; van Rijn, et al., 2013).  Of the two subtypes, women with the early onset subtype have a 
significantly higher risk of cardiovascular disease than the late onset subtype (van Rijn, et al., 
2013.  It is hypothesized that due to the increased cardiac risk associated with non-O blood types, 
non –O blood types may also be associated with the development of early onset preeclampsia.   
 Chapter 2 begins by outlining the philosophical framework from which this study is 
grounded.  Since preeclampsia is a uniquely female cardiac risk factor, feminism provides an 
excellent framework by which to address research gaps and pose questions.  Feminist empiricism 
as well as the role feminism plays in cardiovascular research is described.  Next, the proposed 
pathophysiology of preeclampsia will be described and non-classic biomarkers discussed.  
Finally, a review of the literature that assesses the current evidence on both the relationship 
between both ABO blood type and preeclampsia as well as cardiovascular disease and 
preeclampsia was completed in order to describe common themes. 
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Philosophical Framework 
Cardiovascular disease (CVD) remains the leading cause of death in women in the United 
States, with heart attack the leading cause and stroke the third leading cause of mortality (Tindall 
& Vanderman-Winter, 2011).  Although millions of dollars have been allocated towards research 
on cardiovascular disease, women have not seen the same improvement in outcomes, as have 
men.  Rates of cardiovascular mortality have been declining in men since the early 1980s 
however, rates in women have been declining at a much slower rate, with CVD effecting 1 in 3 
women (American Heart Association, 2015).  Even within this gendered component of the 
disease, there continues to be racial disparities.  CVD disproportionately affects African 
American and Hispanic women (Mosca, Hammond, Mochari-Greenberger, Towfighi, & Albert, 
2013).  In order to appropriately study this vexing problem, taking a gendered approach is 
necessary.  A gendered approach requires studying both biologic as well as socially constructed 
differences between the lives of men and women (Davidson, 2012).  Preeclampsia has significant 
implications for the long-term cardiovascular health of women, and is a cardiovascular risk 
factor unique to women.  Thusly, more in depth study of preeclampsia and its relationship to 
cardiovascular disease needs to occur.  Although blood type is not a uniquely female 
characteristic, it is important to assess how ABO blood type mediates preeclampsia risk as well 
as long-term cardiovascular disease risk in women, as this may improve prediction of both 
diseases. 
Feminist empiricism.  Feminist empiricism supports the basic principles of scientific 
inquiry, accepts that the world can be seen objectively and believes that knowledge is gained 
through experiences.  The feminist empiricist also supports that research should be done by 
women on female participants in order to further maintain the feminist paradigm (Yuill, 2012).  
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There has been much debate as to what constitutes nursing knowledge, particularly how it relates 
to questions of basic science (Perry, 1994).  Biologic research is indeed nursing research.  For as 
nurses, we provide holistic care, and with this said, biologic phenomena cannot be separated 
from the holistic context (Perry, 1994).  Perry et al. (1994) stated that “In order to prevent illness 
and promote health, it is necessary to generate knowledge about cellular processes that is less 
distorted and biased then that produced by a method entrenched in androcentrism” (p. 491).  This 
quote speaks to the fact that the utilization of a feminist framework in biologic studies is 
paramount to the creation of new knowledge in this area.  
 Both women and men perpetuate androcentrism in the basic sciences (Perry, 1994).  
Historically, women and issues of women’s health have been excluded from basic science 
research as well as research agendas.  A scientific community largely made up of men has 
designed these agendas.  Subsequently, the health issues of women as well how women are 
effected by disease has not been studied as extensively due to allocation of funds towards 
androcentric research agendas (Perry, 1994).  It is necessary to begin to focus basic science 
research on the health and wellness of women and continue to acknowledge the effect gender 
bias has had in cardiovascular research (McCormik & Bunting, 2002). 
  Feminist empiricism may be helpful in addressing research gaps specific to the biologic 
functioning of women by accounting for androcentric bias found in theories and methodologies 
often used in basic science (Perry, 1994).  The researcher and the phenomena being studied are 
inextricably linked, thus objectivity in research is value laden (Perry, 1994; Potochnik, 2012).  
Social values shape ways of knowing in the scientific community, and thus scientific practice 
(Potochnik, 2012).  This not only influences what studies are undertaken but also, hypotheses 
postulated, variables chosen, judgments made and answers found (Potochnik, 2012).  Perry 
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(1994) suggests that increasing the number of women working within the scientific realm to 
determine and study biologic problems specific to women, has the potential to alter the research 
agenda and greatly improve outcomes in women.  
Feminist Framework 
      A feminist framework can be used to gather both quantitative and qualitative data, as “it 
is the point of view of the researcher that makes research feminist in nature” (McCormick & 
Bunting, 2002, p.824).  McCormick and Bunting (2002) listed eight criteria gathered from 
multiple authors, which define feminist research: 
 “principle investigator was a woman, 
 feminist methodology was used, 
 the study had the potential to help the subjects as well as the researcher,  
 the research focused on the experience of the woman,  
 the investigator’s purpose was to study women within their role as women,  
 the word “feminist” or “feminism” was used in the report,  
 bibliographic references to feminist literature were made, and  
 nonsexist language was used” (p. 824). 
 
 Several of the above criteria will be addressed as this author sets out to study the 
phenomena of preeclampsia and risk factors related to long-term cardiovascular disease.  
Foundational to this study is the aspect that cardiovascular research, prevention strategies, and 
risk factor identification strategies do not adequately represent the needs and risk factors unique 
to women.  When a feminist viewpoint is used to study cardiovascular disease in women, the 
potential for understanding the phenomena is enhanced.  In addition, this author’s study aims to 
improve the health of women, valuing the experience of pregnancy as unique as well as sex 
specific.   
Women’s Awareness of CVD 
      Clarke (1992) called for the use of a feminist methodology in health promotion research 
and asked researchers to consider gender and sex when designing and conceptualizing research 
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studies.  For many years, CVD was socially constructed as a male illness, however, in the past 
decade, there has been a significant effort to increase women’s awareness of their risk for this 
disease (Long, Taubenheim, Wayman, Temple, & Ruoff, 2008; Mosca, Hammond, Mochari-
Greenberger, Towfighi, & Albert, 2013).  Although awareness is improving, it continues to lag 
particularly in racial and ethnic minorities (Mosca, Mochari-Greenberger, Dolor, Newby, & 
Robb, 2010).  Even with improvement in women’s awareness of CVD risk, due to androcentric 
worldviews and gender bias in health research, how women are affected by, their risk factors for, 
and symptomology of CVD has been under studied (McCormick & Bunting, 2002).   
  Lack of research on how sex and gender specific factors affect cardiovascular disease 
and outcomes provide inadequate science for nurses to adequately educate and care for their 
female clients.  Since health care providers are relatively unaware of the link between certain 
pregnancy complications and long-term cardiovascular risk, women remain under educated 
about their increased CVD risk if they had a pregnancy complicated by preeclampsia (Young, 
Hacker, & Rana, 2012).  Subsequently, women are unable to make decisions to initiate lifestyle 
modifications aimed at prevention of CVD.  Adams et al. (2014) called for improved 
communication and collaboration between obstetrical and primary care providers as well as 
increased patient education about the importance of pregnancy history to cardiovascular 
outcomes. 
Feminist Research 
      In order to improve women’s health research initiatives, in 1993, the NIH Revitalization 
Act required that women be included in clinical trials, the same year the FDA reversed its ruling 
that barred childbearing women from participating in clinical research (Mosca, Barrett-Connor, 
& Kass Wenger, 2011).  Although these were great strides towards improvement and 
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identification of women’s health issues, in 2003, the Food and Drug Administration Office of 
Women’s Health (FDA OWH) reported that although women and men are equally participating 
in research, these results are not presented as gender specific (Mosca, Barrett-Connor, & Kass 
Wenger, 2011).  It is integral to differentiate between the concepts of sex and gender 
(Hammarstrom et al., 2014).  Examining biologic mechanisms unique to women allows 
researchers to begin to better understand their role in long-term health outcomes.  A more clear 
understanding of uniquely female biologic concepts, such as preeclampsia and other pregnancy 
specific complications may be integral to improving health in women.  There are biologic, social 
and environmental factors that must be considered when assessing risk and protective 
mechanisms that occur in the lives of men and women (Lorber & Moore, 2002).  With this said, 
pregnancy is uniquely female, and the effect this process has on the long-term health of women 
must be considered.   
Sex and Gender Specific Factors of Cardiovascular Disease  
Yentl syndrome.  In 1991, Dr. Bernadette Healy published an article in the New England 
Journal of Medicine describing Yentl Syndrome.  Yentl syndrome is named after a woman in a 
short story who had to disguise herself as a man to receive equal treatment.  Dr. Healy felt that 
women did not receive equal treatment for CVD until their symptomology presented like that of 
a man.  She cited research showing that women were less likely to undergo coronary 
angiography, angioplasty and surgery when admitted to the hospital with similar diagnosis as 
their male counterparts; additionally women exhibited more debilitating angina then men and 
continued not to receive cardiac catheterization (Healy, 1991).  It was not until after women had 
procedures such as cardiac catheterization and angioplasty or were determined definitively to 
have had a myocardial infarction that they received treatments at the same rate as men.  At this 
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point, due to delayed treatment, major damage was often done.  Dr. Healy described this 
inequitable treatment of women with cardiovascular symptomology as Yentl syndrome (Healy, 
1991).  Sex specific cardiovascular risk factors such as preeclampsia may further complicate 
identification of women at risk for CVD.  Obstetrical risk factors for CVD such as preeclampsia, 
fetal growth restriction (FGR), and prematurity are not factored into cardiovascular risk models 
or acknowledged by health care providers as CVD risk factors further perpetuating Yentl 
syndrome as described by Dr. Healy over thirty years ago (Smith,  Pudwell, Walker  & Wen, 
2012).  
    Biologic differences.  Although there has been improvement in cardiovascular care in 
the past two decades, there continues to be more women than men living with, and dying from 
CVD and stroke, and women continue to have higher rates of hypertension then men (Mosca et 
al., 2011; McCormick & Bunting, 2002).  Much of the early biomedical health research was 
conducted utilizing male participants, often generalizing these findings to women.  Social issues 
notwithstanding, there are significant biologic as well as anatomical differences between the 
cardiovascular systems of men and women.  Sex specific factors such as pregnancy, menopause, 
and hormones may have an effect on CVD (Craici, Wagner, & Garovic, 2008).  These sex 
specific factors may influence onset and diagnosis of CVD, as well as its clinical course, efficacy 
of therapy, and outcomes (Craici et al., 2008).  Biologic differences between men and women 
include; women have smaller coronary arteries, increased rates of mitral value prolapse and left 
ventricular hypertrophy, lower hematocrit levels, and lower premenopausal blood pressures 
(McSweeney, Pettey, Souder, & Rhoads, 2011).  These biologic dissimilarities can result in 
differences in CVD risk factors between the sexes (McSweeney et al., 2011). 
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Differences in symptoms.  Women with coronary heart disease (CHD) present with 
different symptomology than do men and often present with silent myocardial ischemia.  
However, in contrast to men who often report crushing chest pain during episodes of cardiac 
ischemia, women frequently present with what health care providers often term ‘atypical’ chest 
pain.  Women often report abdominal pain, persistent flu-like symptoms, shortness of breath as 
well as nausea and fatigue during periods of cardiac ischemia (McCormick & Bunting,   2002; 
Nicholson, 2007, p. 44).  This atypical presentation often results in misdiagnosis and delay in 
treatment which may in turn effect long-term outcomes (McSweeney et al., 2011).  However, 
researchers and clinicians should be cautious describing women’s symptoms as ‘atypical’ and 
work to redefine symptoms of heart disease to be inclusive.   
Women as caregivers.  In addition to sex specific factors, gender specific factors also 
play a role as to how women experience cardiovascular disease.  Research has shown that 
women wait longer with symptoms before seeking cardiovascular care (Nicholson, 2007).  A 
women’s delay in seeking care for CVD symptoms is often related to their role as wife, mother, 
and caregiver (Davidson et al., 2012).  When considering timing of cardiovascular interventions 
after preeclampsia it is important to contemplate a women’s role as new mother.  Women are 
often distracted caring for others, and put their own needs last; however, during the postpartum 
period they may be motivated to embrace lifestyle changes in order to promote the health and 
wellness of their family (Cusimano et al., 2014; Mosca et al., 2006; Seely et al., 2013).  Women 
are often faced with role strain as they struggle to care for family, often balancing work outside 
the home.  Having health care providers that honor mutuality in decision-making may improve a 
women’s willingness to access health care (Davidson et al., 2012).  The socially constructed 
roles of women are important to consider when attempting to understand preeclampsia’s 
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relationship to long-term cardiovascular risk as well as when creating interventions to protect 
against or treat cardiovascular disease in women who have had preeclampsia. 
Biomedical discourse.  Historically, uniquely female biologic experiences have been 
characterized by medical establishments as being a flawed state or a deficiency, resulting in 
medicalization (Hyde, Nee, Howlett, Drennan, & Butler, 2010).  This has occurred with 
menopause, which is more often considered a deficiency disorder by the medical community 
subsequently shaping the way women and health care providers view the biologic changes that 
accompany menopause (Hyde et al., 2010).  Many times women feel guilty after a preeclamptic 
pregnancy due to poor infant outcomes that are often associated with this disease and may feel 
overwhelmed when learning of their risk of CVD at such a young age (Seely et al., 2013).  
Although preeclampsia may in fact be an independent risk factor of cardiovascular disease, it 
will be important to acknowledge that pregnancy is not a “flawed” state and not allow medical 
discourse to shape a women’s childbirth experience (McCormick & Bunting, 2002).  Although it 
is important to recognize preeclampsia as a sex specific risk factor of CVD, nurses should use 
this an opportunity to empower women and advocate for improvements in their health and 
wellness as well as that of their family (McCormick & Bunting, 2002). 
Health Care Provider Awareness of Preeclampsia and Cardiovascular Disease  
As with CVD, in preeclampsia, when women are uneducated, they are often unaware of 
the signs and symptoms.  Additionally, the physical complaints associated with preeclampsia are 
often non-descript.  Because of this, health care providers often delay diagnosis and treatment 
(You, Wolf, Bailey, & Grobman, 2012).  In obstetrical patients, health care providers need to be 
encouraged to listen carefully to women when they call into the office with reports of vague 
complaints such as they are “just not feeling right.”  Health care providers in all settings tend to 
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minimize these reports, which are often missed opportunities for early evaluation and improved 
outcomes (Tsigas, 2006; Walsh, 2013).  A common theme of women’s experiences with both 
preeclampsia as well as cardiovascular disease is lack of recognition of symptomology by the 
medical community.  Only 60% of primary care providers are aware of up to date American 
Heart Association guidelines for prevention of CVD in women (Ehrenthal et al., 2013), similarly, 
physician’s awareness of preeclampsia as a risk factor for future cardiovascular disease is also 
low (Young, Hacker, & Rana, 2012).  These gaps in recognition, response, as well as education 
may occur due to gender bias that has been perpetuated through medical and health care texts 
which are often outgrowths of “male-centered medical research” (McCormick & Bunting, 2002, 
p. 823).  Nursing as a female dominated profession is ideally situated to bring voice to the gender 
specific disparities in the cardiovascular care of women (McCormick & Bunting, 2002). 
Pathophysiology of Preeclampsia 
In order to better understand possible shared risk factors between cardiovascular disease 
and preeclampsia an understanding of the hypothesized pathophysiology of preeclampsia is 
necessary.  Preeclampsia has been studied in biologic, immunologic, genetic and 
pathophysiologic research (Charlton, Tooher, Rye, & Hennessy, 2014; Founds et al., 2011; 
Ilekis, Reddy & Roberts, 2007).  The disease seems to be resultant from a complex interplay of 
maternal and fetal factors (Hermes et al., 2013).   
A common pathophysiologic theory of preeclampsia involves abnormal implantation of 
the placenta where trophoblasts insufficiently invade and remodel the uterine spiral arteries 
resulting in inadequate oxygen delivery to the fetus (Warrington, George, Palei, Spradley, & 
Granger, 2013).  What is causative of this maladaptation remains unclear.  It seems that the 
insufficient remodeling of the spiral arteries leads to ischemia, which in turn increases 
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angiogenic factors such as sFLT-1 and other inflammatory cytokines (Warrington et al., 2013).  
The release of these inflammatory factors into maternal circulation may result in fibrin 
disposition in the spiral arteries of the placenta, which can occlude blood to the fetus and result 
in FGR (Alpoim et al., 2011).  There is also a decrease in proangiogenic factors and an increased 
production of reactive oxygen species.  This in turn leads to maternal endothelial dysfunction 
(Warrington et al., 2013).  Subsequently, due to the increased production of endothelin-1 and 
decreased availability of nitric oxide, extensive vascular abnormalities occur in end organs such 
as the brain and kidneys, resulting in hypertension, neurologic disturbances and proteinuria 
(Warrington et al., 2013). 
Risk of CVD Based on Early Versus Late Onset Preeclampsia 
  Risk of CVD.  Globally, one in three women dies of cardiovascular disease (CVD).  
CVD presents itself differently in women than in men, and often goes undiagnosed, making early 
identification of risk factors integral to the prevention of increased morbidity and mortality 
(Rich-Edwards, Fraser, Lawlor & Catov, 2014).  Obstetric history is a unique risk marker in 
women that often goes unassessed (Spaan, Peeters, Spaanderman, & Brown, 2012).  Typically 
early onset preeclampsia has been associated with increased severity of symptoms as well as 
worse maternal and neonatal outcomes than its late onset counterpart (Boyd et al., 2013; van Rijn 
et al., 2013).  A large prospective study by Mongraw-Chaffin, Cirillo, & Cohn (2010) revealed 
that “cumulative cardiovascular disease death survival for women with early preeclampsia was 
85.9% compared to 98.3% for women with late preeclampsia and 99.3% for women without 
preeclampsia” (p.1).  Women with early onset disease have been shown to have a 7-8 fold 
increased risk of cardiovascular disease, whereas women with late onset disease have a twofold 
increase risk (van Rijn et al., 2013).  
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   Shared risk factors.  The link between pregnancy complications such as preeclampsia 
and future cardiovascular disease is not well understood.  Research has revealed shared risk 
factors between cardiovascular disease and preeclampsia.  Shared preeclampsia and CVD risk 
factors include increased prepregnancy lipids, triglycerides, BMI, as well as sub clinical 
elevation in blood pressure (Alsnes et al., Bushnell et al., 2014; 2014; Ray, Diamond, Singh & 
Bell, 2006; Rich-Edwards et al., 2014; Roberts, Bodnar, Patrick & Powers, 2011).  Other 
underlying CVD risk factors such as metabolic syndrome may also play a role in the 
development of preeclampsia (Founds et al., 2011; Smith et al., 2009).  Risk factors such as 
hypertension, diabetes and smoking seem to have more of an adverse effect on cardiovascular 
health in women and young people than in men and the elderly (Spaan et al., 2012).  In young 
women, favorable cardiovascular profiles resulted in an 80% reduction in cardiovascular 
mortality when compared to young women who had two or more cardiovascular risk factors 
(Spaan et al., 2012).  This points to the extreme importance of both primordial and primary 
prevention of cardiovascular disease in this group of women.  With an understanding that women 
with a history of preeclampsia are at higher risk of CVD later in life, research aimed at exploring 
novel risk factors shared between preeclampsia and CVD may be helpful.  Research may be 
helpful in revealing if pregnancy acts a stress test to expose women already at risk of CVD or 
rather if preeclampsia provides added physiologic stress that is in fact causal (Osol & Bernstein, 
2014).  Additional research aimed at revealing risk factors of preeclampsia may help to establish 
the relationship between pregnancy complications and chronic disease risk.  This in turn will 
help clinicians alter the health trajectories of women who have experienced pregnancies 
complicated by preeclampsia.  (Rich-Edwards et al., 2014).  
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      van Rijn (2013) and colleagues suggest that women with early onset preeclampsia had 
two or more independent cardiovascular disease risk factors in addition to their preeclampsia 
diagnosis.  These authors also observed higher BMI’s in women with early onset preeclampsia, 
however elevated BMI could only partially explain the increased cardiovascular risk associated 
with early onset preeclampsia.  In a recent study by Veerbeek et al. (2015), postpartum 
modifiable cardiovascular risk factors did differ by preeclampsia subtype: early, late, and 
pregnancy induced hypertension.  The early onset group had an overall less favorable CVD 
profile postpartum.  Specifically, there were significant differences in postpartum glucose and 
lipid levels in the early onset group.  Interestingly, both early onset and PIH groups had higher 
rates of hypertension postpartum than the late onset group (Veerbeek et al., 2015). 
Postpartum Pathophysiologic Effects of Preeclampsia 
      Hermes et al. (2013) stated that at 2.5 years postpartum, women with a history of 
gestational hypertension or late onset preeclampsia exhibit more cardiovascular risk factors and 
have higher risk of hypertension than women who had a normotensive pregnancy.  These 
cardiovascular risk factors included “higher waist circumferences; higher BMI; higher systolic 
and diastolic blood pressures; higher prevalence of metabolic syndrome; higher levels of 
biochemical risk factors, including glucose, HbA1c, insulin, insulin resistance (HOMA), total 
cholesterol, triglycerides, and hs-CRP; and lower levels of high density lipoprotein (HDL) 
cholesterol” (Heremes et al., 2013, p.  474.e5).   
Endothelial dysfunction.  Endothelial dysfunction has been proposed to be a key factor 
in the pathophysiology of preeclampsia and may be the link between preeclampsia and long-term 
cardiovascular risk (Sandvik et al., 2013).  Soluble fms-like tyrosine kinase (sFlt-1), and 
placental growth factor are antiangiogenic factors produced by the placenta, and may cause the 
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endothelial dysfunction that results from preeclampsia.  Women with a history of preeclampsia 
have been shown to have markers of endothelial dysfunction one year after the index pregnancy.  
These markers of endothelial dysfunction were shown not to normalize until 11 years after the 
index pregnancy (Oslund et al., 2013).  Lao (2014) suggests that in preeclampsia there is a 
decrease in endothelium-dependent dilatation.  Vascular alterations, such as increases in the 
thickness of the carotid intima-media, result in alterations in blood pressure such as “higher 
brachial diastolic pressure, central systolic pressure, mean arterial pressure (MAP), and 
peripheral vascular resistance (PVR)” (Lao, 2014,  p.250).  Aykas et al. (2015) also found that 
alterations in the vascular structure and function associated with preeclampsia persisted after the 
index pregnancy.  Melchiorre, Sharma, &  Thilaganathan, (2014) reported that major adverse 
cardiovascular events occur at much higher rates in pregnancies affected by preeclampsia and 
risk of stroke and myocardial infarction remains significant for >/= three years postpartum.  
Although Oslund (2013) found normalization in endothelial dysfunction, women with a history 
of preeclampsia remained at higher risk for dysrhythmias, heart failure as well as cardiac death.   
Cardiac changes.  In addition to vascular changes, cardiac changes have also been 
shown to occur in patients with preeclampsia.  In late onset preeclampsia, women had left 
ventricular remodeling as well as myocardial damage, whereas women with early preeclampsia 
seem to have more severe cardiac impairment, and in both groups, severe dysfunction and left 
ventricular hypertrophy could still be found at 1 year postpartum although higher rates were 
noted in the early onset group (Lao, 2014).  In women who delivered preterm (<34) with 
preeclampsia, risk of cardiac death was even greater.  In these women with early preeclampsia, 
one in seven would die from a cardiac event within three decades of delivery (Mongraw-Chattin 
et al., 2010).   
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Shared Pathway CVD and Preeclampsia 
In order to bring light to the disparities in the cardiovascular care of women, gender 
specific cardiovascular risk factors must be explored.  Although much research supports the link 
between preeclampsia and future CVD, the mechanism which connects the two is not clear.  
Scantlebury and Hayes (2014) propose several different pathways by which preeclampsia may 
increase risk of CVD 
1) Increased risk of  metabolic syndrome 
2) Persistent endothelial dysfunction 
3) Common underlying risk factors 
4) Altered myocardial structure and function 
5) Renal disease  
6) Other non-classic risk factors 
 
 Non-classic biomarkers 
 A variety of biomarkers have been explored with an aim at improving prediction of 
preeclampsia.  Visser et al. (2014) completed a metanalysis and systematic review of the 
literature looking at novel biomarkers that may predict cardiovascular risk.  Due to the suggested 
common pathophysiology between cardiovascular disease and preeclampsia, Visser et al. (2014) 
hoped to better elucidate if these biomarkers could aid in preeclampsia prediction.  The 
biomarkers which these authors reviewed included:  
“inflammation (intercellular adhesion molecule [ICAM], vascular cell adhesion molecule 
[VCAM], interleukin-6 [IL-6], interleukin-10 [IL-10], and E-selectin), thrombosis 
(homocysteine, von Willebrand factor [VWF], fibrinogen, fibronectin, endothelin, D-
dimer, plasminogen activator inhibitor-1 [PAI-1], tissue plasminogen activator [tPA]), and 
angiogenesis (vascular endothelial growth factor [VEGF], soluble Fms-like tyrosine 
kinase-1 [sFLT-1], and tumor necrosis factor alpha ([TNF-a])” (Visser et al., 2014, p. 
373e2). 
 
The authors broke these biomarkers into categories, those that effected inflammation, 
thrombosis, and angiogenesis (Visser et al., 2014).  Levels of some of the specific biomarkers 
listed above are unique based on blood type.  Although these authors did not find significant 
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differences in thrombotic biomarkers such as von Willebrand factor and fibrinogen in their 
review, previous studies have revealed a shared pathophysiology between thrombosis and 
preeclampsia and elevated levels of these markers in preeclamptic women.  This shared pathway 
could explain the restriction of blood flow and reduced placental perfusion noted in preeclampsia 
(Visser et al., 2014).  It has been shown that levels of VWF as well as other biomarkers vary 
based on blood type (Franchini & Lippi, 2015).  Thusly, it is biologically plausible that ABO 
blood type may mediate the development of preeclampsia (Alpoim et al., 2013).  Additionally, 
since preeclampsia influences risk of future cardiovascular disease and ABO blood type has been 
implicated in the development of both disease processes, this relationship must be further 
explored.  
Review of the Literature: Preeclampsia and ABO Blood Type 
Introduction 
      Preeclampsia effects 3-8% of all pregnancies (Hutcheon et al., 2011).  It is a global issue 
and is related to significant maternal and neonatal morbidly and mortality.  Rates of 
preeclampsia have risen by 25% in the past two decades in the United States and it is listed as a 
major contributor to prematurity (Ferrazzani et al., 2011; Wallis et al., 2008).  Mothers 
diagnosed with preeclampsia have increased risk of poor short and long-term outcomes 
(Bushnell et al., 2014).  Preeclampsia has been called the disease of theories and the 
pathophysiology has yet to elucidated (Founds et al., 2011).  It is hypothesized that different 
subtypes of the disease may exist.   
Preeclampsia is defined by ACOG (2013) as the new onset of hypertension >/=140mm 
Hg systolic or >/=90mmHg diastolic after 20 weeks gestation, and proteinuria (>/=300mg in a 
24-hour urine collection) or in the absence of proteinuria, platelets < 100,000 microliter, serum 
creatinine > 1.1 or doubling of serum creatinine in the absence of renal disease, and elevated 
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concentrations of blood liver transaminases to twice normal levels.  When preeclampsia is 
diagnosed prior to 34 weeks in pregnancy it is defined as early onset preeclampsia, when 
occurring on or after 34 weeks gestation it is defined as late onset preeclampsia (Lisonkova, & 
Joseph, 2013).  Typically early onset preeclampsia has been associated with increased severity of 
symptoms and more severe maternal and neonatal outcomes than late onset preeclampsia (Boyd 
et al., 2013; van Rijn et al., 2013).  ACOG (2013) recently called for more research into the 
subtypes of preeclampsia in order to better determine if each subtype has a unique 
pathophysiology or set of risk factors thus requiring tailored therapies and interventions.   
Preeclampsia and Cardiovascular Disease 
       Previously it was thought that preeclampsia was in fact cured by the imminent delivery of 
the baby.  However, more recently, research has begun to support that preeclampsia is linked to 
long-term risk of cardiovascular disease in affected women (Firoz & Melnik, 2011; Fraser et al., 
2012; Hermes et al., 2013; Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al., 2013).  The 
risk seems to be further increased in women with early onset preeclampsia.  Women who were 
previously affected by early onset preeclampsia have been shown to have a 7-9 fold increased 
risk of cardiovascular disease.  Women with late onset preeclampsia has been shown to impart a 
twofold increased risk of cardiovascular disease later in life in those who have been previously 
affected (van Rijn, et al., 2013).  
Currently, no evidenced based cardiovascular risk reduction programs have been 
designed for women with preeclampsia, nor have screening strategies been created (ACOG, 
2013; Firoz & Melnik, 2011).  Although traditional cardiovascular interventions may be used, 
there is no evidence to support their efficacy in women with preeclampsia (Firoz & Melnik, 
2011).  More research is needed to identify variables, which may increase a woman’s risk for 
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preeclampsia, so prediction, prevention and treatment of preeclampsia can be improved.  
Additionally, we continue to look for what mechanisms connect hypertensive disorders of 
pregnancy to chronic cardiovascular disease later in life in women with a history of preeclampsia 
so that cardiovascular interventions can be tailored to this population (Scantlebury, & Hayes, 
2014).  The following review of literature will explore the link between maternal ABO blood 
type and preeclampsia.  
 Blood Type, Preeclampsia and CVD 
In the early twentieth century scientist, Karl Landsteiner discovered the ABO blood 
phenotype, which was the first genetic polymorphism detected in humans (Etemadi et al., 2015; 
Franchini & Liumbruno, 2013).  There are four ABO blood phenotypes, A, B, AB, and O.  
Today ABO blood type is used in far more than in transfusion medicine alone (Franchini & 
Lippi, 2015).  ABO blood type can be the cause of illness such as the case in hemolytic disease 
of the fetus and the newborn, or in case of hemolytic reactions that occur after transfusion or 
transplantation (Franchini, & Liumbruno, 2013).  ABO blood type has been shown to increase 
the incidence of some disease processes, such as cardiovascular disease, cancer, venous 
thrombus and resistance against certain pathogens (Hiltunen et al., 2009; Phaloprakarn & 
Tangjitgamol, 2013; Seyfizadeh et al., 2014; Than et al., 2011).  With the known link between 
cardiovascular disease and preeclampsia blood type may be a biologically plausible moderator.  
There has also been literature to suggest a correlation between maternal blood type and 
preeclampsia.  However, no current literature explores the correlation between ABO type blood 
and preeclampsia subtype as currently defined by ACOG (2013).  Pike & Dickins (1954) first 
looked into the relationship between a woman’s blood type and preeclampsia and found that 
women with type O blood may be at increased risk for developing preeclampsia.  More recently, 
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several other authors continue to support the relationship between blood type and preeclampsia, 
however, these authors have pointed to women with non-O blood types as being at increased risk 
of preeclampsia.  Phaloprakarn & Tangjitgamol (2013) as well as other authors hypothesized that 
the correlation between non-O blood phenotypes such as A, B and AB and preeclampsia may be 
related to the fact that VWF is higher in non-O blood phenotypes, increasing the risk of 
thrombus (Alpoim et al., 2012; Alpoim et al., 2011).  More research is necessary in order to 
better elucidate if different subsets of preeclampsia require different treatment and follow up and 
if different racial and ethnic populations are at increased risk of preeclampsia related to blood 
type distribution.  The purpose of this author’s dissertation research will be to explore the 
association between maternal blood type and preeclampsia subtype with an aim at improving 
identification and screening of those at increased risk for future cardiovascular disease as well as 
improving prediction, . 
Methods Used to Conduct This Review 
Search for Evidence 
      In order to identify literature relevant to preeclampsia and ABO blood phenotype CINAHL, 
The Cochrane Collaboration and PubMed databases were searched.  These databases were chosen 
due to their inclusion of academic nursing, medical and allied health journals, books and other 
scholarly texts.  The following keywords were used in the review ABO blood group, Rh factor, 
preeclampsia, and gestational hypertensive disorders. 
Inclusion and Exclusion Criteria 
      Inclusion criteria include (a) research conducted on pregnant human subjects, (b) in 
English (c) published between January 2000 and January 2016 (d) in academic, peer reviewed 
journals.  This time frame was used for the search due to the limited number of results returned 
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using a five year search window.  Dissertations, letters to the editor, and other unpublished works 
were not included in the search, nor were solitary case studies.  The initial search yielded 11 
results, and the abstracts were reviewed to assess if each article met the aim of the review.  One 
additional article was found when searching gestational hypertensive disorders and ABO blood 
group.  The reference pages of selected articles were then reviewed to identify if there were other 
articles that may not have been revealed in the original search.  One additional article was 
identified.  Prior to completing the dissertation, the literature was searched in order to ensure the 
review was up to date, one additional article was added to the review.  Subsequently, fourteen 
articles were included in the review.  
Compilation of Evidence 
Table of Evidence 
      The research literature was reviewed, synthesized and leveled using The U.S Preventive 
Task Force Levels of Evidence (Appendix A).  A table of evidence was created (Appendix B).  
The table includes information on title, author name as well as level of evidence, aim of the 
research, sample size, results and strengths and limitations of each study.  All fourteen articles 
are quantitative in nature and are one of the following designs, three systematic review and meta-
analysis, five case-control studies, five cohort studies, and one cross-sectional design.  These 
designs were appropriate for this review, experimental designs, such as randomized control trials 
do not lend themselves to this area of study. 
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Critical Appraisal of the Evidence 
Synthesizing the Evidence 
     Maternal blood type.  Hiltunen et al. (2009) reported that non-O blood group was not 
associated with preeclampsia; however, AB blood group was associated with higher rates of 
subgroups of preeclampsia such as early and severe as well as preeclampsia with FGR.  These 
authors reported that O blood type was protective of pre-eclampsia with FGR (P=0.03) and in 
their study came close to significance in the early pre-eclampsia group (P=0.08) (Hiltunen et al., 
2009).  Lee, Zhang et al. (2012) stated that women with AB blood type had a higher incidence of 
gestational hypertensive disorders, while blood group O had the lowest odds of both 
preeclampsia and severe preeclampsia.  Than et al. (2011) agreed, and reported that maternal 
blood groups may be helpful in early assessment of those pregnancies at risk of IUGR.  
Conversely, Alpoim et al. (2011) found that in their population, O and non-O blood types did not 
differ in frequency between preeclamptic and normotensive pregnancies.  In a meta-analysis, 
Clark & Wu (2008) reported similar results to Alpoim et al. (2011).  In another meta-analysis, 
Alpoim et al. (2013) suggest that maternal type AB blood increased risk for preeclampsia.  While 
Phaloprakarn & Tangjitgamol, (2013) stated a 1.7 fold increased risk of preeclampsia for patients 
with A and AB blood types.  Hentschke and colleagues (2014) also reported no difference in 
blood group distribution between preeclampsia and normotensive women.  There is varied 
evidence on the correlation between maternal blood type and preeclampsia.  More research is 
needed to clarify the association, as each study had differing population characteristics and were 
done on patients of varying ethnicities.  
ABO blood type and ethnicity.  Genetic variants of ABO blood types have been shown 
to be predictive of risk of hypertension in certain cultures in non-pregnant clients (Gasso et al., 
2012).  Distribution of blood group varies based on ethnicity (Hiltunen et al., 2009).  There are a 
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limited number of studies found in the literature exploring the link between maternal blood type 
and preeclampsia diagnosis; this makes it difficult to ascertain the link between blood type and 
preeclampsia.  The research reviewed was completed using various ethnic groups including the 
Thai, Hungarian, Turkish, Scottish, Finnish, Swedish, Iranian, Ecuadorian and Brazilian 
populations (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et al., 2009; Lee, Zhang et al., 
2012; Phaloprakarn & Tangjitgamol, 2013; Seyfizadeh et al., 2014).  Phaloprakarn & 
Tangjitgamol (2013) found that in the Thai population women with A or AB blood types had 
higher rates of preeclampsia.  Type O blood type is the most common blood type found in both 
the Thai population as well as the United States, whereas A is more common in both Japan and 
other European countries (Phaloprakarn & Tangjitgamol, 2013).  None of the studies reviewed 
used American participants, which is an identified gap in the literature.  
      Von Willebrand Factor and FVIII.  Differing ABO blood groups are associated with 
varying plasma concentrations of Von Willebrand Factor (VWF) and FVIII (Than et al., 2011).  
Plasma levels of VWF increase by blood type in the following order O>A>B>AB (Alpoim et al., 
2013).  “Mediators of endothelial cell dysfunction, including relative nitric oxide deficiency, 
fibronectin, von Willebrand factor, cell adhesion molecules, and cytokines, are upregulated in 
preeclampsia” (Bilhartz et al., 2011, p.696).  VWF is a marker of hypercoagulability and may 
mediate platelet adhesion to the vessel wall particularly at sites of vascular injury (He et al., 
2012).  Since preeclampsia has been associated with fibrin disposition in the placental 
microvasculature it may be important to examine the role VWF plays in the development of the 
disease (Alpoim et al., 2011).  ADAMTS13 is shown to remove VWF from circulation, in a 
deficiency of this substrate, VWF levels may rise, increasing the risk of thrombosis in the small 
vessels (Alpoim et al., 2011).  Alpoim et al. (2013) showed that subjects with AB blood type had 
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higher levels of VWF as well as FVIII resulting in increased risk for thrombus formation.  
However, when comparing O and non-O blood types, Alpoim et al. (2011) did not find differing 
levels of ADAMTS13 levels.  Finally, after correction for FVIII levels, Witsenburg and 
colleagues (2005) did not find any difference between ABO blood types in terms of risk of 
pregnancy complications such as hypertensive disorders of pregnancy and IUGR. 
 Platelets.  Pregnancy is a hypercoagulable state; it is hypothesized that in preeclampsia 
there is a deviation in the communication between the inflammation and coagulation cascades 
(Han et al., 2014; Rich-Edwards et al., 2014).  Preeclampsia diagnostic criteria list platelet count 
as >100,000 per microliter  in combination with blood pressure parameters as diagnostic of 
preeclampsia (ACOG, 2013) and in high risk women aspirin therapy is recommended for 
preeclampsia prevention (LeFevre, 2014).  Platelets are formed from megakaryocytes in the bone 
marrow and referent levels indicate a balance in homeostasis and thrombosis.  The imbalance 
that results between coagulation and anticoagulation factors in preeclampsia patients can result in 
poor placental and maternal end organ perfusion due to microthrombosis (Han et al., 2014).  In 
addition to increasing coagulation, the increased platelet activation that occurs in preeclampsia 
may also mediate inflammation (Gonçalves Freitas et al., 2014). 
Blood type antigens A and B are expressed on platelets (Lee, Zhang et al., 2012).  
Alpoim et al. (2011) postulated that the increased levels of Ultra Large VWF (ULVWF) seen in 
preeclamptic patients might be related to occlusion of the renal and placental arterioles that often 
occurs in this disease process.  Interestingly, platelets do not adhere to smaller forms of VWF in 
the circulation after ULVWF binds to ADAMTS13.  This may result in platelets blocking the 
microvascular of the placenta (Alpoim et al., 2011).  Hiltunen et al. (2009) hypothesized that the 
effect blood type has on preeclampsia could be mediated by prothrombitic mechanisms.   
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     PP13.  Than and colleagues (2011) hypothesized that ABO blood type may influence 
gene and environment interactions due to how it functions at what they deem the “cross-roads” 
of the immune and coagulation systems (p. e21564).  PP13 is a galectin, which functions at this 
crossroads and may be available in varying amounts in different blood groups (Than et al., 
2011).  Upon exploration, Than et al. (2011) reported that PP13 is an early marker for 
preeclampsia.  PP13 is produced by the placenta however, is released into maternal circulation 
and works to bind other galactosides found on the ABO blood group antigen (Than et al., 2011).  
It is thought that in severe preeclampsia, PP13 may be more readily shed.  This in turn may result 
in a maternal immune response, which is a suggested pathophysiologic basis for preeclampsia 
(Lee, Zhang et al., 2012).  In their study, Than et al. (2011) state that women with B blood type 
had the highest serum levels of PP13 in all trimesters of pregnancy however, in this blood type, 
red blood cells had the weakest ability to bind to PP13 (Than et al., 2011).  In contrast, AB blood 
type had the lowest serum levels of PP13 in the first trimester suggesting that PP13 more readily 
binds to certain ABO antigens altering serum-circulating levels.  Than et al. (2011) stated that 
the proportion of individuals with AB and B blood type were low in their study so they could not 
adequately evaluate their association with risk of preeclampsia however, this study reveals that 
ABO antigens may play a unique role in preeclampsia risk by regulating the serum availability of 
other biomarkers (Than et al., 2011).  
      Factor V Leiden.  Both Factor V Leiden (FVL) and blood group are common heritable 
influences, which may affect thrombotic risk (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et 
al., 2009).  Other research has shown that FVL may be influenced by the inheritance of a non-O 
blood type (Hiltunen et al., 2009).  FVL has been associated with preeclampsia in previous 
studies (Clark et al., 2007; Hiltunen et al., 2009).  Hiltunen et al. (2009) report an increased risk 
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for preeclampsia in those with FVL and FVL or FII G20210A combined, although this was not a 
statistically significant increased risk.  In a study by Clark et al. (2007), there was no influence of 
either FVL or non-O blood type on risk of preeclampsia.  Subsequently, based off their study, 
Clark et al. (2007) do not recommend routine screening for FVL to assess for risk of thrombotic 
events such as preeclampsia.  
Interaction between blood type and other factors.  Alpoim et al. (2013) and Than et al. 
(2011) both report that how various blood types interact with different biologic and hemostatic 
factors may be what increases risk of thrombotic disease in these patients.  Phaloprakarn & 
Tangjitgamol (2013) suggest that tumor necrosis factor-alpha and intracellular adhesion 
molecule 1 tend to be more readily up regulated by the A allele, possibly increasing risk of 
preeclampsia in both the A and AB blood type.  Seyfizadeh et al. (2014) reported that serum 
creatinine levels were significantly higher in AB blood type women in their sample.  Since 
elevated creatinine is a known risk factor for preeclampsia, it is possible that blood type has an 
association with certain preeclampsia risk factors.  Additionally, Lee, Zhang et al. (2012) 
propose that each ABO blood type may have differing rates of occurrence of certain 
cardiovascular risk factors such as hypocholesteremia, insulin resistance and endothelial damage 
that subsequently increase risk of preeclampsia. 
Rh factor.  Lee, Zhang et al. (2012) discovered that Rh positive women also have a 
slightly increased risk of developing preeclampsia than their Rh negative counterparts (Lee, 
Zhang et al., 2012).  Sezik and colleagues (2002) reported in their study, that subjects with O 
negative blood had a higher risk of HELLP syndrome than other blood types.  This risk was not 
reported in women with type O blood independent of Rh type (Sezik et al., 2002).  These authors 
postulated that the Rh antigen or Rh incompatibility might be important factors in the 
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development of this most severe form of preeclampsia.  They also hypothesized that the 
increased antibody load in O negative individuals could play a role in the increased incidence of 
HELLP syndrome seen in this population (Sezik et al., 2002).   
Than et al.  (2011) did not report any difference in the bioavailability of PP13 based on 
Rh type; no difference was still reported even when assessing levels of PP13 by ethnicity.  
López-Pulles et al. (2010) also found no difference in rates of preeclampsia between Rh negative 
and Rh-positive women in their study.   
Summary of Research Conclusions 
 Implications on Clinical Practice 
      Identification of risk factors specific to preeclampsia may allow clinicians to better 
understand the pathophysiology of the disease, and create an effective risk factor algorithm to 
identify women at risk for preeclampsia prior to conception (Alpoim et al., 2012).  Globally, 
preeclampsia is associated with increased morbidity and mortality.  Identifying biomarkers that 
promote early detection as well improve scientists understanding of the pathophysiology of 
preeclampsia is necessary in order to improve outcomes (Alpoim et al., 2011).  Alpoim et al. 
(2011) suggests that monitoring FVIII, VWF and ADAMTS13 may be relevant.  Phaloprakarn & 
Tangjitgamol (2013) suggest that tumor necrosis factor-alpha and intracellular adhesion 
molecule 1 tend to be more readily up regulated by the A allele.  These inflammatory markers 
have also been associated with cardiovascular disease, further pointing to blood type as a 
mediator between the two disease processes.  
As research continues to advance the science surrounding preeclampsia and with work 
toward prophylaxis, the idea of a specific screening algorithm is alluring (Jørgensen, Hedley, 
Gjerris, & Christiansen, 2014).  With this said, it is important to create an algorithm that has a 
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high detection rate and low false positive rate (Jørgensen, et al., 2014).  Research on biochemical 
markers such as ABO blood type should continue, in order to reach scientific consensus as to 
whether or not blood group would be a valuable addition to a screening algorithm.  A screening 
algorithm could allow for early recognition of patients at risk for preeclampsia, providing 
practitioners with the opportunity to utilize prophylaxis or increase antepartal monitoring in 
order to improve pregnancy outcomes.  Finally, even if ABO Blood type is not significantly 
different between preeclampsia subtypes, collection of data on various biomarkers by 
preeclampsia subtype may help to clarify or refute potential etiologic pathways (Myatt et al., 
2014). 
Limitations of the Review 
      Overall, there were a limited number of studies that have examined the association between 
blood type and preeclampsia.  Many of the studies reviewed were retrospective in nature which 
may not allow for identification of potential confounders (Polit & Beck, 2012).  Additionally, 
many of the studies had relatively small sample sizes and were completed on diverse ethnic 
populations.  Since blood type varies by ethnicity, results are difficult to compare (Hiltunen et al, 
2008; Lee, Zhang et al, 2012; Than et al., 2011).  In 2013, there was a change in preeclampsia 
diagnostic criteria (ACOG, 2013).  Due to the differing diagnostic criteria utilized as well as 
definitions of subtypes utilized, it is difficult to compare studies.  Finally, none of the studies 
included information on neonatal and paternal blood type.  Due to a postulated immunologic 
pathophysiology of preeclampsia, an interaction between fetal and/or paternal antigens and 
maternal ABO blood phenotype could also play a role in preeclampsia development.  
Review of Literature: Cardiovascular Disease and ABO Blood Type 
Introduction 
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Cardiovascular disease is a complex disease with a variety of risk factors (Lee, Lin et al., 
2012).  Cardiovascular disease is a vexing problem in the United States and around the globe.  
Thirty seven percent of deaths of women in the United States are said to be related to 
cardiovascular disease (Freibert, Mannino, Bush & Crofford, 2011).  Scientists and health care 
providers continue to look for risk factors, which may improve early identification and treatment 
of those at risk.  Since ABO blood type has been linked to increased susceptibility to certain 
disease processes, such as preeclampsia and has been associated with varying levels of clotting 
factors that increase risk of thrombus formation and cardiovascular risk it is important to explore 
further explore this association (Jassim, 2012).   
Having a non-O blood type has been associated with nearly 6% of total deaths and as 
many as 9% of cardiovascular deaths (Etemadi et al., 2015; Franchini, & Liumbruno, 2013).  
Lee, Lin et al. (2012) postulated that since ABO blood type is inherited and premature coronary 
artery disease is often linked to inherited risk factors, ABO blood groups could mediate this risk.  
It is well established that ABO blood type increases risk of venous thrombus as ABO antigen 
expression determines levels of VWF and FVIII (Franchini & Lippi, 2015).  Individuals with O 
blood types have 25% increased rates of VWF and FVIII, which is often protective of venous 
thrombus (Franchini & Lippi, 2015).  Many studies suggest that the affect ABO blood type has 
on both hemostasis and plasma lipid levels influence other cardiovascular outcomes such as 
myocardial infarction and coronary heart disease (Franchini & Lippi, 2015).  Accordingly, the 
following review of literature was completed in order to explore research on the relationship 
between ABO blood type and poor cardiovascular outcomes.  
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Methods Used to Conduct This Review 
Search for Evidence 
      In order to identify literature relevant to cardiovascular disease and ABO blood 
phenotype CINAHL and PubMed databases were searched.  These databases were chosen due to 
their inclusion of academic nursing, medical and allied health journals, books and other scholarly 
texts.  The following keywords were used in the review, ABO blood group and cardiovascular 
disease. 
Inclusion and Exclusion Criteria 
      Inclusion criteria were research conducted (a) on human subjects (b) age 19 and older, 
(c) in English (d) published in the past five years, (e) in academic, peer-reviewed journals.  
Dissertations and other unpublished works were not included in the search, nor were solitary 
case studies.  The initial search yielded 75 results, and the abstracts were reviewed to assess if 
each article met the aim of the review.  All articles included in the review used stroke, 
cardiovascular disease or atherosclerosis as the main outcome.  Fourteen met the inclusion 
criteria for this literature review.   
Compilation of Evidence 
Table of Evidence 
      The research literature was reviewed, synthesized and leveled using The U.S Preventive 
Task Force Levels of Evidence (Appendix A).  A table of evidence was created (Appendix C).  
The table includes information on title, author name as well as level of evidence, aim of the 
research, sample size, results and strengths and limitations of each study.  All fourteen articles 
are quantitative in nature and are one of the following designs; one meta-analysis, six case-
control studies, five cohort studies, and two cross-sectional design.  These designs were 
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appropriate for this review, experimental designs, such as randomized control trials do not lend 
themselves to this area of study, as you cannot ethically manipulate blood type. 
Critical Appraisal of the Evidence 
Synthesizing the Evidence 
ABO blood type.  Gong et al. (2014b) found that having type A blood was significantly 
associated with cardiovascular disease even after adjustment for common cardiovascular risk 
factors.  Additionally, type A blood was associated with more severe coronary atherosclerosis 
than other blood types (Gong et al., 2014b).  Lee, Lin et al. (2012) reported in their study that 
participants with type A blood had significantly higher rates of coronary artery disease (CAD) as 
well as CAD that was more severe than in those with other blood types.  This study also revealed 
type A blood to be an independent risk factor for both men and women with early onset CAD 
(Lee, Lin et al., 2012). 
Etemadi et al. (2015) reported that those with non-O blood types had increased risk of 
total mortality, with most mortality being attributable to cardiovascular disease.  In their 
metanalysis, He et al. (2012) noted a statistically significant difference in rates of CAD between 
blood groups, reporting that non-O subjects where at a significantly higher risk of developing 
coronary heart disease than those with an O blood type.  Chen et al. (2014) also reported an 
association between non-O blood type and significant CAD although when analyzed by sex, the 
association was significant in men but not in women in their sample.  Gong et al. (2014b) 
discovered that non-O blood types were an independent risk factor for CAD and MI. 
Of all blood types, AB had the highest risk of CHD, followed by blood groups B and A 
(He et al., 2012).  This risk remained, even after adjusting for other cardiovascular risk factors 
and when excluding diabetic patients (He et al., 2012).  Karabuva, Carević, Radić, and Fabijanić 
 46 
 
(2013) described that coronary artery disease occurred more often in males less than age 50 with 
type AB blood.  A study by Zakai and colleagues (2014) discovered similarly, stating that AB 
blood type is a risk factor for stroke even after adjustment for age and race.  On the contrary, in 
their study population of Bengali East Indians, Biswas et al. (2013) discovered that participants 
with AB blood type had decreased rates of coronary heart disease, compared with those with 
type O blood.  In the review, only one study, Sode, Allin, Dahl, Gyntelberg, and Nordestgaard 
(2013) did not find an association between myocardial infarction and blood type.  
Rh factor.  Only two studies in the review included Rh factor as a variable.  When 
studying Turkish participants, Etemadi et al. (2015) found no association between Rh factor and 
CVD, even when assessing for interaction between Rh factor and ABO blood type, no interaction 
effect was noted.  In their metanalysis He et al. (2012) also did not find an association between 
Rh status and poor cardiovascular outcome.  
ABO as a mediator of CVD.  Several studies performed mediation analysis in order to 
assess the role ABO blood type plays in mediating risk of CVD (Gong et al., 2014a; He et al., 
2012).  He et al. (2012) noted an interaction effect between BMI and ABO blood type.  In obese 
or overweight non-O blood type women, blood type had a stronger relationship to CHD risk than 
in those women with BMI <25.  This interaction was not seen in men (He et al., 2012).  Gong et 
al. (2014a) explored CRP as an inflammatory mediator to CAD and MI. Gasso et al. (2014) 
found that ABO blood type might predict ACE plasma activity, which in turn could mediate 
CVD risk.  The relationship between ACE plasma activity and blood type could prove relevant 
when designing risk models used to predict hypertension or when determining efficacy of ACE 
inhibitor pharmacotherapy (Gasso et al., 2014).  Finally, since ABO antigens are also expressed 
on platelets, which play a role in both coagulation and inflammation, platelets may be an 
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important mediator of association between blood type and cardiovascular risk (Karabuva, 
Carević, Radić, & Fabijanić, 2013).  Sode et al. (2013) reported that reduced activated partial 
thromboplastin time was seen in non-O versus O blood type, which further supports the role of 
coagulatory factors as mediator of cardiovascular risk.  
Cardiovascular risk factors.  Research has explored the link between ABO blood type 
and traditional cardiovascular risk factors.  As described above He et al. (2012) revealed that 
BMI mediated CHD risk.  In a study by Gong and colleagues (2014b), participants with blood 
group O had less traditional cardiovascular risk factors then those with blood type A and more 
severe coronary lesions.  Conversely, Jassim (2012) found in their study that blood group O had 
higher levels of glucose, total cholesterol and higher blood pressures.  Biswas et al. (2013) 
reported that just over 28% of participants with O blood type had a family history of 
cardiovascular disease.  
 Karabuva, Carević, Radić, and Fabijanić (2013) found that in the participants they 
studied with coronary artery disease, those with type B blood had lower HDL levels but did not 
find any difference in self-reported CAD risk factors among all blood types.  Finally, Zakai et al. 
(2014) reported that participants with blood type AB had higher rates of diabetes than all other 
blood types; however, this association was non-significant when adjusted for race.   
Cardiovascular pathogenesis.  Each of the studies explored different cardiovascular end 
outcomes.  Some explored acute cardiovascular events such as MI, while other studies looked at 
CAD as a chronic inflammatory process.  Karabuva, Carević, Radić, and Fabijanić (2013) 
explored coronary artery disease as a chronic inflammatory process and discovered there to be no 
relationship between ABO blood type and magnitude of atherosclerotic lesions.  These authors 
also reported no significant difference in distribution of ABO blood types among patients with 
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CAD versus healthy controls nor was there any difference in distribution of cardiovascular risk 
among blood types (Karabuva, Carević, Radić, & Fabijanić, 2013).  Due to the known increased 
levels of VWF by blood type and subsequent risk of venous thromboembolism, Sode et al., 
(2013) also explored the interaction between ABO blood type, FVL and prothrombin mutations.  
Sode et al. (2013) discovered that there was not a consistent association between ABO blood 
type and MI.  Other studies in this review have suggested a link between more acute 
cardiovascular events and blood type, particularly cardiac events that occur at a younger age and 
in women (Lee, Lin et al., 2012).  
Genetic factors.  In a recent Genome Wide Association Studies (GWAS) Reilly et al. 
(2011) set out to determine what genetic factors predispose participants to plaque rupture or 
myocardial infarction in participants with coronary atherosclerosis versus coronary disease 
without plaque rupture or MI. ABO was identified as a locus for MI in patients who had 
identified angiographic CAD (Reilly et al., 2011).  Reilly and colleagues (2011) reported that 
“ABO GWAS signal for myocardial infarction in patients with angiographic CAD is mediated 
by the glycotransferase-deficient isoform that encodes the ABO blood group O phenotype” (p. 
7).  Subsequently, the higher risk of thrombus at time of MI in non-O blood types, even in those 
with less extensive atherosclerotic plaques, seems to be a related to an interaction between non-O 
ABO glycotransferase activity and coronary thrombus rather than atherosclerosis (Reilly et al., 
2011).  Thus, in patients with angiographic CAD, blood type O is protective of MI.  With an 
understanding of the genetic loci that exist for CAD, Wauters et al. (2013) took the work of 
Reilly and colleagues (2011) further and explored genetic variants of CAD.  With an 
understanding that the development of CAD is heritable and complex, there may be genetic 
factors that overlap and subsequently mediate different pathologic cardiovascular outcomes.  . 
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Inflammation.  ABO antigens are expressed on endothelial cells and platelets, and play a 
role in motility, adhesion and proliferation of these cells (Karabuva, Carević, Radić, & Fabijanić, 
2013).  Subsequently, ABO antigens play a role in the inflammatory process.  Gong et al. 
(2014a) report a higher prevalence of systemic inflammation in non-O blood types.  Recent 
GWAS have linked the ABO locus to “circulating levels of soluble intercellular adhesion 
molecule-1, soluble P-selectin, soluble E-selectin, and angiotensin-converting enzyme” 
(Karabuva, Carević, Radić, & Fabijanić, 2013, p.  351). Interleukin-6 (IL-6) and tumor necrosis 
factor (TNF) have also been found to be mediators between blood type and cardiovascular 
disease (Gong et al., 2014a).  Gong et al. (2014a) discussed the association between the ABO 
gene and C-reactive protein which is a marker of inflammation often elevated in CAD and MI.  
C-reactive protein was found to be higher in non-O blood types and mediated the risk of CAD 
and MI, in these blood types (Gong et al., 2014a).   
Cholesterol.  Genetic studies have revealed that ABO blood types are inherited from 
chromosome 9 locus 9p34 (Gong et al., 2014b).  This chromosomal locus controls cholesterol 
balance and non-O blood types have increased cholesterol absorption (Chen et al., 2014; Gong et 
al, 2014b; Lee et al., 2012).  Other GWAS studies have shown differing levels of plasma lipids 
based off blood type, and a recent study estimated that 10% of CHD risk in non-O blood types is 
mediated by low-density lipoprotein cholesterol levels (Chen et al., 2014; Etemadi et al., 2015).  
Thusly, ABO blood types influence on cardiovascular disease may be mediated at least in part by 
cholesterol (Chen et al., 2014).  Chen et al (2014) found that those with O blood types had lower 
levels of total cholesterol and LDL cholesterol than all other blood types, with mean levels 
among other blood types to be roughly the same.   
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More specifically, studies by Etemadi et al (2015), and Lee, Lin et al. (2012) all reported 
that those with type A blood had higher total cholesterol and LDL.  Etemadi et al (2015) reported 
that those with type B blood had lower lipid levels.  However, in their study, overall, blood 
glucose was the only significant variable and non-O blood groups had higher blood glucose 
levels (Etemadi et al., 2015).  These authors did not believe higher plasma lipid levels in type A 
individuals can alone explain the increased mortality in non-O persons because, lipids levels in 
AB and B type individuals were actually lower than those with O type blood (Etemadi et al., 
2015).  Lee, Lin et al. (2012) found similarly, and reported that the “association of blood group 
A and CAD/MI was independent of atherogenic lipid profiles” (p. 1819).  In a study by Biswas 
and colleagues (2013), AB blood type had the highest levels of HDL with lowest HDL levels in 
individuals with O blood type.   
Conversely, when analyzing LDL levels, highest levels were found in participants with O 
blood type with lowest levels in those with AB blood type (Biswas et al., 2013).  Although these 
findings are contradictory to all other studies in the review this may be related to the ethnicity 
and genetics of the population they studied. 
Summary of Research Conclusions 
 Implications on Clinical Practice  
The majority of the studies reviewed found subjects with non-O blood types to be at 
higher risk of cardiovascular disease than those with O blood types.  Several studies found 
subjects with AB blood types in particular to be at higher risk of cardiovascular events than all 
other blood types (Chen et al., 2014; Etemadi et al., 2015; Gong et al.,  2014a; Gong et al. 2014b; 
He et al., 2012; Karabuva, Carević, Radić, & Fabijanić, 2013; Lee, Lin et al.,  2012; Zakai et al., 
2014).  Etemadi et al. (2015) reported, total mortality is increased in non-O blood types and 
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much of this was attributable to cardiovascular risk.  The association between non-O blood type 
and cardiovascular risk may be related to the 25-30% increase in VWF and FVIII in these 
individuals.  The increase in these blood proteins in non-O individuals may result in increased 
platelet adhesion and subsequent plaque formation.  It may be important for health care providers 
to consider blood type when screening individuals for heart disease risk.  In addition to earlier 
identification, an understanding of how biomarkers differ by blood type may allow from the 
design of more individualized therapies for the prevention and treatment of CVD.  
Limitations 
It is well established that frequencies of blood type vary in different 
ethnicities/populations.  The studies in the review were completed on individuals from Chinese 
(4), Iranian (1), Iraqi (1), Taiwanese (1), European backgrounds (UK, Belgian, Danish) (2), 
Croatian (1), Spanish (1) Indian (1), as well as individuals from the United States (2).  Since 
studies did not include individuals from all ethnicities, findings from the review may not be 
generalizable.  Additionally, the small sample size of some of the studies and lack of 
representation of more rare blood types in certain populations may also make it difficult to 
generalize the findings.  
Cardiovascular endpoints were not well defined in all studies.  Studies reviewed a variety 
of cardiovascular outcomes including MI, stroke and both acute and chronic CAD.  Differences 
in the associations found between blood types in some of the studies could be related to the 
pathophysiology of the cardiac outcome being studied.  Interestingly only one study focused on 
individuals with early onset cardiovascular disease (Lee, Lin et al., 2012).  Early onset CVD may 
have a different pathogenesis than atherosclerotic lesions that accumulate with age and 
subsequently may not stem from the some pathologic background.  It may be possible that ABO 
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blood type plays a more significant role in modulating the outcome in acute coronary events 
versus coronary events that are considered chronic.  
Although A, B, AB and O are the most common blood groups; there are ABO subgroups 
as well.  Subgroups are determined when there are noted to be decreasing amounts of antigens on 
the RBC’s as well as in secretors in the saliva (Franchini & Liumbruno, 2013).  Subgroups are 
most common on the A allele, with the two most common subgroups being A1 and A2.  
Approximately 80% of blood type A or AB are classified as being part of A1 subgroup 
(Franchini & Liumbruno, 2013).  The other 20% are classified at A2 (Franchini & Liumbruno, 
2013).  Since in most studies individuals with type A or AB blood were shown to be at highest 
risk of cardiovascular sequela, further refining research to examine the subgroups of the A allele 
may be helpful in identifying those who are at highest risk for the development of cardiovascular 
disease.  
Conclusion 
Certain ABO blood types have been shown to be convey higher risk of certain disease 
processes.  ABO blood type may mediate the development of certain cardiovascular pathology.  
Most studies in the review implicate non-O blood types with the development of CVD, with 
individuals with blood type A and AB at most cardiovascular risk.  The authors of these studies 
hypothesize that the 25-30% increase in VWF and FVIII in non-O blood types may contribute to 
the increased cardiovascular risk due to the increase in platelet adhesion and plaque formation.  
Other authors explored the link between ABO blood type, inflammatory markers and 
cardiovascular risk.  Interestingly, both markers of coagulation and inflammation have been 
explored in the preeclampsia literature and seem to play a role in the pathogenesis of this disease 
as well.  Cardiovascular disease continues to be the leading cause of death in women and even 
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with new treatments, rates of CVD in women is not decreasing at the same rate as it is in men.  
With that said it is important to consider uniquely female risk factors for CVD.  Exploration of 
risk factors shared between preeclampsia and CVD, such as ABO blood type, may allow for 
earlier identification of women at risk of both outcomes and help to more clearly define the 
pathophysiology of preeclampsia.  
Preeclampsia, ABO and CVD 
In both reviews of the literature, there were similar themes noted.  Although results 
varied, in both reviews, non-O blood type was most frequently cited as increasing risk of both 
CVD and preeclampsia.  With individuals with blood type AB being at highest risk of both 
outcomes.  However, most of the studies in both reviews did not find an association between Rh 
factor with either CVD or preeclampsia.  Since ABO antigens are expressed on platelets, 
platelets were implicated in both reviews as mediators in the risk of development of both disease 
processes.  In the literature review exploring ABO blood type and CVD, increased cholesterol 
absorption as well as increased blood glucose levels were seen in non-O individuals as well as 
increased rates of other traditional cardiovascular risk factors such as increased BMI (Etemadi et 
al., 2015, He et al., 2012; Gong et al., 2012b).  These risk factors have also been proposed as 
preeclampsia risk factors (Lee et al., 2012; Bodnar, Ness, Markovic, & Roberts, 2005).   
Finally, inflammatory mediators were implicated in increasing risk of both CVD and 
preeclampsia.  Traditional cardiovascular risk factors, such as cholesterol absorption and BMI, as 
well as coagulation factors also seem to vary based on blood type.  These factors have also been 
implicated in the development of both CVD and preeclampsia.  Subsequently it is possible that 
blood type mediates this relationship between the two disease processes due to its role in 
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modulating cardiovascular risk factors as well as levels of inflammatory and coagulation factors 
that may increase risk for both disease processes.  
Conclusion 
ABO is expressed on a variety of different tissues, blood components and bodily fluids 
(Seyfizadeh et al., 2014).  ABO blood phenotype has been linked to increases in inflammation 
and coagulation due to differing levels of inflammatory markers and blood clotting proteins that 
have been implicated in both preeclampsia and cardiovascular disease (Gong et al., 2014a; 
Franchini & Lippi, 2015; Visser et al., 2014).  Since preeclampsia leads to increased risk of 
cardiovascular disease and has been linked to many similar pathologic mechanisms it may be 
important to consider if ABO blood type mediates increased risk of preeclampsia.  Research on 
the role of ABO blood type in the development of preeclampsia has yielded inconsistent results.  
However, several of the studies reviewed revealed an association between non-O blood types and 
preeclampsia diagnosis, specifically, AB blood type (Hiltunen et al., 2008; Lee et al., 2012; 
Phaloprakarn & Tangjitgamol, 2013).   
Chapter Summary 
Preeclampsia continues to threaten the health of women.  Implications of the disease are 
far reaching and also include poor neonatal outcomes and increased cardiovascular risk later in 
life.  With an understanding that preeclampsia is a cardiovascular risk factor unique to women, 
the importance of the use of a feminist theoretical framework was discussed.  The 
pathophysiology of preeclampsia is not clear; however, it has been proposed that there are 
different subtypes of the disease.  The role that blood type plays in the development of both 
cardiovascular disease and preeclampsia was explored, and commonalities were discovered in 
the research on the association between blood type and both disease processes.  With an 
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understanding that each preeclampsia subtype may have a distinct pathophysiology, further 
research is necessary to explore the role blood type plays in the development of preeclampsia 
subtype.
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Chapter 3 
Methods 
Chapter Introduction 
Recently, much literature has been published on the relationship between pregnancy 
complications and risk of chronic disease.  Upon further review of the literature, recent evidence 
has revealed an association between preeclampsia and future cardiovascular disease.  The 
pathophysiology of preeclampsia has yet to be elucidated.  Preeclampsia has been called the 
disease of theories because the exact etiology of the disease remains largely unknown (Founds et 
al., 2011).  Currently, there is evidence to support that the disease is heterogeneous in nature and 
varying subtypes of the disease may exist (Barton, & Sibai, 2008; Founds, et al., 2011).  
Pathophysiologic, genetic, metabolic, immunologic, and inflammatory causes have all been 
postulated (Charlton, Tooher, Rye, & Hennessy, 2014; Founds, et al., 2011; Ilekis, Reddy & 
Roberts, 2007).  Due to the heterogeneous nature of the disease, it is important to consider that 
the pathophysiology may also be different amongst subtypes (Barton, & Sibai, 2008).  Blood 
type has also been postulated to increase risk of both cardiovascular disease and preeclampsia 
(Biswas et al., 2013; Etemadi et al., 2015; Franchini, & Liumbruno, 2013; Gong et al., 2014; He 
et al., 2012; Jassim, 2012; Lee et al., 2012).  Due to this shared risk factor, blood type, the 
following study was designed in order to explore the association between maternal blood type 
and preeclampsia subtype. 
More data is needed to better clarify differences in biophysical and biochemical markers 
of women affected by the early and late preeclampsia subtypes.  Data from this study has the 
potential to allow for more effective diagnosis, treatment, and management of patients with 
preeclampsia through a better understanding of risk factors of each preeclampsia subtype.  Since 
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both cardiovascular disease and preeclampsia may be associated with blood type, further 
examination of risk factors shared between the two disease processes is necessary in the hope of 
establishing a clearer pathophysiologic basis for preeclampsia (Biswas et al., 2013; Bushnell et 
al., 2014). 
The purpose of this study is to investigate the association between maternal ABO blood 
type and preeclampsia subtype with an aim at improving prediction and diagnosis as well as 
further exploring risk factors shared with cardiovascular disease.  Furthermore, since 
preeclampsia is said to be heterogeneous in nature, a secondary aim of this study is to better 
describe variables that increase risk of each subtype.  A case-control study was conducted to 
investigate the magnitude of association between ABO blood type and the development of each 
preeclampsia subtype.  The study compared women with both subtypes of preeclampsia to a 
control group of women without preeclampsia. 
This chapter will thoroughly describe the research design and sampling method used in 
this study.  Furthermore, this chapter describes operational definitions utilized for each variable 
as well as the eligibility criteria utilized for both preeclampsia subtypes as well as the control 
groups.  Finally, measurement tools, the data management plan as well as an outline of how data 
was analyzed is described.  
Research Design 
Case control studies provide the opportunity for retrospective assessment of an outcome, 
examining differences in predictor variables between cases, those with the outcome criteria and 
controls.  Case control studies are valuable in instances when it is not ethical or feasible to 
conduct an experiment (Shadish et al., 2002).  This design has also been shown to be efficient 
and less expensive than other designs particularly when studying rare outcomes (Hulley et al., 
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2013).  Although preeclampsia is not rare, this study will be specifically assessing the early onset 
subtype of preeclampsia, which is relatively uncommon compared to its late onset counterpart.  
In their study, MacKay, Berg & Atrash (2001) established the prevalence of early onset 
preeclampsia to be 0.8%.   
Although case control studies cannot yield information on incidence, they provide an 
excellent methodology by which to obtain descriptive information about those cases that meet 
outcome criteria, and allows scientists to estimate the strength of association between the 
independent and dependent variables (Hulley et al., 2013; Lewallen, & Courtright, 1998).  In 
case control methodology the outcome variable is typically dichotomous (Shadish et al., 2002).  
Although the main association of interest in this study is ABO blood type, the case control 
design will allow for the assessment of other variables that may influence the development of 
each subtype of preeclampsia.  A case control study designed to assess the association between 
blood type and preeclampsia subtype will provide data that may be foundational to more costly 
and time-consuming longitudinal studies that could assess the shared relationship between 
preeclampsia and ABO blood phenotype and increased future cardiovascular risk (Lewallen, & 
Courtright, 1998).   
Weaknesses of the design include an increased risk for bias that must be addressed 
(Hulley et al., 2013; Lewallen, & Courtright, 1998).  Sampling bias occurs when cases are 
unrepresentative of the risk factor being studied.  In this study, there is limited concern over 
sampling bias as all pregnant women are followed regularly for prenatal care and are routinely 
screened for preeclampsia per standard obstetrical practice.  During the chart review, if a subject 
was found not have attended prenatal care, they were not included in the study.  The predictor 
variable being studied (ABO phenotype) is represented in the entire population and is commonly 
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tested in all pregnant clients at their first prenatal visit and again at delivery.  Additionally, due to 
the retrospective nature of case control studies there may be concerns with measurement error, 
subsequently clear descriptions of how each variable was measured are described in this chapter 
(Hulley et al., 2013).  All data was extracted from electronic health databases so there was no 
concern over inaccuracy related to poor maternal recall and the majority of the data was recorded 
prior to the occurrence of the outcome under study.  Finally, strict criteria were used to define 
both case and controls groups (Lewallen, & Courtright, 1998).  
Conceptual Framework 
There are four major human blood groups A, B, O and AB (Seyfizadeh et al., 2014).  
Current research supports that ABO blood phenotypes are now far more useful than in 
hematology and transfusion medicine alone (Franchini & Lippi, 2015).  It seems that blood 
phenotype may be linked to risk of cancer, cardiovascular disease as well as a variety of 
infectious disease (Biswas et al., 2013; Franchini & Lippi, 2015).  ABO antigens are expressed 
differently on the red cell surface as well as in a “variety of human cells and tissues, including 
epithelium, sensory neurons, platelets, and vascular endothelium” (Franchini & Lippi, 2015, p. 
1).  Each blood type has differing levels of coagulation factors, such as VWF and Factor VIII.  
Non-O groups have approximately 25% higher levels of VWF than type O individuals (Franchini 
& Lippi, 2015).  Individuals with non-O blood phenotypes have been shown to be at increased 
risk for venous thrombosis, arterial thrombosis, myocardial infarction and ischemic stroke 
(Franchini & Lippi, 2015).  Thus, the link between alteration in hemostasis seen in certain blood 
types as well as preeclampsia supports the biologic plausibility of this study. 
Feminism provides an ideal philosophical framework by which to explore this problem.  
Although this study is highly pathophysiologic, the lens of the researcher frames the research 
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questions posed, how data is extracted and interpreted.  With that said, there is also an 
engendered component to cardiovascular disease.  Women experience different cardiovascular 
signs, symptoms and risk factors than their male counterparts.  Studying sex specific 
cardiovascular risks factors such as preeclampsia may help to improve opportunities for early 
detection and prevention of heart disease in young women.  
Research Question and Hypothesis 
The primary aim of this study was to assess the association between ABO blood type and 
preeclampsia subtype.  After a thorough review of the literature, variables were identified and the 
following research questions were formulated.  The research questions addressed in this study 
included:  
Research Question 1 
What are the maternal characteristics of women with preeclampsia and with each preeclampsia 
subtype? 
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional 
cardiovascular risk factors such as, higher body mass index (BMI), chronic hypertension and 
diabetes.  Additionally, more subjects in the early onset subtype will be of African American 
race, lower socioeconomic class. 
Research Question 2 
Is there an association between preeclampsia subtype and ABO blood phenotype? 
Hypothesis 2: Women with non-O blood types will have greater odds of early-onset 
preeclampsia, compared to those with O blood type.  
Research Question 3 
What is the association between preeclampsia subtype and Rh type? 
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Hypothesis 3:  Rh factor will not be associated with preeclampsia or preeclampsia 
subtype.   
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation and 
preeclampsia development? 
 
Hypothesis 4:  ABO blood type will be associated with platelet count at >/= 28 6/7 week 
in each preeclampsia subtype.  
Research Question 5 
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
 
Hypothesis 5: ABO blood type will be associated with fetal growth restriction in women 
with preeclampsia. 
Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
Hypothesis 6:  Traditional clinical and sociodemographic risk covariates such as 
increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal age 
will increase odds of preeclampsia and early onset preeclampsia subtype.  Non-O blood types 
will have increased odds of preeclampsia and preeclampsia early onset subtype.  
The findings from the study could contribute to a more clear understanding of the 
pathophysiologic basis of each preeclampsia subtype as well as a better understanding of the 
association between preeclampsia and future cardiovascular disease risk.  Additionally, although 
currently there is no reliable risk-screening model for preeclampsia, this study may provide 
knowledge about biophysical characteristics of women with each preeclampsia subtype so that 
health care providers can consider the need for early pregnancy surveillance in certain sub 
groups of women.  
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Measurement Tools 
Gel Agglutination 
When blood type is determined, technologists are assessing the presence of specific 
antigens on the red blood cell (RBC) and antibodies in the plasma.  When the A antigen is 
present the client is type A, when the B antigen is present the client is type B and when both are 
present the client has AB blood type.  When neither A or B antigen are present the client is typed 
as O.  The ABO type is unique in that there is an inverse relationship between the antigens found 
on the RBCs and the antibodies found in the plasma/serum.  Each blood specimen is tested for 
both antigens and antibodies (personal communication, B. Steiber, January 29, 2016).   
In the study site laboratory, gel agglutination is used as their primary testing 
methodology.  Certified Clinical Laboratory Scientists complete all testing.  Gel methodology 
has been shown to be more sensitive than tube methodology, as the reactions are stronger 
(personal communication, Steiber, B, January 29, 2016).  Gel agglutination assay is used “for the 
detection of A, B, and D and for ABO serum grouping, indirect antiglobulin tests (IATs), and 
direct antiglobulin tests (DATs)” (Langston, Procter, Cipolone, & Stroncek, 1999, p. 300).  Six 
microtubules are held in a cassette.  Each microtubule has gel in a column that may be neutral or 
contain a reagent.  Reactants are then added to each microtubule (Langston, Procter, Cipolone, & 
Stroncek, 1999).  The RBC’s are tested with two antibody reagents for anti-A and anti-B, each of 
which has specificity for one antigen.  Antibodies in the plasma/serum are tested with RBC 
reagents known to be A1 cells and B cells.   
Using the same sample of blood as above, Rh factor testing is completed at the same time 
as ABO blood typing described above and the appropriate anti-Rho(D) reagent is included in the 
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gel cassette.  The presence or absence of Rh antigen on the sample’s red blood cells is 
determined by testing the sample with antibody reagent anti-D.   
Regardless of the test performed, the gel cassette is spun for 10 minutes in the centrifuge.  
This is necessary so that the RBCs, whether agglutinated or not, layer in the appropriate area.  
The strength of agglutination reaction is then graded (+1, +2, +3, +4) by the Certified Clinical 
Laboratory Scientist in order to determine the presence or absence of agglutination in each of the 
microtubules.  The presence of agglutination determines a positive reaction (personal 
communication, Steiber, B, January 29, 2016). 
The majority of prenatal ABO testing is routine.  For routine samples, the Ortho ProVue® 
is used to complete gel agglutination testing.  Prior to utilizing the Ortho ProVue®, the machine 
is validated by comparing results from the ProVue® to manually tested specimens which were 
completed according to Blood Bank protocols.  The instrument is tested daily with reagents as 
well as patient specimens in order to achieve 100% accuracy in ABO and Rh blood typing. 
Platelet Measurement 
In the study site laboratory, platelet counts are completed using an automated blood cell 
analyzer called the Sysmex XE-series.  Utilization of impedance technology has resulted in a 
dramatic improvement in precision in platelet counts.  The Sysmex counts platelets using 
electronic resistance detection enhanced by hydrodynamic focusing (WellSpan Lab Services, 
2012).  The study sites laboratory services, cellular microscopy policy CM-IOP-27 outlines 
principles, care and procedures governing the Sysmex XE series. 
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Variables 
Preeclampsia 
  Diagnostic criteria of preeclampsia is defined by ACOG (2013) as the new onset of 
hypertension (>/=140mm Hg systolic or .>/=90mmHg diastolic) on two occasions at least 4 
hours apart after 20 weeks, and proteinuria (> 300mg in a 24-hour urine collection).  In the 
absence of proteinuria the patient may have any one or more of the following in order to meet 
preeclampsia diagnostic criteria: 
● platelets < 100,000 microliter 
● serum creatinine > 1.1 or doubling of serum creatinine in the absence of renal     
      disease 
● elevated concentrations of blood liver transaminases to twice normal levels 
● pulmonary edema  
● new onset of cerebral or visual disturbances (ACOG, 2013, p. 4).   
 
Early and late onset.  Myatt et al. (2014) reports that a better understanding of 
preeclampsia subtypes will lead to a more clear understanding of the pathophysiology of 
preeclampsia and subsequently improved diagnostic prediction.  In this study, two preeclampsia 
subtypes were assessed, early and late onset.  Early onset preeclampsia is defined by ACOG 
(2013) and the ISSHP as occurrence of preeclampsia before or at 33 weeks gestation, while late 
onset preeclampsia occurs at 34 weeks or later (Lisonkova, & Joseph, 2013; Myatt et al, 2014).  
Additionally, since perinatal morbidity is much higher when delivery occurs prior to 34 weeks, 
using this gestational age for designation of subtypes proves important (Myatt et al., 2014).    
       Previous research on early and late preeclampsia subtypes utilized timing of delivery to 
classify subjects, or did not describe how subjects were classified into each subtype.  Myatt et al. 
(2014) recommends using onset of preeclampsia clinical symptoms rather than timing of delivery 
to define each subtype as symptoms may have been clinically present days to weeks before 
delivery.  Prenatal records of each case were reviewed in order to assess gestational age when 
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preeclampsia diagnostic criteria was documented.  Since it is accepted practice to record blood 
pressures and urine protein at all obstetrical visits, both the prenatal record as well as the hospital 
inpatient record were reviewed as most cases of preeclampsia were confirmed in the inpatient 
setting.  The exactness of this may be affected due to timing of antenatal visits during pregnancy 
(Myatt et al., 2014).  Since this study involves gestational age as a variable it is important to 
elucidate method and accuracy of dating.  It is common practice at the study site for all women 
to have first trimester dating ultrasounds to confirm dating.  Cases in which preeclampsia 
occurred in the postpartum period were not included in this study as this may be a separate 
subtype of the disease.  
Major Independent Variables 
ABO blood type.  Myatt et al. (2014) calls for researchers to begin to explore differences 
in laboratory findings between preeclampsia subtypes.  ABO blood type was chosen as a variable 
in this study due to the cardiovascular and thrombotic risk associated with certain blood types.  
There are four major human blood groups A, B, O and AB (Franchini & Lippi, 2015; Seyfizadeh 
et al., 2014).  Blood type is ordered to be drawn as part of prenatal labs on all pregnant clients at 
their first prenatal visit.  ABO was documented as a categorical variable. 
Rh factor.  Rh factor is the major Rh antigen and when it is present the client is deemed 
Rh positive, when the Rh antigen is not present the client is Rh negative.  The Rh antigen is 
present in 85% of the population in the United States (Blood Typing Systems, 2013).  When 
blood type is drawn as part of prenatal labs on all pregnant clients at their first prenatal visit, Rh 
status is included.  Rh factor was documented as a dichotomous categorical variable.  
Platelets.  Platelets are a component of the blood that aid in the clotting process.  
According to ACOG (2013) preeclampsia diagnostic criteria, in the absence of proteinuria, 
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platelet levels less than 100,000 per microliter can be diagnostic of preeclampsia, if hypertensive 
criteria exist.  In preeclampsia, thrombocytopenia reveals systemic disease.  Platelet and 
thrombin activation, have been listed as possible pathogenic mechanisms in the development of 
preeclampsia (Han et al., 2014).  In this study, maternal platelet count was documented at three 
different time periods throughout the subjects pregnancy, less than 20 6/7 weeks gestation (first 
prenatal lab work), between 21 and 28 6/7 weeks gestation, and greater than 29 weeks gestation 
(admission for delivery).  Platelet count was documentated as a continuous variable. 
Maternal body mass index (BMI).  Prepregnancy BMI has been linked to both 
preeclampsia and CVD risk (Bodnar et al., 2005; Roberts et al., 2011).  Additionally, women 
with non-O blood types have been shown to have a greater number of traditional cardiovascular 
risk factors, such as elevated BMI (He et al., 2012).  BMI is calculated at the prenatal teaching or 
first obstetrical visit and is calculated by the electronic health record by taking the persons 
weight in kilograms divided by the square of their height in meters.  Weight is typically 
measured on a standing scale and height may be self-reported or confirmed by the nurse on the 
standing scale if the patient is unsure of their height at the time of the intake visit.  If a 
prepregnancy BMI or weight was documented in the prenatal history and physical, this data was 
utilized.  Otherwise only weights measured prior to the end of the first trimester (<13 weeks) 
were used to calculate maternal BMI’s so as to obtain a BMI as close to a prepregnancy as 
possible. BMI was documented as a continuous variable. 
Race.  There are differing distributions of blood type by racial and ethnic group (Racial and 
Ethnic, 2013).  Risk of preeclampsia is also shown to be increased in certain race (Lisonkova, & 
Joseph, 2013; Paré et al., 2014)).  Below are the racial groups listed in the hospital database.  
Each participant’s race is self-declared and was abstracted from the Premier® database. This 
  67  
 
variable was recoded due to small numbers in many of the racial categories to include White, 
Black and Other. 
A. Asian  
B. Black or African American 
C. Native Hawaiian or Other Pacific Islander 
D. White 
E. Declined-Other 
F. Declined 
G. Unknown to patient 
 
Maternal socioeconomic class.  Socioeconomic status may reflect the access to 
resources of the women in this study.  Other studies have used years of education and income as 
a proxy’s for socioeconomic status (Shavers, 2007).  Due to its availability in the database 
utilized in this study, maternal insurance type was used as a proxy for maternal socioeconomic 
status.  Insurance type was collected as a categorical variable.  The following insurances types 
were listed in the Premier ® database (1) Commercial Indemnity (Private) (2) Managed Care 
Non-Cap (Private); (3) Medicaid Managed Care Non-Cap (Public) (4) Medicaid Traditional 
(Public) (5) Medicaid Traditional (TR) (Public) (6) Medicare Traditional (Public) 7) Self Pay (8) 
Unknown (9) Other Government Payers (Public).  These were recoded into a dichotomous 
variable, public and private insurance. 
Maternal age.  Maternal age was calculated as the number of years completed at the time 
of delivery of the pregnancy.  Maternal age was listed on the electronic delivery found in the 
electronic health record.  Age was documented as a continuous variable. Lisonkova, & Joseph, 
(2013) list extremes in maternal age (<18 or >35) as a risk factor for preeclampsia.  In teen 
pregnancy, researchers have hypothesized that the risk of preeclampsia is elevated due to the 
immaturity of uterine and cervical blood supply.  This in turn may result in increased 
prostaglandin production and subsequent inflammatory response, which may affect blood 
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pressure (Aliyu et al., 2010).  Researchers have also hypothesized that poor dietary intake of 
certain nutrients such as vitamins C and E, calcium, zinc as well as essential fatty acids, which 
have been associated with preeclampsia, particularly in developing countries, could be causative 
of preeclampsia in teens.  In teens, their own growth and bodies’ need for nutrients may result in 
nutrient deprivation of the fetus (Aliyu et al., 2010).  Aliyu et al. (2010) also adds that teenage 
mothers are often nulliparous, and non-white, both of which are risk factors of preeclampsia, 
which in turn could exaggerate the risk of preeclampsia in this age group (Aliyu et al., 2010).  
Alternatively, it is has been proposed that the increased risk of preeclampsia in older mothers 
may be due to aging endothelium which does not adapt as well to the hemodynamic demands 
placed on the maternal vascular system during pregnancy (Rich-Edwards et al., 2014) 
Smoking.  Interestingly, smoking has been shown to be protective of preeclampsia and may 
confer a 50% reduction in risk (Hutcheon et al., 2011; Savitz, Danilack, Engel, Elston, & 
Lipkind, 2014).  This association is dose dependent and if smoking is stopped early in 
pregnancy, there is no protective effect.  This association was not seen with snuff (Hutcheon et 
al., 2011).  This variable was collected by review of the prenatal record in the electronic health 
record and was dichotomized for data collection, as either “yes” or “no.”  Women who reported 
not smoking at their prenatal intake visit were considered nonsmoking.  If a woman had a 
positive smoking status documented in her prenatal record by her health care provider at the first 
prenatal visit, then women were considered smokers.  
Parity.  Nulliparity is a risk factor of preeclampsia.  The “primipaternity hypothesis 
suggests that risks of preeclampsia are increased among women who have limited exposure to 
their partner’s sperm” (Hutcheon et al., 2011’ p. 394).  Although there has been some debate 
over this hypothesis, supporters site higher rates of preeclampsia in women who consistently use 
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barrier contraception, and the three fold higher risk of preeclampsia in women who conceived 
following intracytoplasmic sperm injection for azoospermia, with sperm obtained surgically as 
evidence of this hypothesis (Hutcheon et al., 2011).  Nulliparous women have three times higher 
risk of preeclampsia than do multiparous women.  (Hutcheon et al., 2011).  The lower rates of 
preeclampsia seen in multiparous women further support this hypothesis (Hutcheon et al., 2011).  
Parity will be documented as a dichotomous categorical variable, nulliparous or multiparous.  
Nulliparous women were those who had no documented history of a term or preterm birth in the 
electronic delivery log.  
Gestational age at birth.  At the study site, first trimester ultrasound is routinely 
performed in order to calculate estimated date of confinement.  First trimester ultrasound, 
improves gestational age accuracy and subsequently allowed for more accurate identification of 
preeclampsia subtype.  As per standard of practice, first trimester ultrasound is obtained to 
confirm dating by measuring fetal crown rump length (Myatt et al., 2014).  If a dating ultrasound 
completed before 7 weeks gestation calculates a due date that is ≥ 3 days different from the due 
date that was calculated using the last menstrual period, then the due date was changed in the 
electronic health record to correspond with the ultrasound report.  If a dating ultrasound 
completed before 10 weeks gestation calculates a due date that is ≥ 5 days different from the due 
date that was calculated using the last menstrual period, then the due date will be changed to 
correspond with the ultrasound report.  If a dating ultrasound completed before 13 weeks 
gestation calculates a due date that is ≥ 7 days different from the due date that was calculated 
using the last menstrual period, then the due date will be changed to correspond with the 
ultrasound report (personal communication, S. Bennett, February 9, 2016).  If a patient presents 
after 13 weeks and dating has not yet been confirmed, biometry based on fetal biparietal 
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diameter, abdominal circumference, and femur length is utilized to calculate gestational age.  In 
this case, if the due calculated is  ≥ 11 days different from the due date which was calculated 
using the patients last menstrual period, then ultrasound dating would be used (Myatt et al., 
2014).  Gestational, age was extracted from the delivery record.  This variable will be 
documented as a continuous ratio level variable.  If gestational age was in question at delivery, 
the case was not included in the study.  Based off assigned estimated date of delivery, an 
obstetrical wheel was used to confirm gestational age at onset of preeclampsia symptomology in 
order to appropriately assign each case to the correct subtype.  
Sex of the infant.  There is a strong incidence of sexual dimorphism particularly related 
to disorders of an inflammatory nature (Myatt et al., 2014).  A male fetus has been associated 
with increased risk of preeclampsia ; however, a female fetus has been associated with the early 
subtype (Myatt et al., 2014).  Lisonkova, & Joseph, (2013) reported an association between 
pregnancy with a male fetus and late onset preeclampsia.  In this current study, the sex of the 
infant was extracted from the electronic delivery record and was coded as a dichotomous 
categorical variable.  
Infant birthweight.  Myatt et al. (2014) calls for birth weight to be recorded in all 
studies on preeclampsia.  Fetal growth restriction (FGR) is a common complication of 
preeclampsia, often associated with the more severe early onset subtype (Kucukgoz Gulec et al., 
2013.  A growth-restricted infant is characterized by “a reduced birthweight in relation to its 
length” (Owen, Ogah, Bachmann, & Khan, 2003, p.  411). More specifically, FGR is 
documented when an infant’s “birth weight and/or birth length is below the 10th percentile for 
gestational age” (Zohdi et al., 2012 p. 2).  All infants are weighed shortly after birth on electronic 
scales by registered nurses.  Birth weight was documented in the electronic health record in 
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grams, it was initially measured as a continuous ratio level measurement.  Infant birthweight was 
then recoded into birthweight percentiles to assess for rates of growth restriction within 
subgroups and controls.  A fetal biometry calculator which takes into account gestational age and 
birthweight was used to calculate birthweight percentile.  The calculator can be accessed at 
http://perinatology.com/calculators/exbiometry.htm.  The calculator utilizes the Hadlock (1991) 
equation.  This variable was then dichotomized in order to represent those infants with growth 
restriction (< 10th percentile) and those without growth restriction (> 10th percentile) 
(Unterscheider et al. 2013). 
Comorbid conditions.  Comorbid illnesses to include chronic hypertension (CHTN), 
preexisting diabetes (DM) and gestational diabetes (GDM) will be collected as dichotomous 
categorical variables.  Chronic hypertension, preexisting diabetes and gestational diabetes are 
known risk factors for both CVD as well preeclampsia (Lisonkova, & Joseph, 2013; Paré, 2014).  
In other studies, ABO blood type has been shown to increase risk for diabetes and other 
cardiovascular disease risk factors (Chen et al., 2014; Gong et al, 2014b; Karabuva, Carević, 
Radić, & Fabijanić, 2013; Lee et al., 2012).  Subsequently, ABO blood type may mediate the 
development of these comorbid conditions which in turn may increase risk for preeclampsia.  In 
this current study, CHTN, DM and GDM were initially identified by ICD 9 code and then 
confirmed upon chart review. 
Subjects and Setting 
Location 
  Due to accessibility, the electronic health record (EHR) from a large suburban ethnically 
diverse community hospital in south central Pennsylvania was used for data collection.  The city 
where the hospital is located has a population of 43,935.  In 2015, 3,164 births occurred at this 
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institution.  There is only one other small community hospital in this county.  This hospital is 
considered a tertiary referral center for several other small hospitals in surrounding counties 
subsequently; the majority of high-risk pregnancies are delivered at this hospital due to its NICU 
and high-risk obstetrical facilities.  Thus, utilizing other hospitals in the area would not increase 
access to clients with the desired outcome.  Because the study site is a referral center, more cases 
of early onset preeclampsia delivered at this institution, as these cases often require early 
delivery of the pregnancy and utilization of NICU services that are not offered by other hospitals 
in the area.  
Inclusion and Exclusion Criteria  
Inclusion criteria for controls included: 
 Female clients 
 Singleton pregnancies 
 Presented for delivery at the study site between November 2014 and March 2016  
 ABO blood typing complete  
 No diagnosis code for preeclampsia   
 Live births 
 
Exclusion criteria for controls included: 
 Incomplete ABO blood typing  
 Women who did not deliver at the study site between the defined time period.   
 Women pregnant with multiples  
 Women with a history of preeclampsia 
 
Inclusion criteria for cases included 
 Female clients 
 Singleton pregnancies 
 Presented for delivery at the study site between January 2012 and June 2016  
 ABO blood typing complete  
 Initially must have intrapartum ICD 9 for preeclampsia (Appendix D) 
documented in their medical record.  Then upon chart review must have met 
ACOG (2013) diagnostic criteria for preeclampsia. 
 
Exclusion criteria for cases will include: 
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 Incomplete ABO blood typing  
 Women who did not deliver at the study site between January 2012 and June  
2016  
 Women who delivered prior to 20 weeks gestation  
 Women pregnant with multiples 
 Women who did not meet preeclampsia diagnostic criteria when chart review 
completed  
 
ICD 9 codes were used to exclude women in both the case and control groups with a multiple 
gestation (Appendix D).  Women did not have more than one pregnancy included in the study.  
Women who delivered more than one pregnancy during the study period only had the first 
pregnancy included in the sample. 
Although considered risk factors of preeclampsia, the decision was made to include 
subjects with comorbidities such as diabetes, gestational diabetes and chronic hypertension in 
both the case and control groups.  Typically, with a case control study, you need to exclude diseases 
known to be associated with the exposure of interest.  Since determination of ABO blood type 
predates any disease process it was determined that individuals with these conditions should 
remain in both groups.  Additionally, literature supports that ABO blood type may predispose 
individuals to certain comorbid condition and cardiovascular risk factors, which in turn may 
increase risk of these comorbid conditions (Chen et al., 2014; Etemadi et al., 2015; Gong et al.,  
2014a; Gong et al. 2014b; He et al., 2012; Karabuva, Carević, Radić, & Fabijanić, 2013; Lee et 
al.,  2012; Zakai et al., 2014).  Subsequently, if these subjects were excluded from the sample, 
there may be a loss of an important subset of individuals whom blood type already matters in 
terms of their health status and subsequently may bias the results to the null.  
Sample Size 
Sample size was calculated using openepi.com.  OpenEpi® is free, open source software 
that can be used to calculate epidemiologic statistics (Dean, Sullivan, & Soe, 2004).  In order to 
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complete the sample size calculation “the desired confidence level, power, a hypothetical 
percentage of exposure among the controls, and either an odds ratio or a hypothetical percentage 
of exposure among the cases” must be entered into the statistical software (Dean, Sullivan, & 
Soe, 2004).  In OpenEpi® “results are presented using methods of Kelsey, Fleiss, and Fleiss with 
a continuity correction” (Dean, Sullivan, & Soe, 2004).  The results using the Kelsey method 
were utilized for sample size determination in this study (Appendix E).  
Many similar studies reviewed on this topic did not discuss how they calculated sample 
size.  The power selected for use in the sample size equation was from a study by Shamsi et al. 
(2010) who reported using a power of 80% with an alpha level of 0.05 and an effect size of 0.3.   
 In the current study, the exposure variable is non-O blood type.  The distribution of ABO 
blood type in the United States for all races is O 44%, A 42%, B 10% and AB 4% (“Racial and 
Ethnic Distribution,” 2013) with non-O blood types accounting for 56% of all blood types.  
A review of the literature was completed in order to find a percentage of non-O blood 
type exposure among cases of preeclampsia.  There were only two articles identified in the 
literature that clearly listed the prevalence of blood type in cases of preeclampsia Hiltunen et al., 
(2009) and Spinillo, Capuzzo, Baltaro, Piazzi, & Iasci (1995).  Each uses varying definitions of 
preeclampsia, and none use the strict definitions of early and late preeclampsia utilized in this 
study.  None of the articles reviewed discussed prevalence of blood type by early or late onset 
preeclampsia subtype.   
After reviewing these articles, Hiltunen (2009) was utilized to calculate sample size.  
Hiltunen (2009) used a total of 248 cases that fulfilled the diagnostic criteria for pre-eclampsia 
and 679 controls.  In this article the sample consisted of preeclampsia cases and then was 
analyzed by subsamples 1) severe pre-eclampsia, 2) early pre-eclampsia, and 3) pre-eclampsia 
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with intra-uterine growth restriction (IUGR).  Primigravid women with preeclampsia were also 
analyzed separately.  However, Hiltunen (2009) only reported blood type distribution for the 
entire preeclamptic sample.  Hiltunen (2009) reported a 70.96% prevalence of non-O blood type 
in preeclamptic subjects.  Sample size was calculated using Openepi.com.  In order to add power 
to the study, two controls were added for every case (Lewallen, & Courtright, 1998).  A sample 
size of 126 early cases, 126 late cases, and 252 controls, is able to detect an odds ratio of 1.9 with 
a power of 80% at a significance level of 5%.  Subsequently, each subtype is adequately powered 
to detect differences.  
Matching.  Finally, the decision was made to not utilize matching in the design of the 
study.  “Matching should be considered only for risk factors whose confounding effects need to 
be controlled for but that are not of scientific interest as independent risk factors in the study”  
(Wachoider, Silverman, McLaughlin, & Mandel, 1992, p. 1043).  Because all variables 
considered for matching are clinical risk factors of preeclampsia, the PI chose not to match on 
these variables, as they were of scientific interest.  Additionally, matching can shrink the sample 
and subsequently create difficulty in meeting sample size requirements; this was of concern 
particularity in relation to the overall difficulty in finding early onset cases.  Since none of the 
preeclampsia clinical risk factors under study are predictors of exposure to the primary risk 
factor under investigation (ABO Blood type), other than race, confounding was not a concern 
(Wachoider et al., 1992).  Rose & van der Laan, (2009) cite that confounders can be adjusted for 
in the analysis if necessary.  In this sample, there were no statistically significant differences in 
race (p=.145) and or maternal age (p.279) between the preeclampsia subtypes and controls. 
Data Collection 
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Initially, data was abstracted from the electronic delivery log on all deliveries between 
November 2014-March 2016.  Subjects with multiple gestations were excluded as well as the 
second delivery of subjects who had more than one delivery during this time period.  This group 
of patients was assessed for preeclampsia cases that met inclusion criteria.  From the remaining 
subjects who had live births a randomly selected control group was created using excel.  
Recognizing the rarity of preeclampsia, particularly early onset preeclampsia, the search for 
preeclampsia cases needed to be expanded to include cases identified by the Premier® database 
using ICD-9 codes for preeclampsia between January 2012-June 2016 (Appendix D).   
The electronic health record of each consecutive preeclampsia case was reviewed to 
ensure that each subject met preeclampsia diagnostic criteria until the sample size requirement 
was met for both the early and late onset subtypes.  Accuracy of data collection surrounding 
preeclampsia diagnosis can prove difficult and multiple methods exist.  A strength of this study 
is the strict criteria which was utilized in order to determine a case of preeclampsia.  Many 
population birth cohort studies utilize large data sets consisting of birth certificate data and 
extract data using diagnostic codes.  Diagnostic codes can be used to extract data from electronic 
sources, however, Brown et al. (2013) reported that coding was only accurate 54% of the time in 
meeting the diagnostic criteria set forth by ACOG surrounding preeclampsia.  Since this study is 
assessing the consequences ABO blood type has on preeclampsia risk, the accuracy of 
preeclampsia diagnosis is imperative.  Accurate classification of subjects improves the chances 
of finding real exposure differences between groups.  The exacting way in which cases were 
identified improves the statistical power of the analysis particularly when compared to larger 
studies that may have utilized less sensitive measures for identifying cases of preeclampsia 
(Klemmensen, Olsen, Østerdal & Tabor, 2007).  
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Protection of Human Subjects 
This investigator, as required by the study site, completed WCG® research training.  Prior 
to beginning data collection, this investigator obtained IRB approval from the study site and a 
IRB deferral request was submitted and approved by the University of Wisconsin-Milwaukee.  
The primary investigator also sought approval from the Women’s and Children’s Service Line 
Administration at the study site.  A HIPPA waiver was requested and approved as this study 
posed minimal harm to patients.  Ethical research principles were followed in order to assure 
ethical treatment of data.   
Procedures 
Study site laboratory procedures were assessed and were confirmed that they met quality 
standards for accuracy in blood typing as well in determining platelet count.  Blood bank type 
and Rh processes were assessed with the manager of the Blood Bank at the study site.  Policies 
and adherence to federal regulations surrounding blood banking were ensured. 
Detailed data were collected on a wide variety of biophysical, laboratory as well as socio-
demographic variables.  Although all variables were extracted from the electronic health record, 
not all data was extracted using the same methodology.  Appendix F outlines from which 
database each variable was extracted.  The electronic delivery log, electronic health record and 
the Premier® database were all used to extract data.  Data extracted from the Premier® database 
was merged with data from the electronic delivery log in order to create a cohesive data set.  
Data collected from the Premier® database was collected by a population health data analyst at 
the study site as access to the Premier® database is restricted.  The ICD 9 codes commonly 
utilized for preeclampsia were searched in the Premier® database in order to extract documented 
cases of preeclampsia from the electronic health record during the defined time-period.  
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Preeclampsia diagnosis and gestational age at diagnosis were confirmed through chart review in 
order to separate preeclamptic subjects by appropriate subtype.  The electronic chart of each 
subject was then reviewed to gather data on early pregnancy BMI, platelet counts during three 
gestational time periods, infant birthweight, and to confirm smoking status as well as comorbid 
conditions of interest (GDM, CHTN, DM). Although identified preliminary by ICD 9 code, 
diagnosis of GDM, DM and CHTN were also confirmed during chart review in both cases and 
controls.  Within the electronic health record, the prenatal chart of each control subject was also 
reviewed in order to confirm they had no history of preeclampsia.  
 Since data is often documented in multiple locations within the electronic health record, 
a subsample of cases and controls were assessed in order to attempt to standardize the data 
collection process.  A data collection procedure was formalized, documented and reviewed with 
a research assistant.  A paid research assistant who is a registered nurse at the study site and 
familiar with the electronic health record was utilized to collect chart data on control subjects 
only.  She was paid through the Harriet Werley Doctoral Research Award, which the principal 
investigator received in 2016.   
Data Management and Analysis 
Patient data was extracted from patient charts, the electronic delivery log as well as the 
Premier® database and was stored in a password protect hospital based secured share drive. 
Statistical analysis was performed using SPSS version 23.  Initially data was examined for 
missing data as well as outliers, and data was cleaned.  Missing data was replaced using the 
number 8888.  The data was screened and cleaned in order to check for errors.  Minimum and 
maximum values were assessed as well as number of missing cases for each variable.  Any errors 
or inconsistencies in the data were corrected.  Assumptions for statistical tests were checked.   
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The data was analyzed in order to answer each research question.   
Research Question 1 
What are the maternal characteristics of women with preeclampsia and with each preeclampsia 
subtype? 
Descriptive statistics were performed for each group, early preeclampsia, late 
preeclampsia and controls and were used to describe the sample.  Initially the categorical 
variables, maternal ABO blood type, Rh factor, parity, smoking, race, socioeconomic status, 
infant outcome and infant gender were assessed for frequencies and a table was created to 
compare data on both cases and controls.  Continuous variables such as maternal age, infant 
birthweight, gestational age and BMI were checked for skewness, normality and outliers.  Means 
and standard deviations were calculated on all continuous variables.  Chi square test of 
independence was estimated for categorical variables of interest.  Independent-samples t-test 
were run to determine statistically significant differences between the mean scores for 
continuous variables in the preeclampsia and control groups.  One-way ANOVA was utilized 
when assessing continuous variables against preeclampsia subtypes and controls, in order to 
determine significant differences in the mean scores across the three groups. 
Research Question 2  
Is there an association between preeclampsia subtype and ABO blood type? 
The main aim of the study is the association between preeclampsia subtype and ABO 
blood type.  Initially, Chi square test for independence was estimated to assess association 
between ABO blood type, and both preeclampsia and preeclampsia subtypes.  This test was also 
completed excluding individuals with comorbidities from the sample.  When assessing ABO 
blood type and preeclampsia subtype because the table is larger than 2 x 2, Pearson chi square 
and Cramer’s V were reported.  The analysis was also performed to assess the association 
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between Non-O and O blood types and preeclampsia and preeclampsia subtypes.  When 
assessing Non-O and O blood types and preeclampsia a 2 x 2 table was created, subsequently the 
Yate’s continuity correction value and phi coefficient were reported as appropriate.     
Next, logistic regression was performed and odds of developing preeclampsia for each 
preeclampsia subtype was calculated based of ABO blood type.  Logistic regression aims to 
assess the independent contribution of predictor variables in predicting an outcome (Hulley et al., 
2013).  After assumptions of logistic regression were checked, an unadjusted binary logistic 
regression was run assessing the association between preeclampsia and ABO blood type.  Race 
was then added to the model and the regression rerun.  Odds ratios of each ABO blood type with 
95% confidence intervals (CI) were reported. 
Next, multinomial logistic regression was utilized to assess the association between ABO 
blood type and preeclampsia subtypes.  This statistical test was chosen because there are more 
than two nominal outcomes: early preeclampsia, late preeclampsia, and controls.  Because, these 
groups are unordered it makes them ideal for multinomial logistic regression (Kwak, & Clayton-
Matthews, 2002).  Multinomial regression creates multi-equation models and allows for the 
comparison of one group to a reference group, in this case the controls (Meyers, Gamst, & 
Guarino, 2013).  The control group was set as the reference category.  When running the 
regression, it was confirmed that all cells in the model were populated.  Odds ratios with 95% 
confidence intervals (CI) were reported for significant blood types only.  The regression was 
then performed adjusting for race.  
Research Question 3 
What is the association between preeclampsia subtype and Rh type? 
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In order to answer research question three, Chi square test for independence was 
estimated in order to assess the association between Rh factor and preeclampsia as well as 
preeclampsia subtype.  When assessing Rh factor and preeclampsia a 2 x 2 table was created, 
subsequently the Yates continuity correction value and phi coefficient were reported.  When 
assessing Rh factor and preeclampsia subtype, Pearson chi square and Cramer’s V were reported 
as appropriate.  This analysis was also complete when excluding subjects with comorbidities. 
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and 
preeclampsia development? 
 
A two way between groups ANOVA was performed to assess if ABO blood type 
moderates the relationship between preeclampsia subtype and platelet count at >/= 28 6/7 weeks 
gestation.  Levene’s test was assessed for equal variances and a more stringent p value was used 
as appropriate, and t values were reported appropriately.  Both main and interaction effects are 
reported.  Additionally, mediation analysis was run to determine if the relationship between 
maternal ABO blood type (predictor) and preeclampsia subtype (outcome) is mediated by 
platelet count at > 28 6/7 weeks gestation.   
Research Question 5 
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
Chi square test for independence was estimated to assess the relationship between fetal 
growth restriction (FGR) and ABO blood type in preeclamptic women.  Binary logistic 
regression was also performed.  Odds ratios and 95% confidence intervals were reported for 
significant results.  
Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
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In order to address the most influential preeclampsia risk factors associated with each 
preeclampsia subtype, another regression was run which included all clinical risk factors in the 
model.  The decision was made to not utilize stepwise regression due to the inherent flaws in this 
method, particularly since clinical risk factors of preeclampsia are well established in the 
literature and served as a conceptual model for the development of the model (Field, 2015).  
First, binary logistic regression was run using all clinically significant independent risk factors 
which data was collected on (Portney & Watkins, 2009).  Variables determined in the review of 
literature as risk factors for preeclampsia were utilized in the model regardless of significance in 
this study.  Binary logistic regression was performed to examine the association between 
socioedemographic and clinical covariates and preeclampsia including BMI, maternal age at 
delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance 
type, parity and gestational diabetes.  P-values ≤ 0.05 were considered statistically significant.  
Maternal BMI and age were mean centered prior to being included in the regression modeling.  
Because these variables (BMI and age) cannot have a true value of zero, these variables were 
mean centered in order to improve the interpretability of the output.  Odds ratios with 95% CI’s 
that were statistically significantly associated with preeclampsia were reported.  ABO blood type 
was then added to the model to determine how much variability ABO blood type accounts for in 
the model.  A table was created and odds ratios with 95% CI’s that were statistically significantly 
associated with preeclampsia were reported. 
Secondly, multinomial logistic regression was used to examine the association between 
covariates of interest and preeclampsia subtype.  Initially, the same sociodemographic and 
clinical covariates were included in the model.  Odds ratios and 95% confidence that were 
statistically significantly associated with preeclampsia subtype were reported.  Values of p<0.05 
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were considered significant (Lewallen & Courtright, 1998).  Significant variables in the final 
model were described.  Confidence intervals were assessed and significant variables described 
did not contain the value of 1.0 in the confidence interval (Portney & Watkins, 2009).  Since 
multiple independent variables were included in the regression model, the odds ratio described 
was corrected due to each individual variables influence on each other, and the adjusted values 
were reported  (Portney & Watkins, 2009).  ABO blood type was then added to the model to 
determine how much of the variability in preeclampsia subtype ABO blood type explained.  A 
table was created and odds ratios with 95% CI’s that were statistically significantly associated 
with preeclampsia subtype were reported. 
Supplementary Analysis 
Mediation analysis.  PROCESS which is a statistical program created by Andrew Hayes 
was downloaded to SPSS version 23 in order to perform the mediation analysis (Field, 2015).  
Mediation occurs when a relationship between a predictor and outcome can be explained through 
a third variable (Fields, 2015).  In mediation, the predictor (X) should predict both the outcome 
(Y) and mediator (M).  The mediator (M) also predicts the outcome (Y) variable.  Subsequently 
when a mediator is present, the relationship between the predictor and the outcome may differ 
(Fields, 2015).  Simple mediation analysis was performed to assess if the relationship between 
ABO blood type (X) and preeclampsia subtype (Y) was related to a third variable BMI (M).  
Since the literature supports that individuals with certain blood types may be more at risk for 
certain cardiovascular risk factors such as increased BMI (He et al., 2012), and since obesity is a 
known risk factor of preeclampsia, it is plausible that increased BMI mediates the relationship 
between ABO and preeclampsia (Bodnar et al., 2005; Roberts et al., 2011, ).  A conceptual model 
was created and both the indirect and direct effects were reported. 
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Chapter Summary 
The goal of this case control study was to assess risk factors of each preeclampsia 
subtype, looking specifically at the strength of association between ABO blood phenotype and 
the development of preeclampsia.  This chapter defines the variables included in the study, 
provides an overview of the sample as well as the data collection methods that were utilized in 
this dissertation study.  An overview of data analysis methods was also provided. 
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Chapter 4 
 
Study Findings 
Chapter Introduction 
Both blood type and pre-eclampsia subtype have been established as risk factors for 
cardiovascular disease, yet understanding of the role that blood type may play in shaping pre-
eclampsia subtype remains limited.  For this reason, examination of whether blood type is 
associated with pre-eclampsia subtype is needed to clarify whether the onset of specific pre-
eclampsia subtypes may represent an important physiologic link between blood type and later 
life CVD.  The purpose of this hospital- based case-control study was therefore to explore the 
association between preeclampsia subtype and maternal ABO blood phenotype. 
First, descriptive statistics and sample characteristics are presented for the preeclampsia 
group in its entirety, each preeclampsia subtype, and controls.  Next, the primary results for each 
research question are presented.  Chi square test for independence were reported in order to 
examine associations among categorical variables (Research Questions (RQ’s) 1, 2, 3, 5).  Two 
way between groups ANOVA was performed (RQ 4) and both main and interaction effects were 
reported.  Both binary logistic and/or multinomial logistic regression were used to address RQs 
2, 5, and 6 and odds ratios and 95% confidence intervals were reported.  Additionally, in RQ 6, 
Nagelkerke, Cox, and Snell R2 (and change in these values) are reported to represent an estimate 
of variance explained in each model.  All analyses were conducted in SPSS version 23.  Finally, 
a supplementary analysis of the data was performed using mediation analysis in order to assess if 
the relationship between ABO blood type (X) and preeclampsia subtype (Y) was related to 
maternal BMI (M).    
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Research Questions and Hypotheses 
The following are the research questions addressed in the study: 
Research Question 1 
What are the maternal characteristics of women with preeclampsia and with each preeclampsia 
subtype? 
 
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional 
cardiovascular risk factors such as, higher body mass index (BMI), chronic hypertension and 
diabetes.  Additionally, more subjects in the early onset subtype will be of African American 
race, lower socioeconomic class. 
Research Question 2 
Is there an association between preeclampsia subtype and ABO blood type? 
Hypothesis 2: Women with non-O blood types will have greater odds of early-onset 
preeclampsia, compared to those with O blood type.  
Research Question 3 
What is the association between preeclampsia subtype and Rh type? 
Hypothesis 3:  Rh factor will not be associated with preeclampsia or preeclampsia 
subtype.   
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and 
preeclampsia development? 
 
Hypothesis 4:  ABO blood type will be associated with platelet count at > 28 6/7 week in 
each preeclampsia subtype.  
Research Question 5 
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
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Hypothesis 5: ABO blood type will be associated with fetal growth restriction in women 
with preeclampsia. 
Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
Hypothesis 6:  Traditional clinical and sociodemographic risk covariates such as 
increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal age 
will increase odds of preeclampsia and early onset preeclampsia subtype.  Non-O blood types 
will have increased odds of preeclampsia and preeclampsia early onset subtype.  
Results 
Sample Characteristics 
The following are descriptive statistics for each group.  The sample included women with 
the early onset preeclampsia subtype (≤ 33 6/7 weeks) (n=126), the late onset preeclampsia 
subtype (≥34 0/7 weeks) (n=126) and a control group (n=259) of normotensive women.  Women 
in the control group did not have a current or previous history of preeclampsia.   
Research Question 1 
What are the maternal characteristics of women with preeclampsia and with each 
preeclampsia subtype? 
 
Table 1 provides descriptive statistics for the preeclampsia group in its entirety as well as 
controls. 
Preeclampsia.  Although the main aim of this study was to assess preeclampsia subtypes 
association to ABO blood phenotypes, the preeclampsia group will be described in its entirety in 
Table 1.  Since many previous studies on this association did not assess by preeclampsia subtype, 
this author felt it important to also evaluate this relationship and describe the sample in this way.  
The mean age of women with preeclampsia was 27.7 (SD =6.0 years).  Women in this group had 
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a mean BMI 30.34 (8.4 =SD).  Subjects were also categorically assigned a weight classification 
according to their BMI.  In the preeclampsia group, 42% of women were considered obese (BMI 
> 30).  The mean gestational age at delivery for the preeclampsia group was 34.8 (SD= 3.9 
weeks).  The group was mainly White (77.8), 8.5% were Black, 13.7% were other race.  The 
“other race” category consisted of those that identified as Asian (n=2) or Native Hawaiian 
(n=12); subjects from these races were a very small component of this “other” category.  The 
majority of the “other” racial category were individuals who either declined to report their race, 
or reported other race (n=65).  During the chart review, it was noted that study subjects who 
declined to document their race or self-classified as other race tended to be Hispanic.  
Preeclamptic women overall were more often multiparous (54%) and gave birth to more male 
(53.2%) than female infants (46.8%).  The birthweight percentiles of infants born to mothers in 
this group were also assessed for frequency of growth restriction (<10% percentile).  In the 
preeclampsia group, 36.1% of infants experienced some degree of growth restriction. 
  89  
 
 
Table 1
Characteristics of Preeclampsia Subjects (n=252) versus Controls (n=259)
n % n  % p 
Race .595
White 193 77.8 190 74.2
African American 21 8.5 23 9
Other Races 34 13.7 43 16.8
Parity .032
Nulliparous 116 46 94 36.3
Multiparous 136 54 165 63.7
Insurance Type .621
Public 104 45.6 103 42.9
Private 124 54.4 137 57.1
Neonatal Outcome
Live Birth 249 98.8 259 100 *
Fetal Death 1 0.4 0 --
Neonatal Death 2 0.8 0 --
Season of Birth .495
Winter 72 28.6 90 34.7
Spring 73 29 66 25.5
Summer 45 17.9 45 17.4
Fall 62 24.6 58 22.4
Infant Sex .615
Male 133 53.2 131 49.2
Female 117 46.8 128 50.8
BMI <.001
Underweight 7 3.1 9 3.7
Normal 58 25.9 112 45.7
Overweight 65 29 63 25.7
Obese 94 42 61 24.9
Smoker 59 23.4 45 17.4 .113
ABO Blood Type .156
A 95 37.7 100 38.6
B 32 15.1 32 12.4
AB 13 5.2 5 1.9
O 106 42.1 122 47.1
RhD .874
Neg 29 11.5 32 12.4
Pos 223 88.5 227 87.6
FGR 91 36.1 31 12 <.001
BMI= Body Mass Index  FGR=Fetal Growth Restriction
* statistical significance not calculated due to low frequencies 
Preeclampsia Controls
Characteristic
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Early onset.  The data was further analyzed by preeclampsia subtype and is reported in 
Table 2.  The early onset group consisted of women who met preeclampsia diagnostic criteria on 
or before 33 6/7th week in pregnancy.  The mean gestational age at delivery of the early onset 
preeclampsia group was 31 weeks and 6 days (SD=3.09 weeks) however, gestational age at 
delivery varied from 21 weeks and 6 days to 37 weeks and 4 days (Table 3).  Ages of women in 
the group ranged from 17-46 years of age, with a mean age of 28.2 years (SD=6 years).  Early 
pregnancy BMI of women in the group ranged from 16 to 55.3, with a mean BMI of 31.7 (SD= 
8.15) with 51.4% falling into the obese category (BMI>30).  The majority of the early onset 
subgroup was White (73.8%).  Blacks accounted for 12.7% of the early onset group.  The 
majority of women in the early onset subtype were multiparous (63.5%).  These women gave 
birth to more female infants (54.0%).  Although the overwhelming majority of women in this 
subtype had live births (97.6%), there was one fetal death and two documented neonatal deaths.  
Fetal or neonatal deaths did not occur in either the late onset subtype or the control group.  Over 
a quarter of women in the early onset subtype were smokers (27%).  Blood type distribution in 
the early onset subtype was as follows, A (31.7%), B (19.8%), AB (4.8%), (O 43.7%).  Rh-
positive women made up the majority of the subtype (91.3%), with 8.7% of the group having 
Rh-negative blood types.  Growth restriction most effected infants born to mothers with early 
onset preeclampsia, with 55.6% of infants in this subtype weighing less than the 10 percentile for 
their gestational age.  
Late onset.  The late onset subtype consisted of women who had documented 
preeclampsia diagnostic criteria on or after the 34 0/7 weeks of pregnancy.  Characteristics of 
this subtype are documented in Table 2.  The mean gestational age at delivery was 37 weeks and 
6 days (SD=1.89 weeks), however, gestational age at delivery ranged from 34 weeks and 2 days 
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to 41 weeks and 3 days.  The late onset subtype consisted of more nulliparous women then 
multiparous women, 55.6% vs. 44.4%.  The majority of infants born in the late onset subtype 
were males (60.8%).  Mean maternal age was similar to the early subtype, 27.13 (SD= 6 years).  
Early pregnancy BMI for the late subtype was 29.11 (SD= 8.45), BMI’s ranged from 17.8 to 
66.5.  In the late onset subtype, the highest frequency of women had a normal BMI (BMI 18.5-
24.9) (35.7%), however this was closely followed in the frequency by women in the obese 
category (BMI >30) (33%).  This subtype was also predominately White (82%), however 
consisted of 4.1% Black subjects.  Blood type distribution for the late onset subtype was as 
follows A (43.7%), B (10.3%), AB (5.6%) and O (50.5%).  Rh-negative women of any blood 
type made up 14.3% of the group.  
Controls.  Control subjects (n=259) had no current or previous history of preeclampsia, 
characteristics of this group can be found in Table 2.  The mean gestational age at delivery was 
39 weeks and 2 days (SD=1.72 weeks) with an average birthweight of 3359gms (SD=543.4 
grams).  Many more of the women in the control group were multiparous (63.7%).  The ratio of 
male to female infants was roughly even (49.2% vs 50.8%).  Mean maternal age at delivery was 
similar to the late group, 27.7 years (SD=5.56 years).  Of all groups, the controls had the lowest 
mean early pregnancy BMI, 26.5 (SD=6.8).  BMI in this group ranged from 15.00 to 53.00.  
Most women in this group fell into the normal BMI category (BMI 18.5-24.9) (45.7%).  
Similarly, to the other groups, the control group was also predominately White (74.2%).  Black 
subjects represented 9% of the control group.  Of all the groups, controls had the lowest 
percentage of smokers (17.4%).  In the United States blood type distribution is as follows, 44% 
O, 42% A, 10% B, and 4% AB.  Distribution of blood type within the control group was as 
follows, A 38.6%, B 12.4%, AB 1.9% and O 47%.  In the control group, 12.7% had Rh-negative 
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blood types, 87.6% were Rh positive.  In the control group, 12% of infants were growth 
restricted.  
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Table 2
Characteristics of Early (n=126) Late (n=126) and Control (n=259) Subjects
n  % n % n % p
Race .145
White 93 73.8 100 82 190 74.2
Black 16 12.7 5 4.1 23 9
Other Races 17 13.5 17 13.9 43 16.8
Parity .001
Nulliparous 46 36.5 70 55.6 94 36.3
Multiparous 80 63.5 56 44.4 165 63.7
Insurance Type .106
Public 61 52.1 43 38.7 103 42.9
Private 56 47.9 68 61.3 137 57.1
Neonatal Outcome
Live Birth 123 97.6 126 100 259 100 *
Fetal Death 1 0.8 0 -- 0 --
Neonatal Death 2 1.6 0 -- 0 --
Season of Birth .275
Winter 36 28.6 36 28.6 90 34.7
Spring 40 31.7 33 26.2 66 25.5
Summer 26 20.6 19 15.1 45 17.4
Fall 24 19 38 30.2 58 22.4
Infant Sex .047
Male 57 45.2 76 60.8 131 49.2
Female 68 54 49 39.2 128 50.8
BMI <.001
Underweight 3 2.8 4 3.5 9 3.7
Normal 17 15.6 41 35.7 112 45.7
Overweight 33 30.3 32 27.8 63 25.7
Obese 56 51.4 38 33 61 24.9
Smoker 34 27 25 19.8 45 17.4 .088
ABO Blood Type .062
A 40 31.7 55 43.7 100 38.6
B 25 19.8 13 10.3 32 12.4
AB 6 4.8 7 5.6 5 1.9
O 55 43.7 51 40.5 122 47.1
RhD .380
Neg 11 8.7 18 14.3 32 12.4
Pos 115 91.3 108 85.7 227 87.6
 FGR 70 55.6 21 16.7 31 12 <.001
BMI= Body Mass Index  FGR=Fetal Growth Restriction
* statistical significance not calculated due to low frequencies 
Controls    LateEarly
Characteristics
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Comparison of preeclampsia to controls.  Table 1 provides Chi square test for 
independence results for each variable.  A Chi-square test for independence (with Yates 
Continuity Correction) indicated a significant association between parity and preeclampsia, x2(1, 
N= 511) =4.6, p=.032, phi=-.099.  Additionally, a Chi-square test for independence (with Yates 
Continuity Correction) indicated a significant association between growth restriction and 
preeclampsia, x2(1, N= 511) =39.64, p <.001, phi=0.283.  An independent samples t test was 
conducted to compare age, BMI, gestational age and birthweight between preeclampsia patients 
and controls.  All variables were significant at the p <.001 level except for maternal age which 
was not significant (p=.566) (Table 3).  
 
 
Comparison of preeclampsia subtypes.  Participants were divided into three groups, 
according to onset timing of preeclampsia (early ≤ 33 6/7 weeks, late ≥ 34 0/7 weeks, and 
controls (no preeclampsia)).  A Chi-square test for independence indicated a significant 
association between preeclampsia subtype and infant sex x2 (1, n= 509) = 6.13, p= .047, 
Cramer’s V= .11 as well as between preeclampsia subtype and parity x2 (1, N= 511) = 14.45, 
p=.001, Cramer’s V = .168.  One-way between-groups analysis variance was conducted to 
explore significant differences in the mean scores of BMI and maternal age across each 
Table 3
Means of Age BMI , GA and Infant Birthweight Preeclampsia  versus Controls
Variable M (SD) 95% CI M (SD) 95% CI p
Age 27.7(6) [26.9, 28.4] 27.9 (SD 5.6) [27.3, 28.6] .566
BMI 30.34(8.4) [29.3, 31.5] 26.8 (SD 7.1) [25.6, 27.4]  <.001 
GA 34.8(3.9) [34.3, 35.3] 39.3(SD 1.7) [39.1, 39.5] <.001 
Birthweight 2381.4 (957.3) [2261.1 , 2501.6] 3359(SD 543.4) [3292.7, 3525.6] <.001 
Note  BMI= Body Mass Index; GA =Gestational Age
Preeclampsia (n=252) Control (n=259)
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preeclampsia subtype and controls.  There was a statistically significant difference in BMI for 
the three groups: F (2,468) =15.3, p<.001.  Because a significant difference was found, post hoc 
comparisons using the Tukey HSD test where performed in order to reveal exactly where 
differences in BMI exist between groups.  Post hoc comparison revealed that mean BMI scores 
for all groups were significantly different from each other.  There was not a statistically 
significant difference in age across the three groups (Table 4).  Since preeclampsia subtypes are 
defined based on gestational age, which would result in expected differences in mean birthweight 
and gestational age, these variables were not compared, as this would not provide any clinically 
significant findings.  Mean gestational age and birthweights for each group were reported earlier 
in the chapter.  
 
 
 
  
9
6
 
 
 
 
 
 
Table 4
Means of Age and BMI by Preeclampsia Subgroup
Variable M (SD) 95% CI M (SD) 95% CI M (SD) 95% CI p 
Age 28.2 (SD 6) [27.2, 29.3] 27.13 (SD 6) [26.1, 28.2] 27.7 (SD 5.6) [26, 28.4] .279
BMI 31.7 (SD 8.1) [30.1, 33.2] 29.11 (SD 8.4) [27.5, 30.7] 26.5 (SD 6.8) [25.6, 27.4] <.001
Note: BMI=Body Mass Index
    Early (n=126)     Late (n=126)      Control (n=259)
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Comorbidities in each preeclampsia subtype and controls.  Data on common 
comorbidities such as chronic hypertension (CHTN), gestational diabetes (GDM), and 
preexisting diabetes (DM) were collected on subjects in all three groups (early preeclampsia, late 
preeclampsia and controls).  The early onset preeclampsia subset had subjects with the most 
comorbidities, CHTN (27%), DM (9.5%) and GDM (19.0%).  Of the late onset preeclampsia 
subtype, 15.1% had CHTN, 10.3% had GDM, and 3.2% had DM.  No subjects in the control 
group had DM and one had CHTN.  A Chi square test for independence also identified a 
significant association between gestational diabetes and preeclampsia subtype x2 (2, N= 511) 
=7.54, p= .023, Cramer’s V= .121. 
 
 
Research Question 2  
Is there an association between preeclampsia subtype and ABO blood phenotype? 
 
In order to assess the association between preeclampsia subtype and maternal ABO blood 
phenotype a Chi square test for independence was estimated.  Although some expected cell 
frequencies were small, only 16.7% of the contingency table cells had expected cell frequencies 
Table 5
Prevalence of Comorbidities by Early Preeclampsia (n=126), Late Preeclampsia (n=126)
and Controls (n=259)
n  % n  % n  % p
No  CHTN 92 73 107 84.9 258 99.6 *
CHTN 34 27 19 15.1 1 .40
No Diabetes 114 90.5 122 96.8 259 100 *
Diabetes 12 9.5 4 3.2 0 0
No GDM 102 81 113 89.7 234 90.3 .023
GDM 24 19 13 10.3 25 9.7
* denotes that significance level not reported due to low frequencies
CHTN
Diabetes
GDM
Note: CHTN=Chronic Hypertension and GDM=Gestational Diabetes
Preeclampsia Subtype
Early Late Control
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less than 5, subsequently not violating this assumption (Field, 2015).  A Chi square test for 
independence indicated no significant association between ABO blood type and preeclampsia 
subtype, x2 (6, N=511)=11.99, p= .062, Cramer’s V= .108.  Additionally, no significant 
difference was noted when assessing controls versus the preeclamptic group as a whole (p=.156).  
The percentage of Non-O versus O blood types did not significantly differ by preeclampsia 
subtype (p=.456) or within the preeclampsia group as a whole (p=.29). 
Exclusion of comorbidities.  Since many previous studies excluded individuals with 
comorbid conditions, the decision was made to rerun the analysis without comorbid conditions 
included in order to be able to compare data with other studies to see if results were consistent.  
When subjects with comorbidities (CHTN, GDM and preexisting diabetes) are excluded 
(n=108), from the sample, ABO blood type continues not to be significantly associated with 
preeclampsia x2 (3, n= 403) = 6.94, p= .72, Cramer’s V= .132.  However, after excluding 
subjects with comorbidities from both the control group and each preeclampsia subtype,  the 
Chi-square results were statistically significant indicating an association among ABO blood type 
and preeclampsia subtype, x2 (6, n= 403) =24.06, p= .001, Cramer’s V= .173 (Table 6).  The 
early onset subtype was much more likely to have a B blood type (31%) than those with late 
onset preeclampsia (9.3%) or controls (12%).  Frequency of the AB blood type was fairly even 
between early (4.2%) and late (5.2%) preeclampsia subtypes.  The control group consisted of 
less subjects with the AB blood type then both the early and late subtypes (2.1%)(p=.33).   
When analyzing the sample with comorbidities excluded, non-O versus O blood type, 
was statistically significantly associated with preeclampsia subtype x2 (3, n= 403) = 6.92, p= 
.031, Cramer’s V= .131.  However, there was not a statistically significant association when 
analyzing the preeclampsia group x2 (1, n= 403) = 2.69, p= 0.101, phi= .09. 
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Binary Logistic Regression.  Binary logistic regression was performed to further assess 
the association between ABO blood phenotype and preeclampsia.  Initially the model included 
ABO blood phenotype as the predictor.  Maternal ABO blood type was not significant in 
predicting preeclampsia status x2 (3, N=511) =5.35 p=.148, indicating that the model including 
ABO blood phenotype alone was unable to distinguish between preeclamptic subjects and 
controls.  The model as a whole explained 1% (Cox and Snell R squared) to 1.4% (Nagelkerke R 
squared) of the variance in preeclampsia status and correctly classified 53.4% of preeclampsia 
cases.  As shown in Table 7, of the four blood types, only one was statistically significantly 
associated with preeclampsia.  Of the blood types, AB was associated with the greatest odds of 
preeclampsia (OR= 2.99, 95% CI 1.03, 8.67).  This indicates that women with an AB blood type 
had an almost three times the odds of preeclampsia, compared to those with O blood type. This 
model was re-run including race as a control variable given the relationship between race and 
blood type.  After controlling for race, the results remain consistent; AB blood type was 
significantly associated with preeclampsia (OR= 3.03, 95% CI 1.04, 8.80). 
Table 6
ABO Blood Type and Preeclampsia Subtype Comorbidities Excluded 
n  % n  % n  % p 
A 25 34.7 40 41.2 92 39.3 .001
AB 3 4.2 5 5.2 5 2.1
B 23 31.9 9 9.3 28 12
O 21 29.2 43 44.3 109 46.6
Control (n=234)
ABO 
Blood 
Type 
Preeclampsia Subtype
Early (n=72) Late (n=97)
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Multinomial logistic regression.  Multinomial logistic regression was performed to 
further assess the association between ABO blood type and preeclampsia subtype (early and 
late).  Maternal ABO blood type was not significantly associated with preeclampsia subtype x2 
(6, N=511) =11.81 p=.066, indicating that the model including ABO blood phenotype alone was 
unable to distinguish between subjects with each preeclamptic subtype and controls.  The model 
as a whole explained 2.3% (Cox and Snell R squared) to 2.6% (Nagelkerke R squared) of the 
variance in preeclampsia status.  As shown in Table 8, of the four blood types, only blood type 
AB was statistically significantly associated with late onset preeclampsia (OR= 3.35, 95% CI: 
1.02, 11.05).  Although none of the blood types were statistically significantly associated with 
early onset preeclampsia, it is important to note that B blood type is trending towards being 
significantly associated with early onset preeclampsia in this model (p=.078).  After controlling 
for race, results remained consistent; only AB blood type was statistically significantly 
associated with late onset preeclampsia (OR=3.41, 95% CI, 1.03, 11.29).   
 
Table 7
Summary of Logistic Regression ABO Blood Type and Preeclampsia 
Predictor B SE OR 95% C.I.
Wald 
statistic
p
O .177
A 0.09 0.20 1.09 [0.75, 1.60] 0.21 .648
AB 1.10 0.54 2.99 [1.03, 8.67] 4.08 .043
B 0.31 0.27 1.37 [0.80, 2.34] 1.31 .255
p<.05
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Research Question 3    
What is the association between preeclampsia subtype and Rh type? 
A Chi square test for independence was estimated to assess the relationship between Rh 
factor and preeclampsia subtype.  Rh type was not significantly associated with preeclampsia 
subtype, x2 (2, N=511) = 1.94 p= .38, Cramer’s V= .062 by preeclampsia subtype.  It was also 
not significant when assessing preeclampsia versus controls (p= .874).  After exclusion of 
comorbidities, Rh type continued not to be significant when assessed by subtypes (p=.51) and in 
the preeclampsia group as a whole (p= .65).   
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and 
preeclampsia development? 
 
A two way between groups ANOVA was performed to assess if ABO blood type 
moderates the relationship between preeclampsia and platelet count at >28 6/7 weeks gestation.  
The two grouping variables (preeclampsia subtype and blood type) as well as the interaction 
Table 8
Predictor B SE OR 95% C.I.
Wald 
statistic
p
Early         O
A -0.12 0.25 .89 [0.55, 1.44] 0.23 .629
AB 0.98 0.63 2.66 [0.78, 9.10] 2.44 .118
B 0.55 0.31 1.73 [0.94, 3.21] 3.12 .078
Late          O
A 0.27 0.24 1.32 [0.83, 2.09] 1.34 .246
AB 1.21 0.61 3.35 [1.02, 11.05] 3.94 .047
B -0.03 0.37 .97 [0.47, 2.00] 0.01 .938
p <.05
Summary of Multinomial Logistic Regression ABO Blood Type 
and Preeclampsia Subtype
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between the two were used to predict platelet count.  The Levene’s Test of Equality of Error 
Variances was significant (p=.028), this suggests that the variance of platelet count across groups 
was not equal, subsequently a more stringent significance level was used (p=.01) when 
interpreting results.  There were no statistically significant main effects noted for either blood 
type or preeclampsia subtype.  The interaction effect between maternal ABO blood type and 
preeclampsia subtype was not significant F (6, 482) =.845, p=.536, meaning that the influence of 
preeclampsia subtype on platelet count does not depend on maternal blood type.  Although non-
significant, Figure 1 depicts estimated marginal means of platelet counts at greater than 28 6/7 
weeks gestation by each preeclampsia subtype and ABO blood type.   
 
Figure 1 Estimated Marginal Means of Platelets > 28 weeks 
Mediation analysis.  Mediation analysis was performed using PROCESS 2.16 (Hayes, 
2016).  PROCESS “uses an ordinary least squares or logistic regression-based path analytic 
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b= 1.47    p= .44 
Platelet level >28 
6/7
Preeclampsia 
subtype
Maternal ABO 
Blood Type
Figure 2 Mediation Analysis Platelets > 28 6/7 
framework for estimating direct and indirect effects” of variables in a mediated model (Hayes, 
2016).  Mediation attempts to determine if a relationship between a predictor variable and an 
outcome variable can be explained by their relationship to a third variable (Field, 2015) (Figure 
2).  Literature supports that ABO antigens are reflected on the platelet surface, subsequently 
mediation analysis was run to determine if the relationship between maternal ABO blood type 
(predictor) and preeclampsia subtype (outcome) is mediated by platelet level at > 28 6/7 weeks 
gestation.  Blood type did not significantly predict preeclampsia subtype b=1.47, t = .76, p =.44 
additionally, there was no significant indirect effect noted of ABO blood type on preeclampsia 
subtype through platelet count at >28 6/7 weeks gestation b= .0008, BCa CI [-.0013, .0085]   
 
 
 
 
 
 
 
Research Question 5  
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
A Chi square test for independence was performed to assess the relationship between 
ABO blood type and fetal growth restriction (FGR) in preeclamptic women only.  This test 
indicated a significant association between FGR and ABO blood type in preeclamptic subjects x2 
(3, n=252) = 19.52, p <.001, Cramer’s V =.278.  Table 9 depicts frequency of FGR by maternal 
b= .001 p= .37 
Direct effect, b=-.004, p=.87 
Indirect effect, b=.0008 , 95% CI [-.001, .008] 
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ABO blood type in preeclamptic subjects.  In preeclamptic women with the B blood type, almost 
66% of the subjects had a growth-restricted fetus.  No significant association was noted when 
comparing O versus Non-O blood types (p=.99).  Logistic regression was performed in order to 
assess the odds of developing growth restriction amongst women with each preeclampsia 
subtype.  The model including ABO blood type was statistically significant x2 (3, n=252) = 
19.04, p=<.001, indicating that the model was able to distinguish between preeclampsia subjects 
with growth restriction and those without.  The B blood type was the only blood type that was 
statistically significantly associated with growth restriction in preeclamptic women.  Women 
with the B blood type had three times the odds of having a growth-restricted fetus than did 
women with other blood types (OR=3.44, 95% CI 1.58, 7.50).  
  
 
1
0
5
 
 
 
 
 
 
Table 9
Association of ABO Blood Type to Fetal Growth Restriction in Preeclamptic Subjects (n=252)
n % n % n % n % p
FGR 24 25.3 4 30.8 25 65.8 38 35.8 <.001
No FGR 71 74.7 9 69.2 13 34.2 68 64.2
Note FGR =Fetal Growth Restriction
ABO Blood Type
Variable
A AB B O
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Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
preeclampsia subtype? 
 
Initially, binary logistic regression was performed to test the association between 
preeclampsia and other well-documented risk factors of preeclampsia.  An initial model 
containing eight independent variables (BMI, maternal age at delivery, sex of the neonate, 
smoking status at antenatal enrollment, maternal race, insurance type, parity and gestational 
diabetes diagnosis), was statistically significant x2 (9, n=419) =43.93 p<.001, indicating that the 
model was able to distinguish between participants with preeclampsia and those without.  The 
model as a whole explained between 10% (Cox and Snell R squared) to 13.3% (Nagelkerke R 
squared) of the variance in preeclampsia status and correctly classified 64% of preeclampsia 
cases.  The sensitivity of this model or the ability of the model to identify cases of preeclampsia 
was 51.3%.  The specificity of this model or the ability of the model to correctly identify those 
that did not have preeclampsia was 75%.  Four of the variables were statistically significantly 
associated with preeclampsia, nulliparity (OR=1.68, 95% CI 1.08, 2.61), maternal early 
pregnancy BMI (OR=1.07, 95% CI 1.04, 1.11), smoking (OR=1.79, 95% CI 1.07, 3.02) and 
Black race (OR= .456, 95% CI .209, .995).   
Binary logistic regression was rerun including ABO blood type into the model.  This 
model contained ABO blood type and the same eight independent variables used in the previous 
model (BMI, maternal age at delivery, sex of the neonate, smoking status at antenatal enrollment, 
maternal race, insurance type, parity and gestational diabetes diagnosis).  The full model 
containing all variables including ABO blood type was statistically significant x2 (12, n=419) = 
51.01, p=<.00, indicating that the model was able to distinguish between participants with 
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preeclampsia and those without.  Including ABO blood type explained an additional 1.5-2% of 
the variability in preeclampsia group and the model as a whole explained an 11.5% (Cox and 
Snell R squared) to 15.3% (Nagelkerke R squared) of the variance in preeclampsia status and 
correctly classified 63.7% of preeclampsia cases.  The sensitivity of this model or the ability of 
the model to identify cases of preeclampsia was 51.3%.  The specificity of this model or the 
ability of the model to correctly identify those that did not have preeclampsia was 74.6%.  Four 
of the variables were statistically significantly associated with preeclampsia, nulliparity, maternal 
early pregnancy BMI, smoking, and AB blood type (Table 10).  The strongest odds of 
preeclampsia was for AB blood type (OR= 4.93 95% CI 1.26, 19.38), such that individuals who 
had an AB blood type had almost five times greater odds of preeclampsia, controlling for all 
other factors in the model.  When including ABO blood type into the model, the specificity and 
sensitivity of the model remained the same and there was not an improvement in the 
classification of preeclamptic subjects.   
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Multinomial logistic regression.  Multinomial logistic regression was performed to 
assess the association of well-documented preeclampsia risk factors on each preeclampsia 
subtype (early and late).  This model contained eight independent variables (BMI, maternal age 
at delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance 
type, parity and gestational diabetes diagnosis).  The full model containing all variables was 
statistically significant x2 (16, n=417) =44.17, p=<.000 and was a good fit based off non-
significant Pearson and deviance statistics.  The model as a whole explained between 14.2% 
(Cox and Snell R squared) to 16.4% (Nagelkerke R squared) of the variance in preeclampsia 
subtype and correctly classified 56.1% of subjects.  
Three variables were statistically significantly associated with early onset preeclampsia, 
smoking, White race and BMI.  In this study, White individuals were almost three times more 
Table 10
Summary of Logistic Regression Analysis Preeclampsia with ABO Blood Type
Variable B S.E. Wald df p
Odds 
Ratio
Lower Upper
O 5.99 3 .112
A -.002 .23 .00 1 .991 1.00 .63 1.57
AB 1.60 .70 5.23 1 .022 4.93 1.26 19.38
B .29 .33 .76 1 .384 1.33 .70 2.53
BMI .07 .02 21.17 1 .000 1.07 1.04 1.11
White 6.15 2 .046
Black -.78 .41 3.69 1 .055 .46 .21 1.02
Other Races -.63 .33 3.58 1 .058 .53 .28 1.02
GDM .10 .35 .08 1 .781 1.10 .56 2.16
Smoking .58 .27 4.61 1 .032 1.78 1.05 3.01
Nullipara .53 .23 5.39 1 .020 1.70 1.09 2.65
Age -.03 .02 .02 1 .144 .97 .93 1.01
Insurance .006 ,24 .00 1 .979 1.01 .63 1.61
Sex of Baby .12 .21 .32 1 .572 1.130 .74 1.70
Note. CI=confidence interval for odds ratio
95% C.I.for 
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likely to have early preeclampsia (OR= 2.7, 95% CI: 1.11, 6.72).  The effect of smoking was 
positive, (OR= .53, 95% CI .29, .97), so those that did smoke were roughly 50% less likely to 
develop early onset preeclampsia.  For every one unit increase in BMI there is roughly an 8% 
increase in risk of early preeclampsia (OR= 1.08, 95% CI 1.04, 1.12). 
The association of both parity and BMI were statistically significant with late onset 
preeclampsia.  Nulliparous women had two times greater odds of late onset preeclampsia (OR= 
2.1, 95% CI .1.25, 3.65).  For every 1-unit increase in BMI there is roughly a 7% increase in 
odds of late preeclampsia (OR= 1.06. 95% CI 1.03, 1.11). 
Multinomial logistic regression was rerun including ABO blood type into the model.  
This model contained maternal ABO blood type and the same eight independent variables used 
in the previous model (BMI, maternal age at delivery, sex of the neonate, smoking status at 
antenatal enrollment, maternal race, insurance type, parity and gestational diabetes diagnosis).  
The full model containing all predictors was statistically significant x2 (24, N=418) = 74.81 
p<.001 and was a good fit based off non-significant Pearson and deviance statistics.  Including 
ABO blood type explained an additional 2.2% -2.6% of the variability in preeclampsia subtype 
and the model as a whole explained an 16.4% (Cox and Snell R squared) to 18.8% (Nagelkerke 
R squared) of the variance in preeclampsia subtype and correctly classified 56.8% of subjects 
(early 24%, late 17.9%, controls 87.9%).  When including ABO blood type into the model, the 
model remained significant however, there was only a small improvement in the classification of 
subjects with each preeclamptic subtype (56.1% vs 56.8%).   
As shown in Table 11, only four of the variables were statistically significantly associated 
with early onset preeclampsia, AB blood type, smoking, White race and BMI.  The strongest 
association was between AB blood type and early-onset preeclampsia (OR=5.41, 95% CI 1.19, 
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24.55).  This indicated that participants who had an AB blood type have five times greater odds 
of early onset preeclampsia, controlling for all other factors in the model.  In this study, White 
individuals were almost three times more likely to have early preeclampsia (OR=2.9, 95% CI: 
1.16, 7.26).  Smoking was also statistically significantly associated with early onset preeclampsia 
(OR=.528, 95% CI .286, .974).  For every one unit increase in BMI there is roughly an 8% 
increase in risk of early preeclampsia (OR=1.08, 95% CI 1.04, 1.12).   
The association of both parity and BMI remained statistically significantly associated 
with late onset preeclampsia.  Nulliparous women had two times greater odds of late onset 
preeclampsia (OR=2.2, 95% CI .1.25, 3.65).  For every 1-unit increase in BMI there is roughly a 
7% increase in odds of late preeclampsia (OR=1.07. 95% CI 1.03, 1.11).  AB blood type was 
trend-level in the late onset group (p=.053).  
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Supplementary Analysis 
Body mass index.  A supplementary analysis was performed in order to assess if BMI 
mediates the development of preeclampsia.  Previous literature supports the relationship between 
ABO blood type and cardiovascular risk factors, however, due to the small number of subjects in 
the control group with CHTN (n= 1) and DM (n=0), the mediation effect of these variables could 
Table 11 
Summary of Multinomial Logistic Regression Analysis Preeclampsia Subtype and ABO Blood Type
B S.E Wald df p
Odds 
Ratio
Lower Upper 
Blood Type A .01 .29 .00 1 .982 1.007 .569 1.782
Blood Type AB 1.69 .77 4.79 1 .029 5.414 1.194 24.554
Blood Type B .66 .38 2.99 1 .084 1.927 .916 4.053
Insurance -.19 .29 .42 1 .516 .827 .468 1.464
White 1.07 .47 5.20 1 .023 2.904 1.162 7.258
Black .60 .59 1.01 1 .316 1.812 .567 5.790
GDM -.22 .41 .29 1 .590 .804 .363 1.780
Smoking -.64 .31 4.18 1 .041 .528 .286 .974
Sex of Baby .15 .26 .34 1 .559 1.164 .699 1.939
Nullipara .28 .28 1.00 1 .317 1.325 .764 2.297
BMI .08 .02 18.61 1 .000 1.079 1.042 1.117
Age -.02 .03 .37 1 .545 .985 .938 1.034
Blood Type A -.001 .39 .00 1 .997 .999 .575 1.735
Blood Type AB 1.52 .79 3.73 1 .053 4.574 .979 21.381
Blood Type B -.18 .44 1.60 1 .689 .837 .351 1.997
Insurance .21 .30 .51 1 .474 1.239 .690 2.225
White .28 .39 .51 1 .475 1.322 .614 2.847
Black -1.23 .73 2.85 1 .091 .292 .070 1.219
GDM .001 .43 .00 1 .999 1.001 .435 2.303
Smoking -.48 .33 2.08 1 .150 .620 .324 1.188
Sex of Baby -.40 .26 2.29 1 .131 .674 .404 1.124
Nullipara .28 .28 7.67 1 .006 2.148 1.250 3.690
BMI .02 .02 12.14 1 .000 1.067 1.029 1.106
Age -.04 .03 2.94 1 .086 .957 .910 1.006
BMI and Age are mean centered
Note. CI=confidence interval for odds ratio
95% CI 
Early 
Late
Predictor
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not be assessed.  Mediation analysis was run to determine if the relationship between maternal 
ABO blood type (predictor) and preeclampsia (outcome) is mediated by maternal early 
pregnancy BMI.  Blood type did not have a significant direct effect on BMI, additionally, there 
was no significant indirect effect noted of ABO blood type on preeclampsia subtype through 
BMI b= -0.02, BCa CI [-0.023, .005] (Figure 3).  Even when excluding women with 
comorbidities from the sample, no mediation effect was noted.   
. 
 
Figure 3 Mediation Analysis BMI  
 
Chapter Summary 
This chapter reports the results of the study.  Descriptive statistics for subjects with 
preeclampsia as well as controls were reported.  Descriptive statistics were also reported by 
preeclampsia subtype.  Data was analyzed according to each research question with the main aim 
of the study to assess the relationship between ABO blood type and preeclampsia subtype.  Both 
logistic and multinomial regression modeling were performed.  The findings of this study 
suggest that blood type may play a role in the development of each preeclampsia subtype 
particularly in individuals without preexisting and other comorbid conditions of pregnancy.  
Preeclamptic subjects with B blood type had three times the odds of having a growth-restricted 
BMI
Preeclampsia
Maternal ABO 
Blood Type
b =0.31, p= 0.24 b=-0.025, p=<.001 
Direct effect, b=-0.01, p=.73 
Indirect effect, b=-0.02, 95% CI [-0.02, 0.005] 
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fetus.  Logistic regression, revealed that even when controlling for race, AB blood type was 
statistically significantly associated with increased odds of preeclampsia and late onset 
preeclampsia specifically.  Finally, the inclusion of ABO blood type in a model with other 
clinical risk factors of preeclampsia did not improve the specificity and sensitivity of the model 
and no improvement was see in the classification of preeclamptic subjects. 
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Chapter 5 
Discussion, Conclusion, Recommendations 
Chapter Introduction 
 
The pathophysiology of preeclampsia remains unclear.  Scientists believe there may be 
multiple subtypes of the disease, which have varying pathophysiology.  Biomarkers must be 
explored in order to better elucidate the pathophysiologic basis of each preeclampsia subtype.  
Assessing the association between commonly collected biomarkers such as blood type and 
preeclampsia may prove valuable in risk identification.  This chapter provides a discussion of the 
results of this study.  A hospital-based case control study of 511 subjects was completed with the 
main aim of examining the association between maternal ABO blood type and preeclampsia 
subtype.  Each research question is subsequently addressed.  The results are compared and 
contrasted to existing literature on the topic.  Finally, strengths and limitations of the study are 
presented as well as implications for clinical practice and policy and suggestions for further 
research.   
Research Question 1 
What are the maternal characteristics of women with preeclampsia and with each preeclampsia 
subtype? 
 
Description of Study Groups  
Clinical risk factors.  Although not the primary aim, this study provided rich descriptive 
data of each preeclampsia subtype.  Since many studies do not evaluate preeclampsia in relation 
to distinct early and late subtypes, this current study provided a unique opportunity to collect 
data on differences between these two preeclampsia subtypes.  Due to the number of clinical and 
sociodemographic variables on which data was collected, these variables are discussed 
individually below.  
 115 
 
In this study, maternal age was not significant for preeclampsia subtype (p=.279) or 
preeclampsia (p=.566).  Maternal age continued not to be significant when assessed categorically 
(<18 years, 18-34 years, >35 years) (p=.763).  Lisonkova, & Joseph, (2013) cite maternal age 
<20 years as a risk factor for early onset preeclampsia and reported that older maternal age > 35 
years, was associated with preeclampsia, but not a specific subtype.  However, Trogstad, 
Magnus, and Stoltenberg (2011) states that research is conflicting on whether maternal age is a 
risk factor of preeclampsia. 
Infant sex.  Results of this current study were in line with previous research, more infants 
born to preeclamptic women were male than controls (53.2% v 49.2%) although this difference 
was not significant (p=.615).  However, in this current study there was a significant difference in 
infant sex when assessed by preeclampsia subtype (p=.047).  In this study, 54% of the early 
onset subtype had a female infant versus 39.2% in the late onset subtype and 50.8% in the 
control group.  There seems to be a complex and not well understood interaction between the 
fetus and maternal physiology.  Fetal sex has been shown to have an impact on a variety of 
maternal obstetrical outcomes (Jaskolka, Retnakaran, Zinman, & Kramer, 2016).  A recent 
systematic review by Jaskolka and colleagues (2016) reported male fetal sex only to be a 
maternal risk factor for preeclampsia in the non-Asian population.  Previous research has shown 
that carrying a female fetus is associated with early onset or more severe preeclampsia subtypes 
which is in line with results from this dissertation study (Myatt et al., 2014; Zheng, Deng, Zhong, 
& Shi, 2016).   
Race.  Although maternal race was not significant by subtype (p= .145), there were far 
more Black subjects in the early onset subtype (12.7%) then in the late onset subtype (4.1%) and  
the control group (9%).  This may point to the fact that race may influence the severity of the 
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disease, since the early onset subtype is often considered more severe due to its associated higher 
rates of maternal and neonatal morbidity and mortality.  
 Overall data has been conflicting on the significance of race by preeclampsia subtype.  
Data from this study is in contrast to Trogstad et al. (2011) which lists African American race as 
risk factor of preeclampsia.  Pare' et al. (2014) reported that African American race was not a 
risk factor for early onset preeclampsia.  Conversely, Lisonkova, & Joseph (2013) reported that 
African American race was a risk factor for early onset preeclampsia.  Tucker, Berg, Callaghan, 
and Hsia (2007) reported that although non-Hispanic black women did not have a higher 
prevalence of preeclampsia than white women did, they did have much higher case-fatality rates.  
Results on race garnered from this study may be related to the lack of diversity within the sample 
overall.  Community demographics reported on the 2010 census revealed the racial make-up of 
the community where this current study was completed to  be 88.54% White, 5.6% Black and 
5.86% other race which includes Asian and Native Hawaiian or Pacifica Islander 
(Demographics, 2010).  Due to the lack of racial diversity in the community overall, a larger 
sample size may be necessary to detect true subtype differences by race.  However, the 
differences in racial make-up of each preeclampsia subtype and controls in this current study 
does support that race may in some way mediate severity of the disease.   
Parity.  Rates of nulliparity were significantly different between preeclampsia subtype 
and controls (p <.001).  Interestingly, rates of nulliparity were comparable between early 
preeclamptic subjects and controls (36.5% v 36.3%), however; subjects with late onset 
preeclampsia had the highest rates of nulliparity (44%) of all the groups.  Rates of multiparity 
were significantly higher in the early onset subtype (63.5%) than the late onset subtype (44.4%) 
(p=.004).  Data from this current study, further supports the heterogeneous nature of this disease, 
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possibly suggesting that the pathophysiology of late onset preeclampsia may have an 
immunologic component, possibility related to “primipaternity hypothesis” (Hutcheon et al., 
2011, p. 394).  Since rates of multiparity were significantly higher in the early onset subtype, it 
could point to higher rates of preeclampsia reoccurrence in the early onset subtype.  This in turn 
could suggest a different pathophysiologic basis for the early subtype.  Data on preeclampsia 
recurrence was not collected in this current study; future research should be done assessing the 
association between preeclampsia recurrence and maternal ABO blood type.  
Body mass index.  Body mass index was significantly different by preeclampsia subtype.  
The early onset preeclampsia subtype had the highest mean early pregnancy BMI (M=31.7, 
SD=8.15) and 51.4% of subjects in this subtype were in the obese category (BMI > 30) 
compared to the late onset subtype (33%) and control group (24.9%) which were much more 
comparable in terms of BMI.   
It is well documented that obesity substantially increases the risk of preeclampsia; 
Bodnar et al. (2005) reported that women with a body mass index (BMI) of 30 have threefold 
higher odds of developing preeclampsia.  Roberts et al. (2011) reported that obesity increased 
risk of both the early and late subtypes of preeclampsia.  In this study, data was collected on 
maternal prepregnancy or early pregnancy (<13 weeks gestation) BMI.  Roberts et al. (2011) 
postulate that since both preeclampsia and obesity share a similar dyslipidemic profile, possibly, 
obese women with the most abnormal lipids are at the highest risk of preeclampsia.  In this 
study, lipid profiles on each patient were not collected.  Research supports that dyslipidemic 
profiles may differ by blood type (Etemadi et al., 2015; Lee et al, 2012).  Future research should 
aim to compare lipid profiles by ABO blood type of women in each preeclampsia subtype as this 
my help to further differentiate the pathophysiologic basis of each preeclampsia subtype and 
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provide some clarity about the association between preeclampsia and long-term risk or 
cardiovascular disease.   
Since obesity is one of the only modifiable risk factors of preeclampsia, this study further 
supports the need for health care providers to provide education and counseling on preconception 
and interconception weight loss in order to help women reach a healthy weight prior to 
pregnancy.  Since women with the early onset subtype had higher rates of both multiparty and 
obesity than both the late onset subtype and controls, it is important for providers to have 
conversations about interconception weight loss and management in order to prevent 
complications in future pregnancies.  The provision of evidence based and culturally appropriate 
programs to women of reproductive age on weight management and physical activity may have 
significant implications for maternal and neonatal obstetrical outcomes.   
Smoking.  Due to the retrospective nature of this study, it is difficult to determine how 
much and how often subjects smoked.  There were more smokers in both preeclamptic subtypes 
than in the control group.  Rates of smoking between the preeclampsia subtypes and controls was 
not significant (p=.088), subjects with early onset preeclampsia had the highest rates of smoking 
(27%).  In the regression when all other clinical risk factors were included, smoking was 
protective of early onset preeclampsia, (OR= .53, 95% CI .29, .97), so those that did smoke were 
roughly 50% less likely to develop early onset preeclampsia.  There was no significant 
association with the late onset subtype.  This result was similar to other studies (Hutcheon et al., 
2011; Savitz et al., 2014).  However, this association has been shown to be dose dependent, and 
if smoking is stopped early in pregnancy, there is no protective effect.  In this current study, 
smoking data was collected based off documentation of smoking status early in pregnancy so the 
amount each women smoked was difficult to quantify.  
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Gestational diabetes.  Researchers have documented that preexisting disease such as 
chronic hypertension and diabetes are risk factors for preeclampsia (Bartsch et al., 2016).  As 
expected, the highest rates of the comorbidities studied (GDM, HTN, DM) were seen in subjects 
with early onset preeclampsia.  Rates of gestational diabetes were significantly different between 
the preeclampsia subtypes and control group (p=.023) with the highest rates of GDM seen in the 
early onset preeclampsia subtype (19%).  In the early onset subtype, 22 subjects delivered 
between 21 and 28 weeks.  Although some subjects in the early onset subtype may have had 
early prenatal glucose testing due to clinical risk factors such as BMI > 30, history of GDM or 
previous infant > 8’13oz, because testing for GDM typically occurs at 28 weeks of gestation, it is 
possible, that due to rates of prematurity in this subtype, numbers of subjects with GDM may 
have been far higher in this group and gone undiagnosed (WellSpan High Risk Standing Order 
Set, 2016).  Rates of GDM in the late onset and control group were comparable (10.3% v 9.7%).  
A study by DeSisto, Kim & Sharma (2014) using data from the Pregnancy Risk Assessment 
Monitoring System (PRAMS) found prevalence of GDM might be as high as 9.2% which was 
similar to controls in this study (9.7%).  Rates of GDM in women with the early onset 
preeclampsia subtype were over twice that of controls.  This supports the need for the provision 
of pointed patient education at the time of GDM diagnosis on signs and symptoms of 
preeclampsia, as preeclampsia seems to occur earlier in this patient group.  
Chronic hypertension.  More subjects in the early onset subtype (27%) had CHTN than 
in the late onset (15.1%) or the control group (0.4%).  Rates of CHTN between the early and late 
onset preeclampsia subtypes were significantly different (p=.03).  This further supports the 
increased severity of the disease in women with CHTN.  Providers should be aware of ACOG 
(2013) and the United States Preventive Task Force (2014) guidelines for the use of aspirin 
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therapy for preeclampsia prophylaxis in women with CHTN. The use of aspirin therapy 
beginning as early as 12 weeks gestation may help to decrease risk of preeclampsia in these high-
risk women.  Additionally, recent research has shown that women with early onset preeclampsia 
have 7-9 times increased risk of CVD later in life (van Rijn et al., 2013).  In this current study, 
the higher rates of obesity and chronic hypertension seen in the early preeclampsia subtype could 
further support that the link between early onset preeclampsia and CVD risk may be potentiated 
by the increased rates of cardiovascular risk factors seen in this subtype rather than physiologic 
alterations that occur from preeclampsia.  Further longitudinal studies are needed in this area.  
Neonatal outcome.  There were three fetal (n=1)/neonatal (n=2) deaths in the early onset 
preeclampsia subtype.  However, there were no occurrences of fetal or neonatal death in the late 
onset or control groups.  Subsequently, statistical significance was not reported on this variable.  
However, it is important to consider the clinical significance of this finding.  It is well 
established that the early onset subtype is associated with significant perinatal morbidity and 
mortality (Hutcheon et al., 2011; Lisonkova, & Joseph, 2013).  This may be related to the earlier 
gestational age at birth however, the increased morbidity and mortality in the early subtype may 
also be related to other pathophysiologic changes that occur in subjects with this subtype that 
require further study.  
      Seasonality.  In this current study, infant month of birth was classified according to season 
(winter, spring, summer, and fall).  The current study did not support the seasonality of 
preeclampsia and found no difference in the seasonal rates of the disease by subtype (p=.275).  
Literature on preeclampsia supports the seasonality of the disease.  In non-tropical climates such 
as the U.S., increased rates of preeclampsia have been seen in the winter months (Tepoel, Saftlas, 
& Wallis.2011).  Interestingly, in a metanalysis by Tepoel et al. (2011) three of 14 studies 
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reviewed also did not support the hypothesis that preeclampsia is seasonal in nature; two of the 
three were also hospital based case control studies.  A larger sample size may be necessary to 
detect seasonal differences.  
 
Research Question 2 
Is there an association between preeclampsia subtype and ABO blood phenotype? 
Preeclampsia subtype (early, late) trended towards being significantly associated with 
ABO blood phenotype when assessed by individual blood type (A, B, AB, O) (p=.062).  In this 
current study, when analyzing the frequency of each blood type within each preeclampsia 
subtype, it was noted that 19.8% of the early onset subtype had a B blood type.  This was 
considerably more than in the late onset preeclampsia subtype (10.32%) and control group 
(12.36%) and trended towards statistical significance (p=.06).  Both the AB  (p=.133) and A 
blood types (p=.147) were also not significantly associated with preeclampsia subtype when 
analyzed individually.  Additionally, this author did not find non-O blood type to be significantly 
associated with preeclampsia (p=.29) or preeclampsia subtype (p=.46).   
Excluding comorbidities.  Interestingly, when excluding individuals with comorbidities 
such as GDM, CHTN and DM, ABO blood type was significantly associated with preeclampsia 
subtype (p= .001).  Subsequently, there seems to be a stronger relationship between blood type 
and preeclampsia subtype in healthy individuals than in those with comorbidities.  It is possible 
that in healthy individuals, the pathway to preeclampsia development is influenced by blood 
type’s effect on the regulation of biomarkers of coagulation and inflammation whereas the 
increased risk of preeclampsia in individuals with comorbid conditions may follow a different 
pathophysiologic pathway.  Due to the low number of individuals with CHTN and DM in the 
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control group, mediation analysis was not performed.  In future studies, mediation analysis could 
be done in order assess the role various biomarkers play in mediating the development of 
preeclampsia subtype in women with and without comorbidities and of different blood types.  
This could be done in order to better assess if there are different pathophysiologic pathways that 
lead to the development of preeclampsia in previously healthy women. 
There have been conflicting results in studies that have explored the association between 
ABO blood type and preeclampsia.  The results of this current study were similar to those of 
other authors in the literature review (Alpoim et al., 2012; Hiltunen et al., 2009; Hentschke et al., 
2014) and did not find non-O blood types to be associated with preeclampsia.  Results on the 
association between blood type and preeclampsia have varied, and it is difficult to synthesize the 
literature on ABO blood type and preeclampsia as studies have used varying inclusion criteria.  
Some studies in the literature review chose to exclude subjects with comorbidities or multiparous 
women from their sample (Alpoim et al., 2011; Hiltunen et al., 2009; Lee, Zhang et al., 2012; 
Spinillo et al., 1995).  In this current study, in order to address the possible confounding effect of 
comorbid conditions, subjects with comorbidities (CHTN, DM and GDM) were included in both 
the case(s) and control groups.  Lee, Zhang et al. (2012) also chose to include women with 
preexisting hypertension and diabetes in their study and did not find any evidence of 
confounding.   
Logistic regression.  Binary logistic regression was performed to further assess the 
association between ABO blood phenotype and preeclampsia.  Maternal ABO blood type was 
not significant in predicting preeclampsia, however, AB blood type was statistically significantly 
associated with the greatest odds of preeclampsia (OR 2.99, 95% CI 1.03, 8.67).  Even when 
adjusting for race, subjects with AB blood type continued to have three times the odds of 
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developing preeclampsia (OR 3.03, 95% CI 1.04, 8.80).  Similar results were reported when 
examining the association between blood type and preeclampsia subtype.  Interestingly, even 
when controlling for race, AB blood type (OR 3.41, 95% CI, 1.03, 11.29) was statistically 
significantly associated with the greatest odds of late onset preeclampsia, no blood type was 
statistically significantly associated with early onset preeclampsia.   
This current study supported the findings of other studies on this topic, which also 
reported that women with AB blood type have the highest odds of preeclampsia of all blood 
types.  In these studies, odds ratios ranged from 1.0 to 2.4 (Alpoim et al., 2012; Clark & Wu, 
2008; Hiltunen et al., 2009; Lee & Zhang et al., 2012; Phaloprakarn & Tangjitgamol, 2013).  The 
main aim of these previous studies was to examine the association between ABO blood type and 
preeclampsia as a homogenous group.  To this authors knowledge, this study is the first to 
describe an association between late onset preeclampsia and AB blood type. 
Rationale for the association between preeclampsia and AB blood type may be related to 
the increased levels of Von Willebrand factor noted in non-O blood phenotypes.  Individuals 
with non-O blood types have been shown to have a 25% increase in VWF and FVIII above their 
O blood type counterparts and plasma levels of VWF increase by blood type in the following 
order O>A>B>AB (Alpoim et al., 2012).  It is plausible that the higher levels of these 
coagulation factors may increase the risk of thrombus (Alpoim et al., 2012; Alpoim et al., 2011).  
Researchers have postulated that the increased risk of thrombus in individuals with non-O blood 
types may result in increased risk of micro-thrombus in the placental vasculature subsequently 
decreasing placental blood supply (Alpoim et al., 2011).  Future research should be done to 
examine if levels of VWF vary by blood type and each preeclampsia subtype.   
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In addition to varying level of coagulation factors, blood type has been shown to play a 
role in inflammation and immunity as well as the regulation of other biochemical markers 
(Alpoim et al., 2011; Franchini & Lippi, 2015; Hiltunen et al., 2009; Lee et al., 2012; 
Phaloprakarn & Tangjitgamol, 2013).  Seyfizadeh et al. (2014) reported that serum creatinine 
levels in blood type AB were higher than all other blood groups.  Increasing serum creatinine 
level is considered a diagnostic marker of increasing preeclampsia severity, and could play a role 
in the pathophysiology of the disease (ACOG, 2013).  Future research should address the 
association between levels of biomarkers of preeclampsia seventy such as serum creatinine, and 
maternal blood type.   
Research Question 3 
What is the association between preeclampsia subtype and Rh type? 
Rh factor was not significantly associated with preeclampsia (p=.87) or preeclampsia 
subtype (p=.38) even when controlling for comorbidities (p=.51).  However, the early onset 
preeclampsia group had the lowest frequency of Rh-negative women (8.73%) as compared to the 
late onset group (14.3%) and controls (12.4%).  In this current study, 87.64% of the control 
group was Rh positive, this is similar to population based results which report that 85% of the 
population is Rh positive (“Blood Typing Systems,” 2010).  The results of this current study 
were in line with Shamsi et al. (2010) and López-Pulles et al. (2010) who both also reported no 
significant association between Rh factor and preeclampsia.  Two studies in the review of 
literature did report an association between Rh factor and preeclampsia.  Sezik et al. (2001) 
stated that O Rh negative women had a higher risk of HELLP syndrome.  Lee and Zhang et al. 
(2012) also reported that Rh-positive women had a small increased risk of preeclampsia (OR 
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1.07, 95% CI 1.03-1.10).  More research may be necessary to assess if Rh status plays a role in 
the severity of the disease and in differing populations. 
Research Question 4 
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and 
preeclampsia development? 
 
In this study, blood type did not moderate platelet level at admission for delivery in 
preeclampsia subtypes and controls.  The interaction effect between maternal ABO blood type 
and preeclampsia subtype was not significant F (6, 482) =.845, p=.54, nor were there statistically 
significant main effects noted for either blood type or preeclampsia subtype.  The estimated 
marginal means of platelet levels at > 28 6/7 weeks gestation in both the early and late 
preeclampsia subtype followed a similar pattern by blood type.  The mean platelet count in 
women with B blood type was noted to be less than that of other blood types, although not 
statistically significant.  Additionally, although not statistically significant, the higher platelet 
counts noted in subjects with AB blood type may also be clinically significant (Figure 1).   
ABO antigens are expressed on a variety of human cells and tissues including platelets 
(Karabuva, Carević, Radić, & Fabijanić, 2013).  Subsequently, it is important to consider the role 
blood type may play in mediating platelet count.  The endothelial damage that occurs in cases of 
severe preeclampsia causes increased turnover of platelets resulting in decreased platelet count 
(Özdemirci et al., 2016).  The diagnostic criteria of preeclampsia is defined by ACOG (2013) as 
the new onset of hypertension (≥140mm Hg systolic or .≥90mmHg diastolic) after 20 weeks 
gestation on two occasions at least four hours apart, and proteinuria (≥300mg in a 24-hour urine 
collection).  In the absence of proteinuria, if the patient has a platelet count < 100,000 per 
microliter, the diagnosis of preeclampsia can be made.  A decrease in platelet count to <100,000 
per microliter also marks increasing severity of the disease.  Data from this current study 
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supports the need for future research to explore the relationship between blood type and levels of 
other laboratory markers associated with severe features of preeclampsia such as platelets, liver 
enzymes, and serum creatinine.  
Furthermore, other laboratory measures of platelets may better test their relationship to 
both ABO blood type and preeclampsia subtype.  Han et al. (2014) and Myatt (2009) also did not 
find an association between platelet count and development of preeclampsia, but did find that 
mean platelet volume was significantly greater in women who developed preeclampsia.  Other 
platelet indices, especially mean platelet volume (MPV), may be better indicators of 
preeclampsia severity than platelet count (Han et al., 2014; Myatt, 2009). 
Research Question 5 
What is the association between ABO blood type and fetal growth restriction in preeclamptic 
women?  
 
In this current study, in women with preeclampsia, FGR was significantly associated with 
ABO blood type (p=<.001).  Of the blood types, subjects with B blood type had the highest rates 
of FGR.  In women with preeclampsia, 66% of those with a B blood type experienced FGR.  
Preeclamptic women with the B blood type had three times the odds of having a growth-
restricted fetus than did women with other blood types (OR 3.44, 95% CI 1.58, 7.50).   
Hiltunen et al. (2009) also discovered an association between blood type and growth 
restriction in preeclamptic women, however in their study; preeclamptic subjects with AB blood 
type had higher rates of growth restriction.  Although fetal growth restriction is no longer 
considered diagnostic of preeclampsia, it may point to increasing severity of the disease (Fox, 
Huang & Chasen, 2008).  The American College of Obstetricians and Gynecologists (2013) Task 
Force Statement on Hypertension in Pregnancy recommends that preeclamptic women 
experiencing growth restriction should be monitored closely.  These results further support that B 
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blood type may in some way be associated with increasing severity of preeclampsia and women 
with this blood type may require close monitoring of fetal growth as well as other severe features 
of the disease.  Further research should examine the pathophysiologic mechanism that mediates 
the development of growth restriction in individuals with the B blood type. 
Research Question 6 
What factors are significantly associated with preeclampsia and preeclampsia subtype?  
Preeclampsia.  Initially, binary logistic regression was performed to test the association 
between preeclampsia and other well-documented risk factors of preeclampsia.  The initial 
model containing eight independent variables (BMI, maternal age at delivery, sex of the neonate, 
smoking status at antenatal enrollment, maternal race, insurance type, parity and gestational 
diabetes diagnosis) was statistically significant x2 (9, n=419) =43.93 p<.001.  Binary logistic 
regression was rerun to include ABO blood type and the same eight independent variables used 
in the previous model.  This model was also statistically significant, x2 (12, n=419) = 51.01, 
p=<.00, however, including ABO blood type only explained an additional 1.5-2% of the 
variability in preeclampsia group.  The addition of ABO blood type did not provide much 
improvement when classifying preeclampsia subjects.  However, controlling for all other factors 
in the model, subjects with AB blood type had almost five times greater odds of preeclampsia 
(OR=4.93 95% CI 1.26, 19.38).  The confidence intervals reported are wide, indicating that the 
sample size of individuals with AB blood type were rather small.  Subsequently, results of this 
analysis should be interpreted cautiously.   
Preeclampsia subtype.  Multinomial logistic regression was performed to test the 
association between preeclampsia subtype and other well-documented risk factors of 
preeclampsia.  The initial model containing eight independent variables (BMI, maternal age at 
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delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance 
type, parity and gestational diabetes diagnosis) was statistically significant x2 (16, n=417) 
=44.17, p=<.000.  There were different variables statistically significantly associated with each 
preeclampsia subtype.  Smoking, White race, and BMI were statistically significantly associated 
with early onset preeclampsia, while nulliparity and BMI were statistically significantly 
associated with late onset preeclampsia.   
Multinomial logistic regression was rerun to include ABO blood type as well as the eight 
clinical risk factors used in the previous model.  The model remained significant however; there 
was only a small improvement in the classification of subjects within each preeclamptic subtype.  
When all clinical risk factors are included in the model, AB blood type significantly predicts 
membership in the early onset preeclampsia subtype (OR=5.41, 95% CI, 1.19, 24.55) and was 
trend-level in the late onset group (p=.053).  The other variables that were significant prior to the 
inclusion of blood type into the model remained the same by subtype.  This suggests that the 
utility of blood type as a risk factor for preeclampsia (regardless of onset) is weak after 
considering the other risk factors collected in the study, which is further supported by the small 
amount of variability accounted for in the model by ABO blood type.  ABO blood type may not 
be a valuable addition to a preeclampsia-screening algorithm that already includes common 
clinical risk factors of preeclampsia.  With this said, it is important to consider the role ABO 
blood type has in the regulation of other biomarkers of inflammation and coagulation that may 
influence the development of each preeclampsia subtype.  Than et al. (2011) reported that 
Placental Protein 13 (PP13) an early biomarker of preeclampsia, binds differently to each ABO 
blood type.  Subsequently, serum levels of PP13 may prove to be a better predictor of 
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preeclampsia, and this may explain the association between ABO blood type and preeclampsia 
when other variables are not in the model.  
Strengths and Limitations 
 To this author’s knowledge, this current study demonstrated for the first time an 
association between AB blood type and late onset preeclampsia subtype in women in the United 
States even after controlling for race.  Subjects with AB blood had three fold-increased risk of 
late onset preeclampsia.  Varying definitions of preeclampsia subtypes used in the literature have 
made it difficult to synthesize the outcomes of studies reviewed.  The inclusion of older research 
in reviews may lead to further difficulty in synthesizing outcomes due to recent changes in 
preeclampsia diagnostic criteria.   
Recognizing the heterogeneity of the disease, Myatt et al. (2014) called for researchers to 
begin to examine preeclampsia by the subtypes, early and late onset.  Myatt (2014) suggests that 
researchers should carefully examine medical records for the onset of preeclampsia 
symptomology rather than simply using gestational age at delivery to signify subtype 
membership.  A strength of this study is that preeclampsia was studied by subtype rather than 
studying preeclampsia as a homogenous group.  Additionally, subjects were classified into 
preeclampsia subtypes based on the documented onset of subjective and/or objective 
preeclampsia diagnostic criteria rather than gestational age at delivery.  Chart review was used to 
assess for strict ACOG (2013) diagnostic criteria in order to determine subtype membership 
(early onset ≤ 33 6/7 weeks, late onset ≥ 34 0/7).  Other studies have used diagnostic codes to 
confirm preeclampsia cases, and used gestational age at delivery as a proxy to classify 
preeclampsia subtype, which could result in subtypes being diluted due to lack of stringent 
classification criteria.  Confirming preeclampsia diagnosis was time consuming, but improved 
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the overall reliability of the study as compared to studies that utilized diagnostic codes for 
inclusion without a formal chart review to confirm the diagnosis (Brown et al., 2013; Savitz et 
al., 2014).    
The study was adequately powered to detect differences in O versus non-O blood type by 
preeclampsia subtype.  Many previous studies in this area chose to use subsample analysis to 
assess differences between preeclampsia subtypes, subsequently achieving the appropriate 
sample size for both early and late onset subjects is a strength of this study.   
In order to further improve the overall reliability of the data gleaned, prior to beginning 
data collection, the blood bank was visited and their procedures for calibration and 
documentation of blood type were assessed for quality.  Additionally, standardized data 
collection procedures were utilized when abstracting information from the EHR 
It is necessary to address the limitations of this study and the applicability and 
generalizability of the findings.  Many of the variables included in the study were measured by 
self-report, such as parity and ethnicity.  Although this could potentially affect accuracy of the 
data, collection of data by self-report for these measures is appropriate, as it is standard practice 
(Gorber, Tremblay, Moher, & Gorber, 2007).  It is unknown if height was consistently measured 
or collected by self-report, as this varies by obstetrical practice, this may affect the reliability of 
the data on this variable (Gorber et al., 2007).  Additionally, due to the retrospective nature of 
this study, in terms of measurement of variables, weight measurements were not collected from 
scales that were known to be regularly calibrated.  However, all health care personnel who 
obtained this data are trained on how to obtain these measurements, although it is unknown about 
the rigor of teaching and monitoring the practices of these tasks. 
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  A small sample from one hospital in one geographic region was utilized for this study, 
and a majority of the subjects were White so the findings may not be generalizable to other 
populations.  Additionally, due to the fact that the hospital is a referral center, cases, particularly 
those with the early onset preeclampsia subtype, may have followed a different referral pattern 
than controls.  To this author’s knowledge, no other studies have been conducted in the U.S with 
the primary aim to assess the relationship between preeclampsia subtype and ABO blood type.  
Since blood type varies by ethnicity this study fills an important gap in the literature.   
Recommendations 
Recommendations for Clinical Practice 
Preventative therapy.  Research exploring biophysical characteristics and biochemical 
markers associated with each subset of preeclampsia is integral to the discovery of the distinct 
pathophysiologic mechanisms which drive the onset timing and severity of this heterogeneous 
disease.  Without a clear understanding of the pathophysiology of preeclampsia, the creation of 
targeted therapies has proven difficult.  Recent evidence has shown use of aspirin may be helpful 
in prevention of preeclampsia particularly in high-risk women (Bujold et al., 2010).  In patients 
with preeclampsia, it seems that aspirin improves trophoblast invasion of the uterine spiral 
arteries as well as the cytokine profile, and may decrease cell death and increase production of 
placental growth factor (Middeldorp, 2014).  Literature supports increased levels of certain 
inflammatory cytokines and procoagulation factors by blood type (Franchini, Mengoli, & Lippi, 
2016), and due to the variation in platelet count and FGR noted by blood type in this study, it 
may be valuable to assess if aspirin therapy is more effective in high-risk women with certain 
blood types.  
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Early identification.  In this study, 66% of preeclamptic women with a B blood type 
experienced FGR; preeclamptic women with B blood type had three times the odds of having a 
growth-restricted fetus.  This suggests that health care providers should carefully assess for FGR 
in preelamptic women with the B blood type.  Additionally, the trend in lower platelets in the B 
blood type could also serve as a proxy for risk of increased severity of the disease.  This also 
supports the need to closely monitor pregnant clients with B blood types early in pregnancy for 
manifestations of preeclampsia.  Early in pregnancy, providers may want to begin to educate 
women with B blood type about the signs and symptoms of preeclampsia and keep this 
association in mind if these patients report non-descript symptoms that could be associated with 
preeclampsia.  Furthermore, research currently supports that low dose aspirin therapy started 
earlier in pregnancy (<16 weeks) is more effective particularly in reducing risk of FGR and 
severe preeclampsia (Roberge et al, 2016).  Subsequently, blood type could be useful in 
identifying women at risk for poor outcomes early in pregnancy and thus allow for earlier 
initiation of aspirin therapy.  
 Cardiovascular risk.  ABO blood type, specifically non-O blood type, has been shown 
to increase cardiovascular risk (Etemadi et al., 2015; Gong et al., 2014; He et al., 2012; Jassim, 
2012; Lee, Lin et al., 2012).  With an understanding that preeclampsia not only effects 
pregnancy, but also influences the lifelong cardiovascular health of a woman and her offspring, 
an understanding of risk factors shared between both diseases could provide a foundation for the 
development of programs and therapies aimed at decreasing risk of long-term cardiovascular 
sequela in these women (Herrera-Garcia, & Contag, 2014).  When adjusting for race only, this 
study revealed an association between AB blood type and both preeclampsia, and specifically 
late onset preeclampsia.  Cardiovascular research also supported the link between AB blood type 
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and poor cardiovascular outcomes (He et al., 2012; Karabuva, Carević, Radić, & Fabijanić, 
2013; Zakai et al. 2014).  Health care providers should consider targeting women with AB blood 
type earlier in their lifespan in order to assess for cardiac risk and provide cardiopreventative 
strategies.   
` Maternal weight management.  Although not the main aim of this study,  BMI was 
consistently statistically significantly associated with increased odds of developing preeclampsia 
and each preeclampsia subtype.  With an understanding of the increased maternal and neonatal 
morbidity and mortality associated with preeclampsia this study further supports the importance 
of education on and support towards achieving a healthy weight prior to and between 
pregnancies (Malnory & Johnson, 2011).  
Policy Recommendations 
Documentation.  Although this study yielded interesting statistical results, clinically 
relevant results were also gleaned during the extensive chart review and data collection process 
that may have implications for practice.  It is well documented that the clinical signs and 
symptoms of preeclampsia are often non-descript (You, Wolf, Bailey, & Grobman, 2012).  Upon 
chart review, women reported “not feeling right,” and many reported headache as a clinical 
symptom.  Cerebral disturbance as a symptom was often difficult for providers to interpret as 
many women had a history of migraines that made it difficult to determine if the headache was a 
marker of increasing preeclampsia severity or simply the patient’s medical history.  Additionally, 
in an effort to confirm preeclampsia diagnosis a 24-hour urine specimen was often ordered.  This 
seemed to delay diagnosis (Townsend, R., O’Brien & Khalil, 2015).  Chart review revealed that 
maternal diagnosis of preeclampsia was not consistently documented in the history and physical 
of the newborns born to preeclamptic women.  With an understanding of the association between 
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preeclampsia and risk of hypertension in these offspring, documentation of birth history proves 
important to assessing future health and complications in infants born to preeclamptic women 
(Founds, 2014; Geelhoed et al., 2010; Herrera-Garcia, & Contag, 2014).  
Cardiovascular risk education.  Finally, during documentation review, a few charts 
revealed provider documentation, on conversations with the subject on the association between 
preeclampsia and long-term cardiovascular risk.  The majority of electronic health records of 
preeclampsia cases which were reviewed did not have documentation on education related to the 
association between preeclampsia and long-term cardiovascular health.  Recent literature has 
shown that many obstetricians and primary care physicians are not aware of the association 
between preeclampsia and future cardiovascular disease in previously affected women (Young, 
Hacker & Rana, 2012).  In a study by Young, Hacker & Rana, (2012) “only 9% of internists and 
38% of obstetrician-gynecologists were providing cardiovascular risk reduction counseling to 
women with a history of preeclampsia” (p. 1).  The AHA (2014) reported that many more 
women with a history of preeclampsia experienced a cardiovascular event in the 10 years 
following delivery then those women with uncomplicated pregnancies (Bushnell et al., 2014).  
Best practices on when and how to educate women on the association between CVD and 
preeclampsia are not known.  However, based on the risk of poor cardiovascular outcomes in the 
decade following the index pregnancy, and AHA recommendations for follow up, providers need 
to ensure women are educated on this association soon after delivery so women can begin close 
follow up with their PCP and institute cardiopreventive strategies (Celi et al., 2013).  
Screening algorithms.  It seems that an ideal preeclampsia screening algorithm would 
need to be done in the first trimester, as any preventive intervention would also need to be 
provided early in pregnancy when placentation occurs.  Since abnormal placentation may be a 
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key component of the pathophysiology of preeclampsia, the timing of effective screening tests is 
important to consider (Townsend et al., 2015).  Although, providers and policy makers are 
working to promote early recognition and standardized treatment plans for preeclampsia, 
currently there is currently no valid screening algorithm for preeclampsia.  In this current study, 
when including ABO blood type into a model with other clinical risk factors of preeclampsia, 
ABO blood type did not increase the sensitivity or specificity of the model.  Furthermore, when 
in the model with other clinical risk factors of preeclampsia, AB blood type only increased odds 
of early onset preeclampsia, and each preeclampsia subtype had different variables that were 
significantly associated with the outcome.  Subsequently, it is also important to consider that 
subtypes of preeclampsia may have differing etiology, and one single screening algorithm may 
not be appropriate in order to capture all women at risk of preeclampsia.  Mikat et al. (2012) 
suggests that early detection requires three main components, each that complements the other 
when assessing risk.  These components include biophysical markers, biochemical markers, and 
maternal medical history (Mikat et al., 2012).  Mikat et al. (2012) stated that when using 
maternal history alone for early preeclampsia detection, only 30% of women are detected with a 
5% false positive rate.  More research is needed in order to discover biomarkers specific to each 
preeclampsia subtype in order to improve prediction. 
Recommendations for Further Research 
The primary aim of this study was to determine if maternal ABO blood type was 
associated with preeclampsia subtype.  The subtypes of preeclampsia that were explored were 
related to timing of onset, early (≤ 33 6/7 weeks gestation) versus late (≥ 34 0/7 weeks 
gestation).  There are other preeclampsia subtypes discussed in the literature, such as, proteinuric 
and non-proteinuric preeclampsia and preeclampsia with FGR and preeclampsia without FGR.  
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Future research should be done to explore if there is an association between these other 
preeclampsia subtypes and ABO blood type. 
Previous studies on the association between ABO blood type and preeclampsia have been 
done in various racial and ethnic populations.  Articles in the review of literature consisted of 
studies done in Thai, Hungarian, Turkish, Scottish, Finnish, Swedish, Iranian, Ecuadorian and 
Brazilian populations (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et al., 2009; Lee, Zhang 
et al., 2012; Phaloprakarn & Tangjitgamol, 2013; Seyfizadeh et al., 2014).  Since blood type 
varies by ethnicity, it is important to explore this association in various populations.  
Additionally, since serum levels of certain inflammatory, thrombotic, and angiogenic markers 
such as VWF, PP13, and Tumor necrosis factor, that may mediate the development of 
preeclampsia subtype, vary by blood type and ethnicity, further study is necessary to explore this 
association.  This may help to clarify the role maternal ABO blood phenotype plays in the 
development of each preeclampsia subtype, and support why results are inconsistent in studies 
on ABO blood type and preeclampsia, as the association between certain inflammatory cytokines 
and blood type may vary by ethnicity (Franchini, Mengoli, & Lippi, 2016) 
Data on fetal and paternal blood type should be included in future research on the 
association between maternal ABO blood type and preeclampsia in order to determine if 
differences in maternal and fetal or paternal blood type mediate an immune reaction which 
predisposes women to either preeclampsia subtype (Phaloprakarn & Tangjitgamol, 2013).  Due 
to the high rates of multiparty noted in the early onset subtype in this current study, it may also 
be important for further studies to examine rates of preeclampsia recurrence by ABO blood type. 
In this current study, markers of severity such as growth restriction and lower platelet 
levels were seen more often in individuals with the B blood type.  Although early onset 
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preeclampsia is often considered the more severe of the subtypes, women with both subtypes of 
the disease can have preeclampsia with severe features (Boyd et al., 2013; van Rijn et al., 2013).  
Women who have met the basic criteria for preeclampsia are classified as having severe features 
if their systolic blood pressure is >/= 160 mmHg or diastolic is >/= 110 mmHg on two occasions 
at least 4 hours apart, have platelet counts less than 100,000 per microliter, impaired liver 
function, renal insufficiency, pulmonary edema, or cerebral or visual disturbance (ACOG, 2013).  
Further research should be conducted to assess if certain severe features occur more commonly 
in each ABO blood phenotype.  
Summary and Conclusion 
Preeclampsia has been studied in biologic, immunologic, genetic and pathophysiologic 
research (Charlton, Tooher, Rye, & Hennessy, 2014; Founds et al., 2011; Ilekis, Reddy & 
Roberts, 2007).  The disease seems to result from a complex interplay of maternal and fetal 
factors (Hermes et al., 2013).  There is a growing body of evidence that has begun to explore the 
role of ABO blood phenotypes in the development of disease.  Scientists now recognize the 
influence ABO blood type plays in the body’s inflammatory and hemostatic responses 
(Franchini, & Bonfanti, 2015).   
Although there were significant limitations to the study, this study provides a unique 
contribution to the literature on blood type and preeclampsia.  Current research supports that 
preeclampsia is heterogeneous in nature and must be studied as such (Founds et al., 2011; Myatt 
et al., 2014).  This current study utilized strict definitions that delineated preeclampsia by 
subtype (early and late), instead of assessing preeclampsia as a homogenous group.  
Subsequently, this study may better explain blood type’s association with each preeclampsia 
subtype (early and late).  Similar to other studies with this aim, subjects with the AB blood type 
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had roughly three times higher odds of preeclampsia.  This study added to literature and reported 
that subjects with AB blood type had three times the odds of late onset preeclampsia than 
subjects with other blood types.  Since AB blood type is the rarest of all blood types, larger 
studies done in the United States which utilize strict data collection procedures and assess 
preeclampsia by subtype are necessary to confirm this relationship.  Preeclampsia may provide 
an early opportunity to identify women at risk for cardiovascular disease (Smith, Pudwell, & 
Roddy, 2013).  Further exploration of risk factors, such as blood type, which are shared between 
preeclampsia and cardiovascular disease, may help in the development of interventions which 
could decrease long-term cardiovascular risk in these women.  
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Appendix A:   U.S Preventive Services Task Force Levels of Evidence 
 
I: Evidence obtained from at least one properly designed randomized, controlled trial or meta- 
     analysis of randomized, controlled trials. 
II‐1: Evidence obtained from well‐designed controlled trials without 
         randomization. 
II‐2: Evidence obtained from II well‐designed cohort or case–control analytic 
         studies, preferably from more than one center or research group. 
II‐3: Evidence from multiple time series with or without the intervention. 
III: Opinions of respected authorities, based on clinical experience, descriptive 
        studies or reports of expert committees 
 
U.S. Preventive Services Task Force. (1996). Guide to clinical preventive services (2nd ed.). 
Baltimore: Williams and Wilkins.
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Appendix B: Evidence Table ABO Blood Phenotype and Preeclampsia 
  Title of 
article 
Author 
Level of 
Evidence 
Research Aim Sample Research 
Design 
Results Strengths/Limitations 
Alpoim et al 
(2012) 
 
Preeclampsia 
and ABO 
blood groups: 
a systematic 
review 
and meta-
analysis 
 
Level I 
A systematic review 
of the literature for 
published studies 
investigating whether 
ABO blood groups 
could influence PE 
developing 
Two studies met eligibility 
criteria 
 
N=992 women with PE  
N= 883 healthy pregnant 
women  
Total n = 1,875 
Systematic 
review 
Meta-
Analysis 
Significant 
overall effect 
when comparing 
pregnant women 
of blood group 
AB versus non-
AB ones for the 
risk of PE 
(OR 2.42; 95 % 
CI 1.63–3.58) 
 
No significant 
findings for any 
other blood type 
Very small only found 
two studies that meet 
inclusion criteria 
 
Large group of severe 
preeclamptic patients 
in study 
 
Utilized >/= 2 g of 
prorteinuria as 
diagnositic  
Diagnostic criteria of 
PE has changed since 
publication 
 
Reports >/= 0.3/24 
hours  in discussion as 
inclusion criteria 
different than stated in 
inclusion criteria 
Alpoim et al 
(2012) 
 
ADAMTS13, 
FVIII, von 
FVIII activity, VWF 
and ADAMTS13 
plasma levels, 
according to O and 
“non O” blood 
N= 55 pregnant with sPE 
 
N=35 normotensive 
pregnant  
 
case-control 
study 
FVIII activity 
and VWF 
levels were 
significantly 
higher in sPE 
Fairly small sample 
size. No power 
analysis 
 
Brazilian population 
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6
2
 
Willebrand 
factor, ABO 
blood group 
assessment 
in 
preeclampsia 
 
Level II-2 
 
 
 
 
groups, in women 
with severe PE (sPE). 
N= 50 non-pregnant 
women.  
 
Total N= 140 
group, as 
compared to 
normotensive 
pregnant women 
(P=0.01 and 
P=0.05, 
respectively) 
 
the frequency of 
O and non O 
blood groups in 
sPE and 
normotensive 
pregnancies was 
similar  
31% and 69% in 
sPE; 43% and 
57% in 
normotensive 
pregnancies 
P=0.25 
 
 
4% AB blood type 
 
Definition of 
preeclampsia 
>2 g proteinuria=not 
ACOG definition 
Severe vs mild no 
longer used in 
preeclampsia 
nomenclature 
 
Patients after 29 weeks 
May have lost some 
sPE patients who 
delivered prior to 29 
weeks 
Clark et al 
(2007) 
The GOAL 
study: a 
prospective 
examination 
of the impact 
of 
The impact of 
FVL/ABO(H) on a 
composite of all 
major vascular 
complications (PET, 
IUGR, pregnancy loss 
and VTE) 
N=4157 consented to 
participate. 
 
 
 
 
 
 
Prospective 
cohort study 
No association 
with ABO(H) 
alone, or any 
interaction 
between ABO(H) 
and 
FVL was 
observed. 
Scottish population 
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factor V 
Leiden and 
ABO(H) 
blood groups 
on 
haemorrhagic 
and 
thrombotic 
pregnancy 
outcomes 
 
 
 
 
 
  
 
 
 
Clark & Wu 
(2008) 
ABO(H) 
blood groups 
and pre-
eclampsia.  A 
systematic 
review and 
meta-analysis 
 
Examined the 
literature to see if 
there is a relationship 
between ABO(H) and 
pre-eclampsia, in 
order to reveal 
whether there is a true 
association between 
the two 
17 eligible studies A systematic 
review and 
meta-analysis 
No consistent 
link between 
blood group AB 
and pre-
eclampsia, 
with a pooled 
odds ratio of 
group AB versus 
the remainder of 
1.02 (95%CI 
0.86 to 1.22) 
 
Comparing a 
combined group 
of non-Os (i.e. 
AA, AB and BB) 
with group O 
gave similar 
results, with a 
No specific features 
(disease definition, 
disease severity, 
date of publication, or 
ABO(H) distribution 
in controls) 
distinguished those 
few studies giving any 
form of positive 
association 
from the remainder. 
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6
4
 
pooled odds ratio 
of 
1.01 (95% CI 
0.91 to 1.12), but 
with some 
evidence of 
heterogeneity 
(p=0.01) and 
individual study 
estimate 
inconsistency (I2 
49%) 
Franchini, 
Mengoli, 
Lippi (2016) 
 Relationship 
between ABO 
blood group 
and pregnancy 
complications:  
a systematic 
literature 
analysis 
 
To elucidate the role 
of ABO antigens in 
pregnancy-related 
complications, a 
systematic review of 
the literature 
published in the past 
50 years was 
completed. A meta-
analytical approach 
was also applied to 
the existing literature 
on the association 
between ABO 
status and pre-
eclampsia. 
9 studies (7 case control/2 
cohort)  
Systematic 
Review and  
meta-analysis 
Blood group O 
was associated 
with lower odds 
of preeclampsia  
Effect size .77 
(95% C1 .67-.88) 
(p=<.001). 
 
For group A the 
effect size was 
1.78 (95% CI: 
1.04-3.07), 
higher prevalence 
of this blood 
group among the 
patients with pre-
eclampsia 
(p=0.037). The 
heterogeneity 
Studies included were 
done in varying ethnic 
backgrounds, however 
the ethnic backgrounds 
were not described in 
this meta-analysis.  
 
Review dated back 50 
years. 
  
 
1
6
5
 
was substantial 
(I2=63.7%).  For 
group AB the 
effect size was 
1.94 (95% CI: 
1.20-3.13), also 
higher than one 
(p=0.007) The 
heterogeneity 
was also 
substantial 
(I2=64.2%). 
 
 
Hentschke et 
al. (2014) 
Is there any 
relationship 
between 
ABO/Rh 
blood group 
and patients 
with pre-
eclampsia 
The purpose of this 
study was to evaluate 
the association 
between preeclampsia 
and blood groups in a 
group of pregnant 
women hospitalized 
in a University 
Hospital in Porto 
Alegre, Brazi 
N=414 women were 
diagnosed as 
preeclampsia/eclampsia  
N=9611 women were 
identified to the control 
group. 
Case Control No difference in 
blood group 
distribution  
P>0.05 
Brazilian population 
Hiltunen et al 
(2009) 
Blood group 
AB and factor 
V Leiden as 
risk factors for 
pre-eclampsia: 
ABO blood group, 
seven thrombophilia 
associated 
polymorphisms, and 
anti-beta2-
glycoprotein 
248 cases fulfilling strict 
criteria for pre-eclampsia 
and 679 controls 
A population 
based nested 
case-control 
study 
Blood group AB 
increased the risk 
for pre-eclampsia 
as a whole (OR 
2.1, 95% CI 1.3-
3.5), and in the 
three subgroups 
Population from 
Finland 
Done retrospectively 
on medical records 
Used strict diagnostic 
criteria 
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A population 
based 
nested case-
control study 
I antibodies as risk 
factors for pre-
eclampsia 
(OR 2.3, 3.8, 3.4; 
95% CI 1.3-3.9, 
2.0-7.1, 1.6-7.1). 
Noted lower incidence 
of preeclampsia in 
their study sample than 
in overall population 
 
Lee et al 
(2012) 
ABO and 
RhD blood 
groups and 
gestational 
hypertensive 
disorders: a 
population-
based cohort 
study 
Examined the 
association between 
ABO and RhD 
blood groups and 
gestational 
hypertensive 
disorders in a large 
population-based 
cohort 
All singleton deliveries in 
Sweden born to first-time 
mothers during the period 
1987–2002 [total n = 641 
926; any 
gestational hypertensive 
disorders, n = 39 011 
(6.1%); preeclampsia 
cases, n = 29 337 (4.6%); 
severe pre-eclampsia cases, 
n = 8477 (1.3%)]. 
Cohort study Compared with 
blood group O, 
all non-O blood 
groups 
had modest but 
statistically 
significantly 
higher odds of 
preeclampsia. 
Blood group AB 
had the highest 
risk for pre-
eclampsia 
(OR = 1.10, 95% 
CI 1.04–1.16) 
and severe pre-
eclampsia 
(OR = 1.18, 95% 
CI 1.07–1.30). 
Population from 
Sweden 
 
Utilized ICD 9 codes 
to identify subjects-
outcome  
 
Strict inclusion criteria 
 
Included gestational 
hypertension 
López-Pulles 
et al. (2010) 
 
Assessment of 
Genetic 
Contributions 
To identify the 
immunogenetic 
factors that trigger the 
beginning of 
preeclampsia 
and eclampsia 
142 pregnant women 
in Obstetrics and 
Gynecological Hospital 
Isidro Ayora in Quito, who 
are grouped into 
two different groups, 
diseased and healthy. 
A 
retrospective, 
case-control 
study 
No statistical 
difference when 
comparing the 
blood type and 
Rh factor of the 
two groups (p > 
0.05). 
Ecuadorian 
Women 
Small sample size  
Several blood types 
not represented. 
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to Risk of 
Preeclampsia 
in Ecuadorian 
Women 
Phaloprakarn 
& 
Tangjitgamol 
(2013) 
Maternal 
ABO blood 
group and 
adverse 
pregnancy 
outcomes 
To determine the 
relationship between 
maternal ABO blood 
group and risk of 
adverse pregnancy 
outcomes. 
preeclampsia, 
 gestational diabetes 
mellitus (GDM), 
preterm delivery,  
low birth weight 
(LBW)  
small for gestational 
age (1stSGA) infants 
5320 singleton pregnant 
women 
350 (6.6%), preeclampsia, 
 333 (6.3%) GDM  
543 (10.2%)  
 
Btw 6/08-7/10 
1st PNC < 14vweeks 
No known underlying 
disease or condition 
that could affect the 
pregnancy outcome 
 
 
 
 
 
Retrospective 
cohort 
Women with A 
or AB blood 
types, were found 
at increased risk 
of preeclampsia 
compared with O 
type individuals; 
adjusted relative 
risks were 1.7 
(95% 
confidence 
interval (CI), 1.3 
to 2.3; P¼0.001) 
for A phenotype 
and 1.7 
(95% CI, 1.1 to 
2.6; P¼0.01) for 
AB phenotype 
Thai population  
 
Included GDM, LBW 
& SGA and preterm 
labor as outcomes 
 
Retrospective, 
potential risk factors 
may not have been 
identified 
 
Did not include Rh- 
population 
Seyfizadeh et 
al (2014) 
Is there 
association 
between ABO 
blood group 
and the risk 
factors of 
unfavorable 
Examine the 
relationship between 
blood group and 
pregnancy blood 
levels of  
Fasting blood sugar 
Hgb 
HCT 
Urea 
N= 792 Healthy pregnancy 
women 
Tabriz health centers (Iran) 
 
 
Prospective  
Cohort  
 
The serum 
creatinine of AB 
group was 
significantly 
higher than the 
other 3 groups 
p<0.005) 
 
Confounders not 
discussed 
 
Statistical 
Demographics of study 
populations not shown  
 
Completed in Iran 
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outcomes of 
pregnancy? 
Creatinine 
RBC’s 
 
To determine if blood 
group has an 
association with some 
of the risk factors of 
unfavorable outcomes 
in pregnancy 
Serum urea 
higher in AB 
group than other 
3 groups  
(p<0.005) 
Sezik et al. 
(2002) 
 
Distribution 
of ABO and 
Rh blood 
groups in 
patients with 
HELLP 
syndrome. 
Evaluate the 
relationship between 
HELLP (hemolysis, 
elevated liver 
enzymes, low 
platelets) syndrome 
and the 
maternal blood groups 
N=547  
severe preeclampsia divided 
by blood groups 
Retrospective 
Cohort 
O negative risk 
for HELLP-OR 
3.1  CI (1.28–
7.43)  ( p<0.01) 
 
Did not detect 
increased 
incidence of 
HELLP 
syndrome 
in patients with 
the blood group 0 
(independent of 
the Rh type) 
Turkish Women 
Than et al 
(2011) 
PP13, 
Maternal 
ABO Blood 
Groups and 
the Risk 
Assessment of 
To test whether PP13-
binding to 
erythrocytes, maternal 
blood-group has an 
effect on serum PP13 
and its performance 
as a predictor of 
maternal serum PP13 in 
Caucasian (n = 1078) and 
Hispanic n = 242 women 
were analyzed according to 
blood groups 
Cross-
sectional 
Women with 
preeclampsia 
associated with 
IUGR had 
the lowest PP13 
MoMs in the first 
trimester and the 
highest MoMs 
Placenta sample from 
women in Budapest 
Hungary 
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Pregnancy 
Complications 
preeclampsia and 
IUGR 
in the second and 
third trimesters 
 
In Caucasian 
women: 
AB blood type 
had lowest serum 
levels of PP13 in 
the first trimester. 
 
Blood group B 
had the highest 
median PP13 
MoMs 
throughout 
pregnancy 
 
In Hispanic  
women: 
Same as 
Caucasian cohort 
 
 
PP13 had 
differential 
binding to RBCs 
according 
to ABO blood 
types. PP13-
binding was 
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similar in blood 
groups A 
and O, the 
weakest in blood 
group B, and the 
strongest in 
blood 
group AB in 
comparison to 
other blood 
groups 
 
 
By adjusting to 
ABO blood 
group, 
the prediction 
accuracy of the 
PP13 test is 
improved for 
preeclampsia, 
IUGR and 
preeclampsia 
with IUGR 
Witsenburg et 
al.  
(2005) 
The aim of this study 
was to determine 
whether elevated 
factor VIII levels are 
associated with 
uteroplacental 
insufficiency, in 
N= Controls 272 women 
 
N=Plasma samples of 75 
women with a history of 
pregnancy complicated by 
pre-eclampsia, HELLP 
syndrome, pregnancy 
Case Control VIII:C levels 
were similar at 
123 IU/dl in both 
the patient group 
and the controls. 
In a logistic 
regression model, 
 
Netherlands 
 
Elevated factor VIII 
levels were associated 
with a 
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particular pre-
eclampsia, HELLP 
syndrome or 
pregnancy-induced 
hypertension and 
intrauterine growth 
retardation 
induced hypertension or 
intrauterine growth 
restriction 
after adjusting 
for age and blood 
group, no effect 
of factor VIII:C 
levels on the risk 
of pregnancy 
complications 
was 
observed, with 
the exception of 
IUGR with (OR 
2.9, CI 1.0—8.7) 
or without 
hypertension (OR 
2.0, CI 0.7—6.4). 
two- to three-fold 
increased risk of 
IUGR. 
No observed effect 
from ABO-blood 
group, 
t this is acquired rather 
than genetically 
determined. 
 
Limitations of study 
not addressed 
 
Very small sample size 
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Title of article 
Author 
Level of Evidence 
Research Aim 
 
Sample Resear
ch 
Design 
Results Strengths/ 
Limitations 
Biswas, Ghoshal, Halder, Mandal 
(2013) 
 
Distribution 
of ABO blood group andmajor card
iovascular risk factors with 
coronary heart disease. 
 
Level II-2 
 
 
The purpose of this 
study was to establish 
whether ABO blood g
roup is related to 
coronary 
heart disease in an 
individual in Asian 
Indian Bengali 
population of eastern 
part of India 
N=250 CHD 
patients and 
250 age and 
sex matched 
healthy 
subjects  
 
 
 
 
 
 
 
 
 
 
 
 
 
Case -
control 
The distribution 
of ABO blood groups in 
patients versus 
control group was A in 
24.00 versus 21.60%, B in 
30.80 versus 32.40%, O in 
38.40 versus 21.60%, and 
AB in 6.80 versus 
24.40%. The analysis 
showed significant 
difference in frequency of 
O (OR = 1.857, 95%CI = 
1.112-3.100, P = 0.018) 
and AB (OR = 0.447, 
95%CI = 0.227-0.882, P = 
0.020) blood group betwe
en healthy controls and 
CHD individuals 
 
AB blood group decreases 
the risk of CHD in healthy 
controls, and it might be 
due to the higher 
concentration of high 
density lipoprotein 
cholesterol (HDL-c), 
while the 
 Asian 
Indian 
Bengali 
population 
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O blood group increases 
the risk of CHD due to 
lower HDL-c levels in 
Bengali population of 
eastern part of India. 
Chen et al. (2014) 
 
Analysis of circulating cholesterol 
levels as a mediator of an 
association 
between ABO blood group and 
coronary heart disease. 
 
Level II-2 
 
 
 
To estimate the 
mediation effect size 
between 
cardiovascular 
disease and blood 
type 
 6476 
consecutive 
patients 
Case 
Control 
Subjects of non-
O type had higher levels 
of total cholesterol, low-
density lipoprotein 
cholesterol, and non-high-
density lipoprotein 
cholesterol (mean [SEM] 
in mmol/L: 4.931[0.021], 
3.041 [0.018], and 3.805 
[0.020] in non-
O type compared with 
4.778 [0.026], 2.906 
[0.021], and 3.669 [0.024] 
in O type; P=3.8×10(-7), 
P=1.5×10(-7), and 
P=3.1×10(-7), 
respectively).  
 
10% of the effect of non-
O type on coronary 
artery disease 
susceptibility was 
mediated by increased 
low-density lipoprotein 
cholesterol level 
(P=7.8×10(-4)) and 11% 
Used 
mediation 
analysis 
 
Which 
revealed 
LDL as a 
mediator of 
CHD risk 
on patients 
with Non O 
blood type 
 
Did not 
discuss 
limitations 
of the study 
 
Done in 
Southern 
China 
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of the effect of non-
O type on myocardial 
infarction risk was 
mediated by raised low-
density lipoprotein 
cholesterol level 
(P=2.0×10(-3)). 
Etemadi et al. (2015)   
 
Mortality and cancer in relation to 
ABO blood group phenotypes in 
the Golestan Cohort Study 
 
Level II-3 
 To study the 
association 
between ABO blood 
groups and overall 
and cause-specific 
mortality in the 
Golestan Cohort 
Study 
 
 
 
 
 50,045 people 
40- to 70-years 
old 
Populat
ion 
based 
cohort 
design 
Non-O blood groups were 
associated with 
significantly increased 
total mortality (hazard 
ratio (HR) = 1.09; 95% 
confidence interval (CI): 
1.01 to 1.17) and 
cardiovascular disease 
mortality (HR = 1.15; 
95% CI: 1.03 to 1.27) 
 
plasma total cholesterol 
and  LDL in those with 
blood group A 
Did not 
check for 
differentiati
on between 
Type A  
subtypes.  
 
Study 
population 
in 
northeastern 
Iran 
 
No direct 
analysis of 
the 
mediation 
effect of 
biochemical 
changes in 
the ABO 
mortality 
association. 
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left 
censoring 
of the 
mortality 
data 
Gasso et al.  (2012) 
A common variant of the ABO 
gene protects against hypertension 
in a Spanish population. 
 
Level II-2 
 
The objective of this 
study was to establish 
whether genetic 
polymorphisms that 
could be related to 
angiotensin-
converting enzyme 
(ACE) levels are 
associated with 
hypertension. 
 269 
hypertensive 
patients and 
254 healthy 
controls. 
Case 
Control 
Only one polymorphism 
of the ABO gene 
(rs495828) presented 
nominal pointwise P<0.05 
values (odds ratio = 0.33, 
95% CI 0.19-0.58, P = 6 × 
10(-5)) and achieved 
P<3.8 × 10(-3), the 
nominal P-value 
considered significant 
after Bonferroni 
correction. Analysis of the 
genotype frequencies 
showed that the model 
that correctly explained 
the observed association 
was the recessive model 
(odds ratio = 0.03, 95% CI 
0.01-0.15, P = 1 × 10(-6)). 
These results indicate that 
genetic variants that could 
be related to ACE activity 
are good predictors of 
hypertension, and identify 
ABO as a good candidate 
Further 
studies are 
required to 
confirm this 
association. 
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gene for genetic studies of 
hypertension risk.  
Gong et al.  (2014).  
Relation of ABO blood groups to 
the severity of coronary 
atherosclerosis: an Gensini score 
assessment. 
 
Level II-2 
 
 Investigated the 
relation of 
the ABO blood group
s to the severity of 
coronary 
atherosclerosis 
assessed by Gensini 
score (GS)  
2919 
consecutive 
patients 
undergoing 
coronary 
angiography 
were enrolled 
Cross-
sectiona
l cohort 
study 
The frequency 
of blood group A was 
significantly higher in the 
upper GS tertiles (24.4% 
vs. 28.2% vs. 29.5%, p = 
.032).  
 
Blood group A was 
independently associated 
with GS (β = 0.043, p = 
.017).  Group A remained 
significantly associated 
with mid-high GS (OR = 
1.44, 95% CI 1.16-1.80, p 
= .001),  
 
Group O was showed as a 
protective factor (OR = 
0.77, 95% CI = 0.65-0.92, 
p = .004). 
 
Single 
center study  
 
 
The 
crosssection
al 
nature of 
the study 
limits the 
ability to 
infer a 
causal 
relation 
between 
ABO blood 
group and 
cardiovascu
lar events 
 
Large 
Chinese 
cohort 
Gong et al. (2014)  
High-sensitivity C-reactive protein 
mediates in part the impact 
of ABO blood group on coronary 
artery disease 
CRP might play an 
interesting role in the 
association of ABO 
group with CAD or 
MI 
3806 
consecutive 
patients who 
underwent 
selective 
Cross-
sectiona
l study 
There is a difference in 
blood type distribution 
between controls and 
patients with CAD (p = 
Used 
mediation 
analysis 
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Level II-3 
 
 
 
coronary 
angiography 
for being 
suspected or 
known 
coronary 
atherosclerosis  
 
0.005) and patients with 
MI (p= 0.047) 
 
Non-O blood group 
remained significantly 
association with CAD and 
MI 
(OR = 1.49, 95% CI 1.20–
1.84, p b 0.001; OR = 
1.24, 95% CI = 
1.04–1.47, p = 0.017), 
respectively after 
adjustment for common 
cardiovascular 
risk factors 
 
The effect of non-O blood 
type on CAD and MI 
susceptibility is mediated 
partly by hs-CRP levels. 
Large 
Chinese 
cohort 
He et al. (2012) 
ABO blood group and risk of 
coronary heart disease in two 
prospective cohort studies. 
 
Level I 
 
 
investigate the 
associations 
between ABO blood 
group and CHD risk 
in prospective cohort 
studies. 
(the Nurses' 
Health Study 
[NHS] 
including 62 
073 women 
and the Health 
Professionals 
Follow-up 
Study [HPFS] 
including 27 
428 men)  
Meta-
analysis 
of two 
large 
Prospec
tive 
cohort 
study 
ABO blood group was 
significantly associated 
with the risk of 
developing CHD in both 
women and men (log-rank 
test; P=0.0048 and 0.0002, 
respectively).  
In the combined analysis 
adjusted 
for cardiovascular risk 
factors, compared with 
United 
States 
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participants 
with blood group O, those 
with blood groups A, B, or 
AB were more likely to 
develop CHD (adjusted 
hazard ratios [95% CI] for 
incident CHD were 1.06 
[0.99-1.15], 1.15 [1.04-
1.26], and 1.23 [1.11-
1.36], respectively).  
Overall, 6.27% of the 
CHD cases were 
attributable to inheriting a 
non-O blood group. Meta-
analysis indicated that 
non-O blood group had 
higher risk of CHD 
(relative risk =1.11; 95% 
CI, 1.05-1.18; P=0.001) 
compared with 
O blood group. 
Jassim W.E.  (2012)  
Association of ABO blood group in 
Iraqis with hypercholesterolaemia, 
hypertension and diabetes mellitus. 
 
Level II-2 
 
Investigated the 
possible association 
of diabetes mellitus, 
hypercholesterolaemi
a and hypertension 
with ABO type. 
920 patients 
with diabetes 
mellitus, 
hypertension 
and 
hypercholester
olemia 
Case 
control 
Levels of total cholesterol, 
glucose and 
systolic/diastolic blood          
pressure were all 
significantly higher in 
male and female patients 
in blood group O than 
other groups, with a 
decreasing trend 
Iraqi 
population 
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from group A to B then 
AB.  
Similar trends 
by blood group were seen 
for the healthy controls 
although the differences 
were less marked 
Karabuva, Carević, Radić & 
Fabijanić (2013) 
The association of ABO blood 
groups with extent of coronary 
atherosclerosis in Croatian patients 
suffering from chronic coronary 
artery disease. 
Level II-2 
 Examined the 
relationship 
between ABO blood 
groups and extent of 
coronary 
atherosclerosis in 
patients with chronic 
coronary 
artery disease (CAD), 
2) 
compare ABO blood 
groups distribution in 
CAD patients and 
general population, 3) 
examine possible 
differences in 
traditional risk factors 
frequency in CAD 
patients with 
different ABO blood 
group 
N= 646 
chronic CAD 
patients 
Cohort No association 
between ABO blood grou
ps and the extent of 
coronary atherosclerosis 
in Croatian CAD patients 
is observed. Observation 
that 
AB blood group might 
possibly identify Croatian 
males at risk to develop 
the premature CAD has to 
be tested in larger cohort 
of patients. 
Croatian 
population 
Lee et al. (2012) Aimed to investigate 
the association 
between 
277 
consecutive 
subjects (men 
Case 
Control  
Patients with CAD 
showed a significantly 
different blood group distr
Taiwanese 
population. 
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Association of blood group A with 
coronary artery disease in young 
adults in Taiwan. 
 
Level II-2 
 
the ABO blood group
s and the risk of 
coronary 
artery disease (CAD) 
and myocardial 
infarction (MI) in a 
young Taiwanese 
population 
younger than 
45 years and 
women 
younger than 
55 years) who 
underwent 
coronary 
angiography 
(136 with 
documented 
CAD and 129 
without CAD) 
at our center, 
between 2005 
and 2008 
ibution (O, 30.1%; A, 
39.7%; B, 26.5%; AB, 
3.7%) than that shown by 
the controls (O, 42.6%; A, 
24.0%; B, 27.1%; AB, 
6.2%; p=0.032). Patients 
with blood group A had a 
greater risk of CAD and 
MI than those with non-
A blood groups (OR=2.08, 
95% CI=1.23-3.54; 
OR=2.21, 95% CI=1.19-
4.09, respectively). After 
adjustment for 
common cardiovascular ri
sk factors such as age, 
gender, hypertension, 
cigarette smoking, 
diabetes mellitus, body 
mass index, family history 
of CAD, and lipid 
profiles; blood group A 
remained significantly 
associated with an 
increased risk of CAD and 
MI (OR=2.61, 95% CI 
1.11-6.14, p=0.028; 
OR=3.53, 95% CI=1.21-
10.29, p=0.021, 
respectively). 
Angiograph
ically 
determined 
CAD 
 
Focused on 
younger 
patients 
 
Single-
center 
design 
retrospectiv
e 
 
Small 
sample size,  
 
incomplete 
lipid profile 
data, and 
lack of 
detailed 
genotype 
information 
of the ABO 
alleles 
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Reilly et al. (2011)  
Identification of ADAMTS7 as a 
novel locus for coronary 
atherosclerosis and association of 
ABO with myocardial infarction in 
the presence of coronary 
atherosclerosis: two genome-wide 
association studies. 
 
Level II-2 
 
Tested whether 
genetic factors 
distinctly contribute 
to either development 
of coronary 
atherosclerosis or, 
specifically, to 
myocardial infarction 
in existing coronary 
atherosclerosis. 
N= patients 
who had 
angiographic 
CAD and 
myocardial 
infarction 
(n=5783)   
N=those who 
had 
angiographic 
CAD but no 
myocardial 
infarction 
(n=3644). 
Case 
control 
In the comparison of 
patients with angiographic 
CAD who had myocardial 
infarction versus those 
with angiographic CAD 
but no myocardial 
infarction, there was a 
novel association at the 
ABO locus (p=7·62×10(-
9)). The ABO association 
was attributable to the 
glycotransferase-deficient 
enzyme that encodes the 
ABO blood group O 
phenotype previously 
proposed to protect 
against myocardial 
infarction. 
 
CAD in 
patients of 
European 
ancestry 
genetic 
predispositi
ons promote 
the 
developmen
t of 
coronary 
atherosclero
sis whereas 
others lead 
to 
myocardial 
infarction in 
the presence 
of coronary 
atherosclero
sis. The 
relation to 
specific 
CAD 
phenotypes 
might 
modify how 
novel loci 
are applied 
in 
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personalize
d risk 
assessment 
and used in 
the 
developmen
t of novel 
therapies 
for CAD. 
 
CAD  was 
defined by 
angiograph
y 
 
Multistudy 
design  
 
Misclassific
ation 
possible as 
patient with 
CAD might 
develop MI 
 
Sode, et al. (2013) 
Risk of venous thromboembolism 
and myocardial infarction 
associated with factor V Leiden 
and prothrombin mutations 
and blood type. 
Examined 
if ABO blood 
type alone and in 
combination with 
mutations in factor V 
Leiden R506Q and 
Genotype of 
66,001 white 
participants 
for ABO blood 
type, factor V 
Leiden R506Q 
Prospec
tive 
Cohort 
Multivariable adjusted 
HRs for myocardial 
infarction by genotypes 
did not differ from 1.0. 
White and 
Danish 
population 
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Level II-2 
prothrombin 
G20210A is 
associated with the 
risk of venous 
thromboembolism 
and myocardial 
infarction in the 
general population. 
and 
prothrombin 
G20210A.  
Used ICD 9 
codes to 
define MI  
 
Large 
sample 
Wauters E.  et al. (2013).   
Influence of 23 coronary 
artery disease variants on recurrent 
myocardial infarction or cardiac 
death: the GRACE Genetics Study. 
 
Level II-2 
Evaluated whether 
these 23 loci also 
predispose to 
recurrent MI or 
cardiac death 
following an acute 
coronary syndrome 
(ACS). 
2099 ACS 
patients 
enrolled in the 
Global 
Registry of 
Acute 
Coronary 
Events 
(GRACE) UK-
Belgian study 
Prospec
tive 
Cohort 
 
C-allele carriers of the 
rs579459 variant, which is 
located upstream of 
the ABO gene and 
correlates 
with blood group A, were 
independently associated 
with recurrent MI 
[multivariable-adjusted 
hazard ratio (HR) 2.25, CI 
= 1.37-3.71; P = 0.001] 
and with recurrent MI or 
cardiac death 
[multivariable-adjusted 
(HR) 1.80, CI = 1.09-2.95; 
P = 0.021] within 5 years 
after an index ACS. The 
association of rs579459 
was replicated in 1250 
Polish patients with 6 
months follow-up after an 
index ACS [multivariable-
adjusted (HR) 2.70, CI = 
European 
population 
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1.26-5.82; P = 0.011 for 
recurrent MI]. Addition of 
rs579459 to a prediction 
model of 17 clinical risk 
factors improved risk 
classification for recurrent 
MI or cardiac death at 6 
months as calculated by 
the integrated 
discrimination 
improvement method (P = 
0.037), but not by C-
statistics (P = 0.096). 
Zakai et al. (2014) 
ABO blood type and stroke risk: 
The Reasons for Geographic And 
Racial Differences in Stroke Stud 
 
Level II-2 
 
Assess the association 
of blood type with 
stroke and 
whether blood 
type contributes to 
racial disparities in 
stroke in the United 
States. 
30,239 
participants  
Case-
cohort  
Blood type AB is 
associated with an 
increased risk of stroke 
that is not attenuated by 
conventional stroke risk 
factors, and factor VIII 
levels were associated 
with 60% of the 
association. While blood 
type AB is rare in the US 
population, it is a 
significant stroke risk 
factor and may play an 
important role in stroke 
risk in these individuals. 
Blacks and 
Whites 
from the 
United 
States 
 185 
 
 
Appendix D:   ICD 9 Codes 
 
Diagnosis ICD 9 Codes 
Preeclampsia 642.41/642.42/ 642.0/642.1/ 642.2/642.3/642.4/642.5/642.6 
642.7/642.9 
 
Premier queried using 4 digit ICD 9 codes, but asked system to include all cases with 
5 digit codes which are inclusive of the 4 digit ICD 9 codes listed above. 
Gestational 
Hypertension 
642.31/642.32                            
Severe Preeclampsia 642.51/642.52                            
Eclampsia 780.39 
HELLP syndrome 642.51/642.52 
Multiple Gestation 651.01/651.11/651.21/651.31/651.41/651.51/ 
651.61/651.71/651.81/651.91 
Diabetes 250.00 
Chronic 
Hypertension 
642.22/642.21/642.02/642.01/642.72/642.71 
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Appendix E:  Sample Size Calculation Using Hiltunen (2009)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 Two-sided confidence level(1-alpha) 95  
 Power(% chance of detecting) 80  
 Ratio of Controls to Cases 2  
 Hypothetical proportion of controls with exposure 56  
 Hypothetical proportion of cases with exposure: 70.96  
 Least extreme Odds Ratio to be detected: 1.92  
       
 Kelsey Fleiss Fleiss with CC 
Sample Size - Cases 126 123 133  
Sample Size - Controls 251 245 265  
Total sample size: 377 368 398  
       
References 
Kelsey et al., Methods in Observational Epidemiology 2nd Edition, Table 12-15 
Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19 
      
CC = continuity correction 
Results are rounded up to the nearest integer. 
Results from OpenEpi, Version 3, open source calculator--SSCC 
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Appendix F:   Database by Variable 
 
Variable Level of Measurement Database 
 
ABO blood type 
 A 
 B 
 AB 
 O 
Categorical Delivery Log 
Platelets  
 < 20 weeks gestation 
 >20 weeks -28 weeks 
 Admission for delivery 
Continuous  
< 20; > 20-28 weeks -Chart 
Review 
 
Rh Factor 
 Rh - 
 Rh + 
Categorical Delivery Log 
Early Pregnancy BMI 
 
 
Continuous 
Also assessed at the 
categorical level 
Chart Review 
Infant Birthdate 
 
Collected as 
Continuous 
Recoded into 
categorical levels by 
season 
Delivery Log 
Comorbid Disease 
 DM 
 CHTN 
 GDM 
Categorical Premier ® (ICD 9/10 Codes) 
Confirmed during chart review 
Parity 
 Nulliparous 
 Multiparous 
Categorical Delivery Log 
Age at delivery 
 
 
Continuous Delivery Log 
Infant Outcome 
 Live Birth 
 Fetal Death 
 Neonatal Death 
 
Categorical  Delivery Log 
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Socioeconomic status 
(insurance type proxy) 
 Public Insurance 
 Private Insurance 
Categorical Premier® 
Race 
 White 
 Black 
 Other 
 
Categorical Delivery Log 
Smoking 
 Non smoking 
 Smoking 
Categorical Premier or Delivery Log using 
ICD 9-10 code and Chart Review 
Gestational age at birth 
 
 
Continuous Delivery Log 
Infant sex 
 Male 
 Female 
Categorical Delivery Log 
Infant birthweight-grams 
 
 
Continuous 
Recoded to assess fetal 
growth restriction. 
Categorical (> 10% 
<10%) 
Delivery Log and Chart Review  
Preeclampsia 
 Early onset </= 33 6/7 
weeks 
 Late onset >/= 34 
weeks 
 
Categorical Cases identified through Premier 
® using (ICD 9/10 Codes) 
Onset timing confirmed with 
Chart Review 
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